{"id": "AIMed.d80.s682_AIMed.d80.s682.p0", "text": "FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis.", "text_with_entity_marker": "[E1]FADD[/E1], a novel death domain-containing protein, interacts with the death domain of [E2]Fas[/E2] and initiates apoptosis.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FADD", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[82, 85]], "entity_2_idx_in_text_with_entity_marker": [95, 98], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p0", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of [E1]Fas[/E1] in the yeast two-hybrid system, we have identified a novel interacting protein, [E2]FADD[/E2], which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[32, 35]], "entity_1_idx_in_text_with_entity_marker": [36, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FADD", "entity_2_idx": [[116, 120]], "entity_2_idx_in_text_with_entity_marker": [129, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p1", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of [E1]Fas[/E1] in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds [E2]Fas[/E2] and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[32, 35]], "entity_1_idx_in_text_with_entity_marker": [36, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[134, 137]], "entity_2_idx_in_text_with_entity_marker": [147, 150], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p2", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of [E1]Fas[/E1] in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and [E2]Fas[/E2]-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[32, 35]], "entity_1_idx_in_text_with_entity_marker": [36, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[142, 145]], "entity_2_idx_in_text_with_entity_marker": [155, 158], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p3", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of [E1]Fas[/E1] in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-[E2]FD5[/E2], a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[32, 35]], "entity_1_idx_in_text_with_entity_marker": [36, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FD5", "entity_2_idx": [[146, 149]], "entity_2_idx_in_text_with_entity_marker": [159, 162], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p4", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of [E1]Fas[/E1] in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of [E2]Fas[/E2] possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[32, 35]], "entity_1_idx_in_text_with_entity_marker": [36, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[163, 166]], "entity_2_idx_in_text_with_entity_marker": [176, 179], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p5", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of [E1]Fas[/E1] in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants [E2]Fas[/E2]-LPR and Fas-FD8.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[32, 35]], "entity_1_idx_in_text_with_entity_marker": [36, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[247, 250]], "entity_2_idx_in_text_with_entity_marker": [260, 263], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p6", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of [E1]Fas[/E1] in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-[E2]LPR[/E2] and Fas-FD8.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[32, 35]], "entity_1_idx_in_text_with_entity_marker": [36, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LPR", "entity_2_idx": [[251, 254]], "entity_2_idx_in_text_with_entity_marker": [264, 267], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p7", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of [E1]Fas[/E1] in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and [E2]Fas[/E2]-FD8.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[32, 35]], "entity_1_idx_in_text_with_entity_marker": [36, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[259, 262]], "entity_2_idx_in_text_with_entity_marker": [272, 275], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p8", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of [E1]Fas[/E1] in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-[E2]FD8[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[32, 35]], "entity_1_idx_in_text_with_entity_marker": [36, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FD8", "entity_2_idx": [[263, 266]], "entity_2_idx_in_text_with_entity_marker": [276, 279], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p9", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, [E1]FADD[/E1], which binds [E2]Fas[/E2] and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FADD", "entity_1_idx": [[116, 120]], "entity_1_idx_in_text_with_entity_marker": [120, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[134, 137]], "entity_2_idx_in_text_with_entity_marker": [147, 150], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p10", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, [E1]FADD[/E1], which binds Fas and [E2]Fas[/E2]-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FADD", "entity_1_idx": [[116, 120]], "entity_1_idx_in_text_with_entity_marker": [120, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[142, 145]], "entity_2_idx_in_text_with_entity_marker": [155, 158], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p11", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, [E1]FADD[/E1], which binds Fas and Fas-[E2]FD5[/E2], a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FADD", "entity_1_idx": [[116, 120]], "entity_1_idx_in_text_with_entity_marker": [120, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FD5", "entity_2_idx": [[146, 149]], "entity_2_idx_in_text_with_entity_marker": [159, 162], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p12", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, [E1]FADD[/E1], which binds Fas and Fas-FD5, a mutant of [E2]Fas[/E2] possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FADD", "entity_1_idx": [[116, 120]], "entity_1_idx_in_text_with_entity_marker": [120, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[163, 166]], "entity_2_idx_in_text_with_entity_marker": [176, 179], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p13", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, [E1]FADD[/E1], which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants [E2]Fas[/E2]-LPR and Fas-FD8.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FADD", "entity_1_idx": [[116, 120]], "entity_1_idx_in_text_with_entity_marker": [120, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[247, 250]], "entity_2_idx_in_text_with_entity_marker": [260, 263], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p14", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, [E1]FADD[/E1], which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-[E2]LPR[/E2] and Fas-FD8.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FADD", "entity_1_idx": [[116, 120]], "entity_1_idx_in_text_with_entity_marker": [120, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LPR", "entity_2_idx": [[251, 254]], "entity_2_idx_in_text_with_entity_marker": [264, 267], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p15", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, [E1]FADD[/E1], which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and [E2]Fas[/E2]-FD8.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FADD", "entity_1_idx": [[116, 120]], "entity_1_idx_in_text_with_entity_marker": [120, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[259, 262]], "entity_2_idx_in_text_with_entity_marker": [272, 275], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p16", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, [E1]FADD[/E1], which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-[E2]FD8[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FADD", "entity_1_idx": [[116, 120]], "entity_1_idx_in_text_with_entity_marker": [120, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FD8", "entity_2_idx": [[263, 266]], "entity_2_idx_in_text_with_entity_marker": [276, 279], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p17", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds [E1]Fas[/E1] and [E2]Fas[/E2]-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[134, 137]], "entity_1_idx_in_text_with_entity_marker": [138, 141], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[142, 145]], "entity_2_idx_in_text_with_entity_marker": [155, 158], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p18", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds [E1]Fas[/E1] and Fas-[E2]FD5[/E2], a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[134, 137]], "entity_1_idx_in_text_with_entity_marker": [138, 141], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FD5", "entity_2_idx": [[146, 149]], "entity_2_idx_in_text_with_entity_marker": [159, 162], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p19", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds [E1]Fas[/E1] and Fas-FD5, a mutant of [E2]Fas[/E2] possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[134, 137]], "entity_1_idx_in_text_with_entity_marker": [138, 141], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[163, 166]], "entity_2_idx_in_text_with_entity_marker": [176, 179], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p20", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds [E1]Fas[/E1] and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants [E2]Fas[/E2]-LPR and Fas-FD8.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[134, 137]], "entity_1_idx_in_text_with_entity_marker": [138, 141], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[247, 250]], "entity_2_idx_in_text_with_entity_marker": [260, 263], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p21", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds [E1]Fas[/E1] and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-[E2]LPR[/E2] and Fas-FD8.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[134, 137]], "entity_1_idx_in_text_with_entity_marker": [138, 141], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LPR", "entity_2_idx": [[251, 254]], "entity_2_idx_in_text_with_entity_marker": [264, 267], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p22", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds [E1]Fas[/E1] and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and [E2]Fas[/E2]-FD8.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[134, 137]], "entity_1_idx_in_text_with_entity_marker": [138, 141], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[259, 262]], "entity_2_idx_in_text_with_entity_marker": [272, 275], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p23", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds [E1]Fas[/E1] and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-[E2]FD8[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[134, 137]], "entity_1_idx_in_text_with_entity_marker": [138, 141], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FD8", "entity_2_idx": [[263, 266]], "entity_2_idx_in_text_with_entity_marker": [276, 279], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p24", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and [E1]Fas[/E1]-[E2]FD5[/E2], a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[142, 145]], "entity_1_idx_in_text_with_entity_marker": [146, 149], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FD5", "entity_2_idx": [[146, 149]], "entity_2_idx_in_text_with_entity_marker": [159, 162], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p25", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and [E1]Fas[/E1]-FD5, a mutant of [E2]Fas[/E2] possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[142, 145]], "entity_1_idx_in_text_with_entity_marker": [146, 149], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[163, 166]], "entity_2_idx_in_text_with_entity_marker": [176, 179], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p26", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and [E1]Fas[/E1]-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants [E2]Fas[/E2]-LPR and Fas-FD8.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[142, 145]], "entity_1_idx_in_text_with_entity_marker": [146, 149], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[247, 250]], "entity_2_idx_in_text_with_entity_marker": [260, 263], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p27", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and [E1]Fas[/E1]-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-[E2]LPR[/E2] and Fas-FD8.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[142, 145]], "entity_1_idx_in_text_with_entity_marker": [146, 149], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LPR", "entity_2_idx": [[251, 254]], "entity_2_idx_in_text_with_entity_marker": [264, 267], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p28", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and [E1]Fas[/E1]-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and [E2]Fas[/E2]-FD8.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[142, 145]], "entity_1_idx_in_text_with_entity_marker": [146, 149], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[259, 262]], "entity_2_idx_in_text_with_entity_marker": [272, 275], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p29", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and [E1]Fas[/E1]-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-[E2]FD8[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[142, 145]], "entity_1_idx_in_text_with_entity_marker": [146, 149], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FD8", "entity_2_idx": [[263, 266]], "entity_2_idx_in_text_with_entity_marker": [276, 279], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p30", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-[E1]FD5[/E1], a mutant of [E2]Fas[/E2] possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FD5", "entity_1_idx": [[146, 149]], "entity_1_idx_in_text_with_entity_marker": [150, 153], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[163, 166]], "entity_2_idx_in_text_with_entity_marker": [176, 179], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p31", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-[E1]FD5[/E1], a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants [E2]Fas[/E2]-LPR and Fas-FD8.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FD5", "entity_1_idx": [[146, 149]], "entity_1_idx_in_text_with_entity_marker": [150, 153], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[247, 250]], "entity_2_idx_in_text_with_entity_marker": [260, 263], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p32", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-[E1]FD5[/E1], a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-[E2]LPR[/E2] and Fas-FD8.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FD5", "entity_1_idx": [[146, 149]], "entity_1_idx_in_text_with_entity_marker": [150, 153], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LPR", "entity_2_idx": [[251, 254]], "entity_2_idx_in_text_with_entity_marker": [264, 267], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p33", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-[E1]FD5[/E1], a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and [E2]Fas[/E2]-FD8.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FD5", "entity_1_idx": [[146, 149]], "entity_1_idx_in_text_with_entity_marker": [150, 153], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[259, 262]], "entity_2_idx_in_text_with_entity_marker": [272, 275], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p34", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-[E1]FD5[/E1], a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-[E2]FD8[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FD5", "entity_1_idx": [[146, 149]], "entity_1_idx_in_text_with_entity_marker": [150, 153], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FD8", "entity_2_idx": [[263, 266]], "entity_2_idx_in_text_with_entity_marker": [276, 279], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p35", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of [E1]Fas[/E1] possessing enhanced killing activity, but not the functionally inactive mutants [E2]Fas[/E2]-LPR and Fas-FD8.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[163, 166]], "entity_1_idx_in_text_with_entity_marker": [167, 170], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[247, 250]], "entity_2_idx_in_text_with_entity_marker": [260, 263], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p36", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of [E1]Fas[/E1] possessing enhanced killing activity, but not the functionally inactive mutants Fas-[E2]LPR[/E2] and Fas-FD8.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[163, 166]], "entity_1_idx_in_text_with_entity_marker": [167, 170], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LPR", "entity_2_idx": [[251, 254]], "entity_2_idx_in_text_with_entity_marker": [264, 267], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p37", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of [E1]Fas[/E1] possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and [E2]Fas[/E2]-FD8.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[163, 166]], "entity_1_idx_in_text_with_entity_marker": [167, 170], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[259, 262]], "entity_2_idx_in_text_with_entity_marker": [272, 275], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p38", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of [E1]Fas[/E1] possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-[E2]FD8[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[163, 166]], "entity_1_idx_in_text_with_entity_marker": [167, 170], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FD8", "entity_2_idx": [[263, 266]], "entity_2_idx_in_text_with_entity_marker": [276, 279], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p39", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants [E1]Fas[/E1]-[E2]LPR[/E2] and Fas-FD8.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[247, 250]], "entity_1_idx_in_text_with_entity_marker": [251, 254], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LPR", "entity_2_idx": [[251, 254]], "entity_2_idx_in_text_with_entity_marker": [264, 267], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p40", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants [E1]Fas[/E1]-LPR and [E2]Fas[/E2]-FD8.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[247, 250]], "entity_1_idx_in_text_with_entity_marker": [251, 254], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[259, 262]], "entity_2_idx_in_text_with_entity_marker": [272, 275], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p41", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants [E1]Fas[/E1]-LPR and Fas-[E2]FD8[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[247, 250]], "entity_1_idx_in_text_with_entity_marker": [251, 254], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FD8", "entity_2_idx": [[263, 266]], "entity_2_idx_in_text_with_entity_marker": [276, 279], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p42", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-[E1]LPR[/E1] and [E2]Fas[/E2]-FD8.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LPR", "entity_1_idx": [[251, 254]], "entity_1_idx_in_text_with_entity_marker": [255, 258], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[259, 262]], "entity_2_idx_in_text_with_entity_marker": [272, 275], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p43", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-[E1]LPR[/E1] and Fas-[E2]FD8[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LPR", "entity_1_idx": [[251, 254]], "entity_1_idx_in_text_with_entity_marker": [255, 258], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FD8", "entity_2_idx": [[263, 266]], "entity_2_idx_in_text_with_entity_marker": [276, 279], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p44", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and [E1]Fas[/E1]-[E2]FD8[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[259, 262]], "entity_1_idx_in_text_with_entity_marker": [263, 266], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FD8", "entity_2_idx": [[263, 266]], "entity_2_idx_in_text_with_entity_marker": [276, 279], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s684_AIMed.d80.s684.p0", "text": "FADD contains a death domain homologous to the death domains of Fas and TNFR-1.", "text_with_entity_marker": "[E1]FADD[/E1] contains a death domain homologous to the death domains of [E2]Fas[/E2] and TNFR-1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FADD", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[64, 67]], "entity_2_idx_in_text_with_entity_marker": [77, 80], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s684_AIMed.d80.s684.p1", "text": "FADD contains a death domain homologous to the death domains of Fas and TNFR-1.", "text_with_entity_marker": "[E1]FADD[/E1] contains a death domain homologous to the death domains of Fas and [E2]TNFR-1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FADD", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNFR-1", "entity_2_idx": [[72, 78]], "entity_2_idx_in_text_with_entity_marker": [85, 91], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s684_AIMed.d80.s684.p2", "text": "FADD contains a death domain homologous to the death domains of Fas and TNFR-1.", "text_with_entity_marker": "FADD contains a death domain homologous to the death domains of [E1]Fas[/E1] and [E2]TNFR-1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[64, 67]], "entity_1_idx_in_text_with_entity_marker": [68, 71], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNFR-1", "entity_2_idx": [[72, 78]], "entity_2_idx_in_text_with_entity_marker": [85, 91], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s685_AIMed.d80.s685.p0", "text": "A point mutation in FADD, analogous to the lpr mutation of Fas, abolishes its ability to bind Fas, suggesting a death domain to death domain interaction.", "text_with_entity_marker": "A point mutation in [E1]FADD[/E1], analogous to the lpr mutation of [E2]Fas[/E2], abolishes its ability to bind Fas, suggesting a death domain to death domain interaction.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FADD", "entity_1_idx": [[20, 24]], "entity_1_idx_in_text_with_entity_marker": [24, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[59, 62]], "entity_2_idx_in_text_with_entity_marker": [72, 75], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s685_AIMed.d80.s685.p1", "text": "A point mutation in FADD, analogous to the lpr mutation of Fas, abolishes its ability to bind Fas, suggesting a death domain to death domain interaction.", "text_with_entity_marker": "A point mutation in [E1]FADD[/E1], analogous to the lpr mutation of Fas, abolishes its ability to bind [E2]Fas[/E2], suggesting a death domain to death domain interaction.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FADD", "entity_1_idx": [[20, 24]], "entity_1_idx_in_text_with_entity_marker": [24, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[94, 97]], "entity_2_idx_in_text_with_entity_marker": [107, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s685_AIMed.d80.s685.p2", "text": "A point mutation in FADD, analogous to the lpr mutation of Fas, abolishes its ability to bind Fas, suggesting a death domain to death domain interaction.", "text_with_entity_marker": "A point mutation in FADD, analogous to the lpr mutation of [E1]Fas[/E1], abolishes its ability to bind [E2]Fas[/E2], suggesting a death domain to death domain interaction.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[59, 62]], "entity_1_idx_in_text_with_entity_marker": [63, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[94, 97]], "entity_2_idx_in_text_with_entity_marker": [107, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s686_AIMed.d80.s686.p0", "text": "Overexpression of FADD in MCF7 and BJAB cells induces apoptosis, which, like Fas-induced apoptosis, is blocked by CrmA, a specific inhibitor of the interleukin-1 beta-converting enzyme.", "text_with_entity_marker": "Overexpression of [E1]FADD[/E1] in MCF7 and BJAB cells induces apoptosis, which, like [E2]Fas[/E2]-induced apoptosis, is blocked by CrmA, a specific inhibitor of the interleukin-1 beta-converting enzyme.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FADD", "entity_1_idx": [[18, 22]], "entity_1_idx_in_text_with_entity_marker": [22, 26], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[77, 80]], "entity_2_idx_in_text_with_entity_marker": [90, 93], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s686_AIMed.d80.s686.p1", "text": "Overexpression of FADD in MCF7 and BJAB cells induces apoptosis, which, like Fas-induced apoptosis, is blocked by CrmA, a specific inhibitor of the interleukin-1 beta-converting enzyme.", "text_with_entity_marker": "Overexpression of [E1]FADD[/E1] in MCF7 and BJAB cells induces apoptosis, which, like Fas-induced apoptosis, is blocked by [E2]CrmA[/E2], a specific inhibitor of the interleukin-1 beta-converting enzyme.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FADD", "entity_1_idx": [[18, 22]], "entity_1_idx_in_text_with_entity_marker": [22, 26], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CrmA", "entity_2_idx": [[114, 118]], "entity_2_idx_in_text_with_entity_marker": [127, 131], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s686_AIMed.d80.s686.p2", "text": "Overexpression of FADD in MCF7 and BJAB cells induces apoptosis, which, like Fas-induced apoptosis, is blocked by CrmA, a specific inhibitor of the interleukin-1 beta-converting enzyme.", "text_with_entity_marker": "Overexpression of [E1]FADD[/E1] in MCF7 and BJAB cells induces apoptosis, which, like Fas-induced apoptosis, is blocked by CrmA, a specific inhibitor of the [E2]interleukin-1 beta[/E2]-converting enzyme.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FADD", "entity_1_idx": [[18, 22]], "entity_1_idx_in_text_with_entity_marker": [22, 26], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin-1 beta", "entity_2_idx": [[148, 166]], "entity_2_idx_in_text_with_entity_marker": [161, 179], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s686_AIMed.d80.s686.p3", "text": "Overexpression of FADD in MCF7 and BJAB cells induces apoptosis, which, like Fas-induced apoptosis, is blocked by CrmA, a specific inhibitor of the interleukin-1 beta-converting enzyme.", "text_with_entity_marker": "Overexpression of [E1]FADD[/E1] in MCF7 and BJAB cells induces apoptosis, which, like Fas-induced apoptosis, is blocked by CrmA, a specific inhibitor of the [E2]interleukin-1 beta-converting enzyme[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FADD", "entity_1_idx": [[18, 22]], "entity_1_idx_in_text_with_entity_marker": [22, 26], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin-1 beta-converting enzyme", "entity_2_idx": [[148, 184]], "entity_2_idx_in_text_with_entity_marker": [161, 197], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s686_AIMed.d80.s686.p4", "text": "Overexpression of FADD in MCF7 and BJAB cells induces apoptosis, which, like Fas-induced apoptosis, is blocked by CrmA, a specific inhibitor of the interleukin-1 beta-converting enzyme.", "text_with_entity_marker": "Overexpression of FADD in MCF7 and BJAB cells induces apoptosis, which, like [E1]Fas[/E1]-induced apoptosis, is blocked by [E2]CrmA[/E2], a specific inhibitor of the interleukin-1 beta-converting enzyme.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[77, 80]], "entity_1_idx_in_text_with_entity_marker": [81, 84], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CrmA", "entity_2_idx": [[114, 118]], "entity_2_idx_in_text_with_entity_marker": [127, 131], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s686_AIMed.d80.s686.p5", "text": "Overexpression of FADD in MCF7 and BJAB cells induces apoptosis, which, like Fas-induced apoptosis, is blocked by CrmA, a specific inhibitor of the interleukin-1 beta-converting enzyme.", "text_with_entity_marker": "Overexpression of FADD in MCF7 and BJAB cells induces apoptosis, which, like [E1]Fas[/E1]-induced apoptosis, is blocked by CrmA, a specific inhibitor of the [E2]interleukin-1 beta[/E2]-converting enzyme.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[77, 80]], "entity_1_idx_in_text_with_entity_marker": [81, 84], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin-1 beta", "entity_2_idx": [[148, 166]], "entity_2_idx_in_text_with_entity_marker": [161, 179], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s686_AIMed.d80.s686.p6", "text": "Overexpression of FADD in MCF7 and BJAB cells induces apoptosis, which, like Fas-induced apoptosis, is blocked by CrmA, a specific inhibitor of the interleukin-1 beta-converting enzyme.", "text_with_entity_marker": "Overexpression of FADD in MCF7 and BJAB cells induces apoptosis, which, like [E1]Fas[/E1]-induced apoptosis, is blocked by CrmA, a specific inhibitor of the [E2]interleukin-1 beta-converting enzyme[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[77, 80]], "entity_1_idx_in_text_with_entity_marker": [81, 84], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin-1 beta-converting enzyme", "entity_2_idx": [[148, 184]], "entity_2_idx_in_text_with_entity_marker": [161, 197], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s686_AIMed.d80.s686.p7", "text": "Overexpression of FADD in MCF7 and BJAB cells induces apoptosis, which, like Fas-induced apoptosis, is blocked by CrmA, a specific inhibitor of the interleukin-1 beta-converting enzyme.", "text_with_entity_marker": "Overexpression of FADD in MCF7 and BJAB cells induces apoptosis, which, like Fas-induced apoptosis, is blocked by [E1]CrmA[/E1], a specific inhibitor of the [E2]interleukin-1 beta[/E2]-converting enzyme.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CrmA", "entity_1_idx": [[114, 118]], "entity_1_idx_in_text_with_entity_marker": [118, 122], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin-1 beta", "entity_2_idx": [[148, 166]], "entity_2_idx_in_text_with_entity_marker": [161, 179], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s686_AIMed.d80.s686.p8", "text": "Overexpression of FADD in MCF7 and BJAB cells induces apoptosis, which, like Fas-induced apoptosis, is blocked by CrmA, a specific inhibitor of the interleukin-1 beta-converting enzyme.", "text_with_entity_marker": "Overexpression of FADD in MCF7 and BJAB cells induces apoptosis, which, like Fas-induced apoptosis, is blocked by [E1]CrmA[/E1], a specific inhibitor of the [E2]interleukin-1 beta-converting enzyme[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CrmA", "entity_1_idx": [[114, 118]], "entity_1_idx_in_text_with_entity_marker": [118, 122], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin-1 beta-converting enzyme", "entity_2_idx": [[148, 184]], "entity_2_idx_in_text_with_entity_marker": [161, 197], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s686_AIMed.d80.s686.p9", "text": "Overexpression of FADD in MCF7 and BJAB cells induces apoptosis, which, like Fas-induced apoptosis, is blocked by CrmA, a specific inhibitor of the interleukin-1 beta-converting enzyme.", "text_with_entity_marker": "Overexpression of FADD in MCF7 and BJAB cells induces apoptosis, which, like Fas-induced apoptosis, is blocked by CrmA, a specific inhibitor of the [E1-E2]interleukin-1 beta[/E1]-converting enzyme[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin-1 beta", "entity_1_idx": [[148, 166]], "entity_1_idx_in_text_with_entity_marker": [155, 173], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin-1 beta[/E1]-converting enzyme", "entity_2_idx": [[148, 184]], "entity_2_idx_in_text_with_entity_marker": [155, 196], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s687_AIMed.d80.s687.p0", "text": "These findings suggest that FADD may play an important role in the proximal signal transduction of Fas.", "text_with_entity_marker": "These findings suggest that [E1]FADD[/E1] may play an important role in the proximal signal transduction of [E2]Fas[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FADD", "entity_1_idx": [[28, 32]], "entity_1_idx_in_text_with_entity_marker": [32, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[99, 102]], "entity_2_idx_in_text_with_entity_marker": [112, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1084_AIMed.d127.s1084.p0", "text": "Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID.", "text_with_entity_marker": "Interaction of [E1]IL-2R beta[/E1] and gamma c chains with [E2]Jak1[/E2] and Jak3: implications for XSCID and XCID.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-2R beta", "entity_1_idx": [[15, 25]], "entity_1_idx_in_text_with_entity_marker": [19, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jak1", "entity_2_idx": [[50, 54]], "entity_2_idx_in_text_with_entity_marker": [63, 67], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1084_AIMed.d127.s1084.p1", "text": "Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID.", "text_with_entity_marker": "Interaction of [E1]IL-2R beta[/E1] and gamma c chains with Jak1 and [E2]Jak3[/E2]: implications for XSCID and XCID.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-2R beta", "entity_1_idx": [[15, 25]], "entity_1_idx_in_text_with_entity_marker": [19, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jak3", "entity_2_idx": [[59, 63]], "entity_2_idx_in_text_with_entity_marker": [72, 76], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1084_AIMed.d127.s1084.p2", "text": "Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID.", "text_with_entity_marker": "Interaction of IL-2R beta and gamma c chains with [E1]Jak1[/E1] and [E2]Jak3[/E2]: implications for XSCID and XCID.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Jak1", "entity_1_idx": [[50, 54]], "entity_1_idx_in_text_with_entity_marker": [54, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jak3", "entity_2_idx": [[59, 63]], "entity_2_idx_in_text_with_entity_marker": [72, 76], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1085_AIMed.d127.s1085.p0", "text": "Interleukin-2 (IL-2) signaling requires the dimerization of the IL-2 receptor beta.(IL-2R beta) and common gamma (gamma c) chains.", "text_with_entity_marker": "[E1]Interleukin-2[/E1] ([E2]IL-2[/E2]) signaling requires the dimerization of the IL-2 receptor beta.(IL-2R beta) and common gamma (gamma c) chains.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Interleukin-2", "entity_1_idx": [[0, 13]], "entity_1_idx_in_text_with_entity_marker": [4, 17], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2", "entity_2_idx": [[15, 19]], "entity_2_idx_in_text_with_entity_marker": [28, 32], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1085_AIMed.d127.s1085.p1", "text": "Interleukin-2 (IL-2) signaling requires the dimerization of the IL-2 receptor beta.(IL-2R beta) and common gamma (gamma c) chains.", "text_with_entity_marker": "[E1]Interleukin-2[/E1] (IL-2) signaling requires the dimerization of the [E2]IL-2[/E2] receptor beta.(IL-2R beta) and common gamma (gamma c) chains.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Interleukin-2", "entity_1_idx": [[0, 13]], "entity_1_idx_in_text_with_entity_marker": [4, 17], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2", "entity_2_idx": [[64, 68]], "entity_2_idx_in_text_with_entity_marker": [77, 81], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1085_AIMed.d127.s1085.p2", "text": "Interleukin-2 (IL-2) signaling requires the dimerization of the IL-2 receptor beta.(IL-2R beta) and common gamma (gamma c) chains.", "text_with_entity_marker": "[E1]Interleukin-2[/E1] (IL-2) signaling requires the dimerization of the [E2]IL-2 receptor beta[/E2].(IL-2R beta) and common gamma (gamma c) chains.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Interleukin-2", "entity_1_idx": [[0, 13]], "entity_1_idx_in_text_with_entity_marker": [4, 17], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2 receptor beta", "entity_2_idx": [[64, 82]], "entity_2_idx_in_text_with_entity_marker": [77, 95], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1085_AIMed.d127.s1085.p3", "text": "Interleukin-2 (IL-2) signaling requires the dimerization of the IL-2 receptor beta.(IL-2R beta) and common gamma (gamma c) chains.", "text_with_entity_marker": "[E1]Interleukin-2[/E1] (IL-2) signaling requires the dimerization of the IL-2 receptor beta.([E2]IL-2R beta[/E2]) and common gamma (gamma c) chains.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Interleukin-2", "entity_1_idx": [[0, 13]], "entity_1_idx_in_text_with_entity_marker": [4, 17], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2R beta", "entity_2_idx": [[84, 94]], "entity_2_idx_in_text_with_entity_marker": [97, 107], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1085_AIMed.d127.s1085.p4", "text": "Interleukin-2 (IL-2) signaling requires the dimerization of the IL-2 receptor beta.(IL-2R beta) and common gamma (gamma c) chains.", "text_with_entity_marker": "Interleukin-2 ([E1]IL-2[/E1]) signaling requires the dimerization of the [E2]IL-2[/E2] receptor beta.(IL-2R beta) and common gamma (gamma c) chains.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2", "entity_1_idx": [[15, 19]], "entity_1_idx_in_text_with_entity_marker": [19, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2", "entity_2_idx": [[64, 68]], "entity_2_idx_in_text_with_entity_marker": [77, 81], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1085_AIMed.d127.s1085.p5", "text": "Interleukin-2 (IL-2) signaling requires the dimerization of the IL-2 receptor beta.(IL-2R beta) and common gamma (gamma c) chains.", "text_with_entity_marker": "Interleukin-2 ([E1]IL-2[/E1]) signaling requires the dimerization of the [E2]IL-2 receptor beta[/E2].(IL-2R beta) and common gamma (gamma c) chains.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2", "entity_1_idx": [[15, 19]], "entity_1_idx_in_text_with_entity_marker": [19, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2 receptor beta", "entity_2_idx": [[64, 82]], "entity_2_idx_in_text_with_entity_marker": [77, 95], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1085_AIMed.d127.s1085.p6", "text": "Interleukin-2 (IL-2) signaling requires the dimerization of the IL-2 receptor beta.(IL-2R beta) and common gamma (gamma c) chains.", "text_with_entity_marker": "Interleukin-2 ([E1]IL-2[/E1]) signaling requires the dimerization of the IL-2 receptor beta.([E2]IL-2R beta[/E2]) and common gamma (gamma c) chains.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2", "entity_1_idx": [[15, 19]], "entity_1_idx_in_text_with_entity_marker": [19, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2R beta", "entity_2_idx": [[84, 94]], "entity_2_idx_in_text_with_entity_marker": [97, 107], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1085_AIMed.d127.s1085.p7", "text": "Interleukin-2 (IL-2) signaling requires the dimerization of the IL-2 receptor beta.(IL-2R beta) and common gamma (gamma c) chains.", "text_with_entity_marker": "Interleukin-2 (IL-2) signaling requires the dimerization of the [E1-E2]IL-2[/E1] receptor beta[/E2].(IL-2R beta) and common gamma (gamma c) chains.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2", "entity_1_idx": [[64, 68]], "entity_1_idx_in_text_with_entity_marker": [71, 75], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2[/E1] receptor beta", "entity_2_idx": [[64, 82]], "entity_2_idx_in_text_with_entity_marker": [71, 94], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1085_AIMed.d127.s1085.p8", "text": "Interleukin-2 (IL-2) signaling requires the dimerization of the IL-2 receptor beta.(IL-2R beta) and common gamma (gamma c) chains.", "text_with_entity_marker": "Interleukin-2 (IL-2) signaling requires the dimerization of the [E1]IL-2[/E1] receptor beta.([E2]IL-2R beta[/E2]) and common gamma (gamma c) chains.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2", "entity_1_idx": [[64, 68]], "entity_1_idx_in_text_with_entity_marker": [68, 72], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2R beta", "entity_2_idx": [[84, 94]], "entity_2_idx_in_text_with_entity_marker": [97, 107], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1085_AIMed.d127.s1085.p9", "text": "Interleukin-2 (IL-2) signaling requires the dimerization of the IL-2 receptor beta.(IL-2R beta) and common gamma (gamma c) chains.", "text_with_entity_marker": "Interleukin-2 (IL-2) signaling requires the dimerization of the [E1]IL-2 receptor beta[/E1].([E2]IL-2R beta[/E2]) and common gamma (gamma c) chains.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2 receptor beta", "entity_1_idx": [[64, 82]], "entity_1_idx_in_text_with_entity_marker": [68, 86], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2R beta", "entity_2_idx": [[84, 94]], "entity_2_idx_in_text_with_entity_marker": [97, 107], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1087_AIMed.d127.s1087.p0", "text": "IL-2, IL-4, IL-7 (whose receptors are known to contain gamma c), and IL-9 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3.", "text_with_entity_marker": "[E1]IL-2[/E1], [E2]IL-4[/E2], IL-7 (whose receptors are known to contain gamma c), and IL-9 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-4", "entity_2_idx": [[6, 10]], "entity_2_idx_in_text_with_entity_marker": [19, 23], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1087_AIMed.d127.s1087.p1", "text": "IL-2, IL-4, IL-7 (whose receptors are known to contain gamma c), and IL-9 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3.", "text_with_entity_marker": "[E1]IL-2[/E1], IL-4, [E2]IL-7[/E2] (whose receptors are known to contain gamma c), and IL-9 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7", "entity_2_idx": [[12, 16]], "entity_2_idx_in_text_with_entity_marker": [25, 29], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1087_AIMed.d127.s1087.p2", "text": "IL-2, IL-4, IL-7 (whose receptors are known to contain gamma c), and IL-9 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3.", "text_with_entity_marker": "[E1]IL-2[/E1], IL-4, IL-7 (whose receptors are known to contain gamma c), and [E2]IL-9[/E2] (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-9", "entity_2_idx": [[69, 73]], "entity_2_idx_in_text_with_entity_marker": [82, 86], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1087_AIMed.d127.s1087.p3", "text": "IL-2, IL-4, IL-7 (whose receptors are known to contain gamma c), and IL-9 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3.", "text_with_entity_marker": "[E1]IL-2[/E1], IL-4, IL-7 (whose receptors are known to contain gamma c), and IL-9 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases [E2]Jak1[/E2] and Jak3.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jak1", "entity_2_idx": [[213, 217]], "entity_2_idx_in_text_with_entity_marker": [226, 230], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1087_AIMed.d127.s1087.p4", "text": "IL-2, IL-4, IL-7 (whose receptors are known to contain gamma c), and IL-9 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3.", "text_with_entity_marker": "[E1]IL-2[/E1], IL-4, IL-7 (whose receptors are known to contain gamma c), and IL-9 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and [E2]Jak3[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jak3", "entity_2_idx": [[222, 226]], "entity_2_idx_in_text_with_entity_marker": [235, 239], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1087_AIMed.d127.s1087.p5", "text": "IL-2, IL-4, IL-7 (whose receptors are known to contain gamma c), and IL-9 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3.", "text_with_entity_marker": "IL-2, [E1]IL-4[/E1], [E2]IL-7[/E2] (whose receptors are known to contain gamma c), and IL-9 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-4", "entity_1_idx": [[6, 10]], "entity_1_idx_in_text_with_entity_marker": [10, 14], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7", "entity_2_idx": [[12, 16]], "entity_2_idx_in_text_with_entity_marker": [25, 29], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1087_AIMed.d127.s1087.p6", "text": "IL-2, IL-4, IL-7 (whose receptors are known to contain gamma c), and IL-9 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3.", "text_with_entity_marker": "IL-2, [E1]IL-4[/E1], IL-7 (whose receptors are known to contain gamma c), and [E2]IL-9[/E2] (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-4", "entity_1_idx": [[6, 10]], "entity_1_idx_in_text_with_entity_marker": [10, 14], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-9", "entity_2_idx": [[69, 73]], "entity_2_idx_in_text_with_entity_marker": [82, 86], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1087_AIMed.d127.s1087.p7", "text": "IL-2, IL-4, IL-7 (whose receptors are known to contain gamma c), and IL-9 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3.", "text_with_entity_marker": "IL-2, [E1]IL-4[/E1], IL-7 (whose receptors are known to contain gamma c), and IL-9 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases [E2]Jak1[/E2] and Jak3.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-4", "entity_1_idx": [[6, 10]], "entity_1_idx_in_text_with_entity_marker": [10, 14], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jak1", "entity_2_idx": [[213, 217]], "entity_2_idx_in_text_with_entity_marker": [226, 230], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1087_AIMed.d127.s1087.p8", "text": "IL-2, IL-4, IL-7 (whose receptors are known to contain gamma c), and IL-9 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3.", "text_with_entity_marker": "IL-2, [E1]IL-4[/E1], IL-7 (whose receptors are known to contain gamma c), and IL-9 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and [E2]Jak3[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-4", "entity_1_idx": [[6, 10]], "entity_1_idx_in_text_with_entity_marker": [10, 14], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jak3", "entity_2_idx": [[222, 226]], "entity_2_idx_in_text_with_entity_marker": [235, 239], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1087_AIMed.d127.s1087.p9", "text": "IL-2, IL-4, IL-7 (whose receptors are known to contain gamma c), and IL-9 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3.", "text_with_entity_marker": "IL-2, IL-4, [E1]IL-7[/E1] (whose receptors are known to contain gamma c), and [E2]IL-9[/E2] (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7", "entity_1_idx": [[12, 16]], "entity_1_idx_in_text_with_entity_marker": [16, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-9", "entity_2_idx": [[69, 73]], "entity_2_idx_in_text_with_entity_marker": [82, 86], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1087_AIMed.d127.s1087.p10", "text": "IL-2, IL-4, IL-7 (whose receptors are known to contain gamma c), and IL-9 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3.", "text_with_entity_marker": "IL-2, IL-4, [E1]IL-7[/E1] (whose receptors are known to contain gamma c), and IL-9 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases [E2]Jak1[/E2] and Jak3.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7", "entity_1_idx": [[12, 16]], "entity_1_idx_in_text_with_entity_marker": [16, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jak1", "entity_2_idx": [[213, 217]], "entity_2_idx_in_text_with_entity_marker": [226, 230], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1087_AIMed.d127.s1087.p11", "text": "IL-2, IL-4, IL-7 (whose receptors are known to contain gamma c), and IL-9 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3.", "text_with_entity_marker": "IL-2, IL-4, [E1]IL-7[/E1] (whose receptors are known to contain gamma c), and IL-9 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and [E2]Jak3[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-7", "entity_1_idx": [[12, 16]], "entity_1_idx_in_text_with_entity_marker": [16, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jak3", "entity_2_idx": [[222, 226]], "entity_2_idx_in_text_with_entity_marker": [235, 239], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1087_AIMed.d127.s1087.p12", "text": "IL-2, IL-4, IL-7 (whose receptors are known to contain gamma c), and IL-9 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3.", "text_with_entity_marker": "IL-2, IL-4, IL-7 (whose receptors are known to contain gamma c), and [E1]IL-9[/E1] (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases [E2]Jak1[/E2] and Jak3.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-9", "entity_1_idx": [[69, 73]], "entity_1_idx_in_text_with_entity_marker": [73, 77], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jak1", "entity_2_idx": [[213, 217]], "entity_2_idx_in_text_with_entity_marker": [226, 230], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1087_AIMed.d127.s1087.p13", "text": "IL-2, IL-4, IL-7 (whose receptors are known to contain gamma c), and IL-9 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3.", "text_with_entity_marker": "IL-2, IL-4, IL-7 (whose receptors are known to contain gamma c), and [E1]IL-9[/E1] (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and [E2]Jak3[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-9", "entity_1_idx": [[69, 73]], "entity_1_idx_in_text_with_entity_marker": [73, 77], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jak3", "entity_2_idx": [[222, 226]], "entity_2_idx_in_text_with_entity_marker": [235, 239], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1087_AIMed.d127.s1087.p14", "text": "IL-2, IL-4, IL-7 (whose receptors are known to contain gamma c), and IL-9 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3.", "text_with_entity_marker": "IL-2, IL-4, IL-7 (whose receptors are known to contain gamma c), and IL-9 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases [E1]Jak1[/E1] and [E2]Jak3[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Jak1", "entity_1_idx": [[213, 217]], "entity_1_idx_in_text_with_entity_marker": [217, 221], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jak3", "entity_2_idx": [[222, 226]], "entity_2_idx_in_text_with_entity_marker": [235, 239], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1088_AIMed.d127.s1088.p0", "text": "Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.", "text_with_entity_marker": "[E1]Jak1[/E1] and [E2]Jak3[/E2] associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Jak1", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jak3", "entity_2_idx": [[9, 13]], "entity_2_idx_in_text_with_entity_marker": [22, 26], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1088_AIMed.d127.s1088.p1", "text": "Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.", "text_with_entity_marker": "[E1]Jak1[/E1] and Jak3 associated with [E2]IL-2R beta[/E2] and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Jak1", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2R beta", "entity_2_idx": [[30, 40]], "entity_2_idx_in_text_with_entity_marker": [43, 53], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1088_AIMed.d127.s1088.p2", "text": "Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.", "text_with_entity_marker": "[E1]Jak1[/E1] and Jak3 associated with IL-2R beta and gamma c, respectively; [E2]IL-2[/E2] induced Jak3-IL-2R beta and increased Jak3-gamma c associations.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Jak1", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2", "entity_2_idx": [[68, 72]], "entity_2_idx_in_text_with_entity_marker": [81, 85], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1088_AIMed.d127.s1088.p3", "text": "Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.", "text_with_entity_marker": "[E1]Jak1[/E1] and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced [E2]Jak3[/E2]-IL-2R beta and increased Jak3-gamma c associations.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Jak1", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jak3", "entity_2_idx": [[81, 85]], "entity_2_idx_in_text_with_entity_marker": [94, 98], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1088_AIMed.d127.s1088.p4", "text": "Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.", "text_with_entity_marker": "[E1]Jak1[/E1] and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-[E2]IL-2R beta[/E2] and increased Jak3-gamma c associations.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Jak1", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2R beta", "entity_2_idx": [[86, 96]], "entity_2_idx_in_text_with_entity_marker": [99, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1088_AIMed.d127.s1088.p5", "text": "Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.", "text_with_entity_marker": "[E1]Jak1[/E1] and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased [E2]Jak3[/E2]-gamma c associations.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Jak1", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jak3", "entity_2_idx": [[111, 115]], "entity_2_idx_in_text_with_entity_marker": [124, 128], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1088_AIMed.d127.s1088.p6", "text": "Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.", "text_with_entity_marker": "Jak1 and [E1]Jak3[/E1] associated with [E2]IL-2R beta[/E2] and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Jak3", "entity_1_idx": [[9, 13]], "entity_1_idx_in_text_with_entity_marker": [13, 17], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2R beta", "entity_2_idx": [[30, 40]], "entity_2_idx_in_text_with_entity_marker": [43, 53], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1088_AIMed.d127.s1088.p7", "text": "Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.", "text_with_entity_marker": "Jak1 and [E1]Jak3[/E1] associated with IL-2R beta and gamma c, respectively; [E2]IL-2[/E2] induced Jak3-IL-2R beta and increased Jak3-gamma c associations.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Jak3", "entity_1_idx": [[9, 13]], "entity_1_idx_in_text_with_entity_marker": [13, 17], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2", "entity_2_idx": [[68, 72]], "entity_2_idx_in_text_with_entity_marker": [81, 85], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1088_AIMed.d127.s1088.p8", "text": "Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.", "text_with_entity_marker": "Jak1 and [E1]Jak3[/E1] associated with IL-2R beta and gamma c, respectively; IL-2 induced [E2]Jak3[/E2]-IL-2R beta and increased Jak3-gamma c associations.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Jak3", "entity_1_idx": [[9, 13]], "entity_1_idx_in_text_with_entity_marker": [13, 17], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jak3", "entity_2_idx": [[81, 85]], "entity_2_idx_in_text_with_entity_marker": [94, 98], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1088_AIMed.d127.s1088.p9", "text": "Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.", "text_with_entity_marker": "Jak1 and [E1]Jak3[/E1] associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-[E2]IL-2R beta[/E2] and increased Jak3-gamma c associations.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Jak3", "entity_1_idx": [[9, 13]], "entity_1_idx_in_text_with_entity_marker": [13, 17], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2R beta", "entity_2_idx": [[86, 96]], "entity_2_idx_in_text_with_entity_marker": [99, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1088_AIMed.d127.s1088.p10", "text": "Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.", "text_with_entity_marker": "Jak1 and [E1]Jak3[/E1] associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased [E2]Jak3[/E2]-gamma c associations.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Jak3", "entity_1_idx": [[9, 13]], "entity_1_idx_in_text_with_entity_marker": [13, 17], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jak3", "entity_2_idx": [[111, 115]], "entity_2_idx_in_text_with_entity_marker": [124, 128], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1088_AIMed.d127.s1088.p11", "text": "Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.", "text_with_entity_marker": "Jak1 and Jak3 associated with [E1]IL-2R beta[/E1] and gamma c, respectively; [E2]IL-2[/E2] induced Jak3-IL-2R beta and increased Jak3-gamma c associations.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2R beta", "entity_1_idx": [[30, 40]], "entity_1_idx_in_text_with_entity_marker": [34, 44], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2", "entity_2_idx": [[68, 72]], "entity_2_idx_in_text_with_entity_marker": [81, 85], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1088_AIMed.d127.s1088.p12", "text": "Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.", "text_with_entity_marker": "Jak1 and Jak3 associated with [E1]IL-2R beta[/E1] and gamma c, respectively; IL-2 induced [E2]Jak3[/E2]-IL-2R beta and increased Jak3-gamma c associations.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2R beta", "entity_1_idx": [[30, 40]], "entity_1_idx_in_text_with_entity_marker": [34, 44], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jak3", "entity_2_idx": [[81, 85]], "entity_2_idx_in_text_with_entity_marker": [94, 98], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1088_AIMed.d127.s1088.p13", "text": "Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.", "text_with_entity_marker": "Jak1 and Jak3 associated with [E1]IL-2R beta[/E1] and gamma c, respectively; IL-2 induced Jak3-[E2]IL-2R beta[/E2] and increased Jak3-gamma c associations.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2R beta", "entity_1_idx": [[30, 40]], "entity_1_idx_in_text_with_entity_marker": [34, 44], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2R beta", "entity_2_idx": [[86, 96]], "entity_2_idx_in_text_with_entity_marker": [99, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1088_AIMed.d127.s1088.p14", "text": "Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.", "text_with_entity_marker": "Jak1 and Jak3 associated with [E1]IL-2R beta[/E1] and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased [E2]Jak3[/E2]-gamma c associations.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2R beta", "entity_1_idx": [[30, 40]], "entity_1_idx_in_text_with_entity_marker": [34, 44], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jak3", "entity_2_idx": [[111, 115]], "entity_2_idx_in_text_with_entity_marker": [124, 128], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1088_AIMed.d127.s1088.p15", "text": "Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.", "text_with_entity_marker": "Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; [E1]IL-2[/E1] induced [E2]Jak3[/E2]-IL-2R beta and increased Jak3-gamma c associations.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2", "entity_1_idx": [[68, 72]], "entity_1_idx_in_text_with_entity_marker": [72, 76], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jak3", "entity_2_idx": [[81, 85]], "entity_2_idx_in_text_with_entity_marker": [94, 98], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1088_AIMed.d127.s1088.p16", "text": "Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.", "text_with_entity_marker": "Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; [E1]IL-2[/E1] induced Jak3-[E2]IL-2R beta[/E2] and increased Jak3-gamma c associations.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2", "entity_1_idx": [[68, 72]], "entity_1_idx_in_text_with_entity_marker": [72, 76], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2R beta", "entity_2_idx": [[86, 96]], "entity_2_idx_in_text_with_entity_marker": [99, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1088_AIMed.d127.s1088.p17", "text": "Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.", "text_with_entity_marker": "Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; [E1]IL-2[/E1] induced Jak3-IL-2R beta and increased [E2]Jak3[/E2]-gamma c associations.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2", "entity_1_idx": [[68, 72]], "entity_1_idx_in_text_with_entity_marker": [72, 76], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jak3", "entity_2_idx": [[111, 115]], "entity_2_idx_in_text_with_entity_marker": [124, 128], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1088_AIMed.d127.s1088.p18", "text": "Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.", "text_with_entity_marker": "Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced [E1]Jak3[/E1]-[E2]IL-2R beta[/E2] and increased Jak3-gamma c associations.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Jak3", "entity_1_idx": [[81, 85]], "entity_1_idx_in_text_with_entity_marker": [85, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2R beta", "entity_2_idx": [[86, 96]], "entity_2_idx_in_text_with_entity_marker": [99, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1088_AIMed.d127.s1088.p19", "text": "Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.", "text_with_entity_marker": "Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced [E1]Jak3[/E1]-IL-2R beta and increased [E2]Jak3[/E2]-gamma c associations.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Jak3", "entity_1_idx": [[81, 85]], "entity_1_idx_in_text_with_entity_marker": [85, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jak3", "entity_2_idx": [[111, 115]], "entity_2_idx_in_text_with_entity_marker": [124, 128], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1088_AIMed.d127.s1088.p20", "text": "Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-IL-2R beta and increased Jak3-gamma c associations.", "text_with_entity_marker": "Jak1 and Jak3 associated with IL-2R beta and gamma c, respectively; IL-2 induced Jak3-[E1]IL-2R beta[/E1] and increased [E2]Jak3[/E2]-gamma c associations.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2R beta", "entity_1_idx": [[86, 96]], "entity_1_idx_in_text_with_entity_marker": [90, 100], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jak3", "entity_2_idx": [[111, 115]], "entity_2_idx_in_text_with_entity_marker": [124, 128], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d127.s1090_AIMed.d127.s1090.p0", "text": "Thus, gamma c mutations in at least some XSCID and XCID patients prevent normal Jak3 activation, suggesting that mutations of Jak3 may result in an XSCID-like phenotype.", "text_with_entity_marker": "Thus, gamma c mutations in at least some XSCID and XCID patients prevent normal [E1]Jak3[/E1] activation, suggesting that mutations of [E2]Jak3[/E2] may result in an XSCID-like phenotype.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Jak3", "entity_1_idx": [[80, 84]], "entity_1_idx_in_text_with_entity_marker": [84, 88], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jak3", "entity_2_idx": [[126, 130]], "entity_2_idx_in_text_with_entity_marker": [139, 143], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d169.s1424_AIMed.d169.s1424.p0", "text": "Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor alpha chain.", "text_with_entity_marker": "Cloning and characterization of a specific [E1]interleukin (IL)-13[/E1] binding protein structurally related to the [E2]IL-5[/E2] receptor alpha chain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin (IL)-13", "entity_1_idx": [[43, 62]], "entity_1_idx_in_text_with_entity_marker": [47, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-5", "entity_2_idx": [[107, 111]], "entity_2_idx_in_text_with_entity_marker": [120, 124], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d169.s1424_AIMed.d169.s1424.p1", "text": "Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor alpha chain.", "text_with_entity_marker": "Cloning and characterization of a specific [E1]interleukin (IL)-13[/E1] binding protein structurally related to the [E2]IL-5 receptor[/E2] alpha chain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin (IL)-13", "entity_1_idx": [[43, 62]], "entity_1_idx_in_text_with_entity_marker": [47, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-5 receptor", "entity_2_idx": [[107, 120]], "entity_2_idx_in_text_with_entity_marker": [120, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d169.s1424_AIMed.d169.s1424.p2", "text": "Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor alpha chain.", "text_with_entity_marker": "Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the [E1-E2]IL-5[/E1] receptor[/E2] alpha chain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-5", "entity_1_idx": [[107, 111]], "entity_1_idx_in_text_with_entity_marker": [114, 118], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-5[/E1] receptor", "entity_2_idx": [[107, 120]], "entity_2_idx_in_text_with_entity_marker": [114, 132], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d169.s1425_AIMed.d169.s1425.p0", "text": "Interleukin-13 (IL-13) is a cytokine secreted by activated T lymphocytes that shares many, but not all, biological activities with IL-4.", "text_with_entity_marker": "[E1]Interleukin-13[/E1] ([E2]IL-13[/E2]) is a cytokine secreted by activated T lymphocytes that shares many, but not all, biological activities with IL-4.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Interleukin-13", "entity_1_idx": [[0, 14]], "entity_1_idx_in_text_with_entity_marker": [4, 18], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-13", "entity_2_idx": [[16, 21]], "entity_2_idx_in_text_with_entity_marker": [29, 34], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d169.s1425_AIMed.d169.s1425.p1", "text": "Interleukin-13 (IL-13) is a cytokine secreted by activated T lymphocytes that shares many, but not all, biological activities with IL-4.", "text_with_entity_marker": "[E1]Interleukin-13[/E1] (IL-13) is a cytokine secreted by activated T lymphocytes that shares many, but not all, biological activities with [E2]IL-4[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Interleukin-13", "entity_1_idx": [[0, 14]], "entity_1_idx_in_text_with_entity_marker": [4, 18], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-4", "entity_2_idx": [[131, 135]], "entity_2_idx_in_text_with_entity_marker": [144, 148], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d169.s1425_AIMed.d169.s1425.p2", "text": "Interleukin-13 (IL-13) is a cytokine secreted by activated T lymphocytes that shares many, but not all, biological activities with IL-4.", "text_with_entity_marker": "Interleukin-13 ([E1]IL-13[/E1]) is a cytokine secreted by activated T lymphocytes that shares many, but not all, biological activities with [E2]IL-4[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-13", "entity_1_idx": [[16, 21]], "entity_1_idx_in_text_with_entity_marker": [20, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-4", "entity_2_idx": [[131, 135]], "entity_2_idx_in_text_with_entity_marker": [144, 148], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d169.s1427_AIMed.d169.s1427.p0", "text": "Two proteins have been described as constituents of the IL-4 receptor, a approximately 140-kDa glycoprotein (IL-4R) and the gamma chain (gammac) of the IL-2 receptor, but neither of these proteins binds IL-13.", "text_with_entity_marker": "Two proteins have been described as constituents of the [E1]IL-4[/E1] receptor, a approximately 140-kDa glycoprotein ([E2]IL-4R[/E2]) and the gamma chain (gammac) of the IL-2 receptor, but neither of these proteins binds IL-13.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-4", "entity_1_idx": [[56, 60]], "entity_1_idx_in_text_with_entity_marker": [60, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-4R", "entity_2_idx": [[109, 114]], "entity_2_idx_in_text_with_entity_marker": [122, 127], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d169.s1427_AIMed.d169.s1427.p1", "text": "Two proteins have been described as constituents of the IL-4 receptor, a approximately 140-kDa glycoprotein (IL-4R) and the gamma chain (gammac) of the IL-2 receptor, but neither of these proteins binds IL-13.", "text_with_entity_marker": "Two proteins have been described as constituents of the [E1]IL-4[/E1] receptor, a approximately 140-kDa glycoprotein (IL-4R) and the gamma chain (gammac) of the [E2]IL-2[/E2] receptor, but neither of these proteins binds IL-13.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-4", "entity_1_idx": [[56, 60]], "entity_1_idx_in_text_with_entity_marker": [60, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2", "entity_2_idx": [[152, 156]], "entity_2_idx_in_text_with_entity_marker": [165, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d169.s1427_AIMed.d169.s1427.p2", "text": "Two proteins have been described as constituents of the IL-4 receptor, a approximately 140-kDa glycoprotein (IL-4R) and the gamma chain (gammac) of the IL-2 receptor, but neither of these proteins binds IL-13.", "text_with_entity_marker": "Two proteins have been described as constituents of the [E1]IL-4[/E1] receptor, a approximately 140-kDa glycoprotein (IL-4R) and the gamma chain (gammac) of the [E2]IL-2 receptor[/E2], but neither of these proteins binds IL-13.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-4", "entity_1_idx": [[56, 60]], "entity_1_idx_in_text_with_entity_marker": [60, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2 receptor", "entity_2_idx": [[152, 165]], "entity_2_idx_in_text_with_entity_marker": [165, 178], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d169.s1427_AIMed.d169.s1427.p3", "text": "Two proteins have been described as constituents of the IL-4 receptor, a approximately 140-kDa glycoprotein (IL-4R) and the gamma chain (gammac) of the IL-2 receptor, but neither of these proteins binds IL-13.", "text_with_entity_marker": "Two proteins have been described as constituents of the [E1]IL-4[/E1] receptor, a approximately 140-kDa glycoprotein (IL-4R) and the gamma chain (gammac) of the IL-2 receptor, but neither of these proteins binds [E2]IL-13[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-4", "entity_1_idx": [[56, 60]], "entity_1_idx_in_text_with_entity_marker": [60, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-13", "entity_2_idx": [[203, 208]], "entity_2_idx_in_text_with_entity_marker": [216, 221], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d169.s1427_AIMed.d169.s1427.p4", "text": "Two proteins have been described as constituents of the IL-4 receptor, a approximately 140-kDa glycoprotein (IL-4R) and the gamma chain (gammac) of the IL-2 receptor, but neither of these proteins binds IL-13.", "text_with_entity_marker": "Two proteins have been described as constituents of the IL-4 receptor, a approximately 140-kDa glycoprotein ([E1]IL-4R[/E1]) and the gamma chain (gammac) of the [E2]IL-2[/E2] receptor, but neither of these proteins binds IL-13.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-4R", "entity_1_idx": [[109, 114]], "entity_1_idx_in_text_with_entity_marker": [113, 118], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2", "entity_2_idx": [[152, 156]], "entity_2_idx_in_text_with_entity_marker": [165, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d169.s1427_AIMed.d169.s1427.p5", "text": "Two proteins have been described as constituents of the IL-4 receptor, a approximately 140-kDa glycoprotein (IL-4R) and the gamma chain (gammac) of the IL-2 receptor, but neither of these proteins binds IL-13.", "text_with_entity_marker": "Two proteins have been described as constituents of the IL-4 receptor, a approximately 140-kDa glycoprotein ([E1]IL-4R[/E1]) and the gamma chain (gammac) of the [E2]IL-2 receptor[/E2], but neither of these proteins binds IL-13.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-4R", "entity_1_idx": [[109, 114]], "entity_1_idx_in_text_with_entity_marker": [113, 118], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2 receptor", "entity_2_idx": [[152, 165]], "entity_2_idx_in_text_with_entity_marker": [165, 178], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d169.s1427_AIMed.d169.s1427.p6", "text": "Two proteins have been described as constituents of the IL-4 receptor, a approximately 140-kDa glycoprotein (IL-4R) and the gamma chain (gammac) of the IL-2 receptor, but neither of these proteins binds IL-13.", "text_with_entity_marker": "Two proteins have been described as constituents of the IL-4 receptor, a approximately 140-kDa glycoprotein ([E1]IL-4R[/E1]) and the gamma chain (gammac) of the IL-2 receptor, but neither of these proteins binds [E2]IL-13[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-4R", "entity_1_idx": [[109, 114]], "entity_1_idx_in_text_with_entity_marker": [113, 118], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-13", "entity_2_idx": [[203, 208]], "entity_2_idx_in_text_with_entity_marker": [216, 221], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d169.s1427_AIMed.d169.s1427.p7", "text": "Two proteins have been described as constituents of the IL-4 receptor, a approximately 140-kDa glycoprotein (IL-4R) and the gamma chain (gammac) of the IL-2 receptor, but neither of these proteins binds IL-13.", "text_with_entity_marker": "Two proteins have been described as constituents of the IL-4 receptor, a approximately 140-kDa glycoprotein (IL-4R) and the gamma chain (gammac) of the [E1-E2]IL-2[/E1] receptor[/E2], but neither of these proteins binds IL-13.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2", "entity_1_idx": [[152, 156]], "entity_1_idx_in_text_with_entity_marker": [159, 163], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-2[/E1] receptor", "entity_2_idx": [[152, 165]], "entity_2_idx_in_text_with_entity_marker": [159, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d169.s1427_AIMed.d169.s1427.p8", "text": "Two proteins have been described as constituents of the IL-4 receptor, a approximately 140-kDa glycoprotein (IL-4R) and the gamma chain (gammac) of the IL-2 receptor, but neither of these proteins binds IL-13.", "text_with_entity_marker": "Two proteins have been described as constituents of the IL-4 receptor, a approximately 140-kDa glycoprotein (IL-4R) and the gamma chain (gammac) of the [E1]IL-2[/E1] receptor, but neither of these proteins binds [E2]IL-13[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2", "entity_1_idx": [[152, 156]], "entity_1_idx_in_text_with_entity_marker": [156, 160], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-13", "entity_2_idx": [[203, 208]], "entity_2_idx_in_text_with_entity_marker": [216, 221], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d169.s1427_AIMed.d169.s1427.p9", "text": "Two proteins have been described as constituents of the IL-4 receptor, a approximately 140-kDa glycoprotein (IL-4R) and the gamma chain (gammac) of the IL-2 receptor, but neither of these proteins binds IL-13.", "text_with_entity_marker": "Two proteins have been described as constituents of the IL-4 receptor, a approximately 140-kDa glycoprotein (IL-4R) and the gamma chain (gammac) of the [E1]IL-2 receptor[/E1], but neither of these proteins binds [E2]IL-13[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-2 receptor", "entity_1_idx": [[152, 165]], "entity_1_idx_in_text_with_entity_marker": [156, 169], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-13", "entity_2_idx": [[203, 208]], "entity_2_idx_in_text_with_entity_marker": [216, 221], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d169.s1428_AIMed.d169.s1428.p0", "text": "We have cloned a cDNA encoding an IL-13 binding protein (IL-13R) from the Caki-1 human renal carcinoma cell line.", "text_with_entity_marker": "We have cloned a cDNA encoding an [E1]IL-13[/E1] binding protein ([E2]IL-13R[/E2]) from the Caki-1 human renal carcinoma cell line.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-13", "entity_1_idx": [[34, 39]], "entity_1_idx_in_text_with_entity_marker": [38, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-13R", "entity_2_idx": [[57, 63]], "entity_2_idx_in_text_with_entity_marker": [70, 76], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d169.s1430_AIMed.d169.s1430.p0", "text": "The IL-13R shows homology with the IL-5 receptor, and to a lesser extent, with the prolactin receptor.", "text_with_entity_marker": "The [E1]IL-13R[/E1] shows homology with the [E2]IL-5[/E2] receptor, and to a lesser extent, with the prolactin receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-13R", "entity_1_idx": [[4, 10]], "entity_1_idx_in_text_with_entity_marker": [8, 14], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-5", "entity_2_idx": [[35, 39]], "entity_2_idx_in_text_with_entity_marker": [48, 52], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d169.s1431_AIMed.d169.s1431.p0", "text": "COS-7 cells transfected with the IL-13R cDNA bind IL-13 with high affinity but do not bind IL-4.", "text_with_entity_marker": "COS-7 cells transfected with the [E1]IL-13R[/E1] cDNA bind [E2]IL-13[/E2] with high affinity but do not bind IL-4.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-13R", "entity_1_idx": [[33, 39]], "entity_1_idx_in_text_with_entity_marker": [37, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-13", "entity_2_idx": [[50, 55]], "entity_2_idx_in_text_with_entity_marker": [63, 68], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d169.s1431_AIMed.d169.s1431.p1", "text": "COS-7 cells transfected with the IL-13R cDNA bind IL-13 with high affinity but do not bind IL-4.", "text_with_entity_marker": "COS-7 cells transfected with the [E1]IL-13R[/E1] cDNA bind IL-13 with high affinity but do not bind [E2]IL-4[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-13R", "entity_1_idx": [[33, 39]], "entity_1_idx_in_text_with_entity_marker": [37, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-4", "entity_2_idx": [[91, 95]], "entity_2_idx_in_text_with_entity_marker": [104, 108], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d169.s1431_AIMed.d169.s1431.p2", "text": "COS-7 cells transfected with the IL-13R cDNA bind IL-13 with high affinity but do not bind IL-4.", "text_with_entity_marker": "COS-7 cells transfected with the IL-13R cDNA bind [E1]IL-13[/E1] with high affinity but do not bind [E2]IL-4[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-13", "entity_1_idx": [[50, 55]], "entity_1_idx_in_text_with_entity_marker": [54, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-4", "entity_2_idx": [[91, 95]], "entity_2_idx_in_text_with_entity_marker": [104, 108], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d169.s1432_AIMed.d169.s1432.p0", "text": "COS-7 cells co-transfected with the cloned IL-13R cDNA and IL-4R cDNA resulted in the reconstitution of a small number of receptors that recognized both IL-4 and IL-13.", "text_with_entity_marker": "COS-7 cells co-transfected with the cloned [E1]IL-13R[/E1] cDNA and [E2]IL-4R[/E2] cDNA resulted in the reconstitution of a small number of receptors that recognized both IL-4 and IL-13.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-13R", "entity_1_idx": [[43, 49]], "entity_1_idx_in_text_with_entity_marker": [47, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-4R", "entity_2_idx": [[59, 64]], "entity_2_idx_in_text_with_entity_marker": [72, 77], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d169.s1432_AIMed.d169.s1432.p1", "text": "COS-7 cells co-transfected with the cloned IL-13R cDNA and IL-4R cDNA resulted in the reconstitution of a small number of receptors that recognized both IL-4 and IL-13.", "text_with_entity_marker": "COS-7 cells co-transfected with the cloned [E1]IL-13R[/E1] cDNA and IL-4R cDNA resulted in the reconstitution of a small number of receptors that recognized both [E2]IL-4[/E2] and IL-13.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-13R", "entity_1_idx": [[43, 49]], "entity_1_idx_in_text_with_entity_marker": [47, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-4", "entity_2_idx": [[153, 157]], "entity_2_idx_in_text_with_entity_marker": [166, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d169.s1432_AIMed.d169.s1432.p2", "text": "COS-7 cells co-transfected with the cloned IL-13R cDNA and IL-4R cDNA resulted in the reconstitution of a small number of receptors that recognized both IL-4 and IL-13.", "text_with_entity_marker": "COS-7 cells co-transfected with the cloned [E1]IL-13R[/E1] cDNA and IL-4R cDNA resulted in the reconstitution of a small number of receptors that recognized both IL-4 and [E2]IL-13[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-13R", "entity_1_idx": [[43, 49]], "entity_1_idx_in_text_with_entity_marker": [47, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-13", "entity_2_idx": [[162, 167]], "entity_2_idx_in_text_with_entity_marker": [175, 180], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d169.s1432_AIMed.d169.s1432.p3", "text": "COS-7 cells co-transfected with the cloned IL-13R cDNA and IL-4R cDNA resulted in the reconstitution of a small number of receptors that recognized both IL-4 and IL-13.", "text_with_entity_marker": "COS-7 cells co-transfected with the cloned IL-13R cDNA and [E1]IL-4R[/E1] cDNA resulted in the reconstitution of a small number of receptors that recognized both [E2]IL-4[/E2] and IL-13.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-4R", "entity_1_idx": [[59, 64]], "entity_1_idx_in_text_with_entity_marker": [63, 68], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-4", "entity_2_idx": [[153, 157]], "entity_2_idx_in_text_with_entity_marker": [166, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d169.s1432_AIMed.d169.s1432.p4", "text": "COS-7 cells co-transfected with the cloned IL-13R cDNA and IL-4R cDNA resulted in the reconstitution of a small number of receptors that recognized both IL-4 and IL-13.", "text_with_entity_marker": "COS-7 cells co-transfected with the cloned IL-13R cDNA and [E1]IL-4R[/E1] cDNA resulted in the reconstitution of a small number of receptors that recognized both IL-4 and [E2]IL-13[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-4R", "entity_1_idx": [[59, 64]], "entity_1_idx_in_text_with_entity_marker": [63, 68], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-13", "entity_2_idx": [[162, 167]], "entity_2_idx_in_text_with_entity_marker": [175, 180], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d169.s1432_AIMed.d169.s1432.p5", "text": "COS-7 cells co-transfected with the cloned IL-13R cDNA and IL-4R cDNA resulted in the reconstitution of a small number of receptors that recognized both IL-4 and IL-13.", "text_with_entity_marker": "COS-7 cells co-transfected with the cloned IL-13R cDNA and IL-4R cDNA resulted in the reconstitution of a small number of receptors that recognized both [E1]IL-4[/E1] and [E2]IL-13[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-4", "entity_1_idx": [[153, 157]], "entity_1_idx_in_text_with_entity_marker": [157, 161], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-13", "entity_2_idx": [[162, 167]], "entity_2_idx_in_text_with_entity_marker": [175, 180], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d59.s518_AIMed.d59.s518.p0", "text": "Analysis of the oligomerization of myogenin and E2A products in vivo using a two-hybrid assay system.", "text_with_entity_marker": "Analysis of the oligomerization of [E1]myogenin[/E1] and [E2]E2A[/E2] products in vivo using a two-hybrid assay system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "myogenin", "entity_1_idx": [[35, 43]], "entity_1_idx_in_text_with_entity_marker": [39, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2A", "entity_2_idx": [[48, 51]], "entity_2_idx_in_text_with_entity_marker": [61, 64], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d59.s520_AIMed.d59.s520.p0", "text": "Myogenin is a muscle-specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins, such as the E2A gene products E12 and E47.", "text_with_entity_marker": "[E1]Myogenin[/E1] is a muscle-specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins, such as the [E2]E2A[/E2] gene products E12 and E47.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Myogenin", "entity_1_idx": [[0, 8]], "entity_1_idx_in_text_with_entity_marker": [4, 12], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2A", "entity_2_idx": [[139, 142]], "entity_2_idx_in_text_with_entity_marker": [152, 155], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d59.s520_AIMed.d59.s520.p1", "text": "Myogenin is a muscle-specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins, such as the E2A gene products E12 and E47.", "text_with_entity_marker": "[E1]Myogenin[/E1] is a muscle-specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins, such as the E2A gene products [E2]E12[/E2] and E47.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Myogenin", "entity_1_idx": [[0, 8]], "entity_1_idx_in_text_with_entity_marker": [4, 12], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E12", "entity_2_idx": [[157, 160]], "entity_2_idx_in_text_with_entity_marker": [170, 173], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d59.s520_AIMed.d59.s520.p2", "text": "Myogenin is a muscle-specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins, such as the E2A gene products E12 and E47.", "text_with_entity_marker": "[E1]Myogenin[/E1] is a muscle-specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins, such as the E2A gene products E12 and [E2]E47[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Myogenin", "entity_1_idx": [[0, 8]], "entity_1_idx_in_text_with_entity_marker": [4, 12], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E47", "entity_2_idx": [[165, 168]], "entity_2_idx_in_text_with_entity_marker": [178, 181], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d59.s520_AIMed.d59.s520.p3", "text": "Myogenin is a muscle-specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins, such as the E2A gene products E12 and E47.", "text_with_entity_marker": "Myogenin is a muscle-specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins, such as the [E1]E2A[/E1] gene products [E2]E12[/E2] and E47.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E2A", "entity_1_idx": [[139, 142]], "entity_1_idx_in_text_with_entity_marker": [143, 146], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E12", "entity_2_idx": [[157, 160]], "entity_2_idx_in_text_with_entity_marker": [170, 173], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d59.s520_AIMed.d59.s520.p4", "text": "Myogenin is a muscle-specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins, such as the E2A gene products E12 and E47.", "text_with_entity_marker": "Myogenin is a muscle-specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins, such as the [E1]E2A[/E1] gene products E12 and [E2]E47[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E2A", "entity_1_idx": [[139, 142]], "entity_1_idx_in_text_with_entity_marker": [143, 146], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E47", "entity_2_idx": [[165, 168]], "entity_2_idx_in_text_with_entity_marker": [178, 181], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d59.s520_AIMed.d59.s520.p5", "text": "Myogenin is a muscle-specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins, such as the E2A gene products E12 and E47.", "text_with_entity_marker": "Myogenin is a muscle-specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins, such as the E2A gene products [E1]E12[/E1] and [E2]E47[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E12", "entity_1_idx": [[157, 160]], "entity_1_idx_in_text_with_entity_marker": [161, 164], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E47", "entity_2_idx": [[165, 168]], "entity_2_idx_in_text_with_entity_marker": [178, 181], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d59.s523_AIMed.d59.s523.p0", "text": "The results show that myogenin heterodimerizes with E12 and E47 in vivo, but it does not homodimerize to a measurable extent.", "text_with_entity_marker": "The results show that [E1]myogenin[/E1] heterodimerizes with [E2]E12[/E2] and E47 in vivo, but it does not homodimerize to a measurable extent.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "myogenin", "entity_1_idx": [[22, 30]], "entity_1_idx_in_text_with_entity_marker": [26, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E12", "entity_2_idx": [[52, 55]], "entity_2_idx_in_text_with_entity_marker": [65, 68], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d59.s523_AIMed.d59.s523.p1", "text": "The results show that myogenin heterodimerizes with E12 and E47 in vivo, but it does not homodimerize to a measurable extent.", "text_with_entity_marker": "The results show that [E1]myogenin[/E1] heterodimerizes with E12 and [E2]E47[/E2] in vivo, but it does not homodimerize to a measurable extent.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "myogenin", "entity_1_idx": [[22, 30]], "entity_1_idx_in_text_with_entity_marker": [26, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E47", "entity_2_idx": [[60, 63]], "entity_2_idx_in_text_with_entity_marker": [73, 76], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d59.s523_AIMed.d59.s523.p2", "text": "The results show that myogenin heterodimerizes with E12 and E47 in vivo, but it does not homodimerize to a measurable extent.", "text_with_entity_marker": "The results show that myogenin heterodimerizes with [E1]E12[/E1] and [E2]E47[/E2] in vivo, but it does not homodimerize to a measurable extent.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E12", "entity_1_idx": [[52, 55]], "entity_1_idx_in_text_with_entity_marker": [56, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E47", "entity_2_idx": [[60, 63]], "entity_2_idx_in_text_with_entity_marker": [73, 76], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d59.s524_AIMed.d59.s524.p0", "text": "Peptide growth factors, as well as the immediate early gene products c-Jun, v-Fos, and c-Myc, inhibit the activity of myogenin through a mechanism independent of its association with E2A products.", "text_with_entity_marker": "Peptide growth factors, as well as the immediate early gene products [E1]c-Jun[/E1], [E2]v-Fos[/E2], and c-Myc, inhibit the activity of myogenin through a mechanism independent of its association with E2A products.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Jun", "entity_1_idx": [[69, 74]], "entity_1_idx_in_text_with_entity_marker": [73, 78], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "v-Fos", "entity_2_idx": [[76, 81]], "entity_2_idx_in_text_with_entity_marker": [89, 94], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d59.s524_AIMed.d59.s524.p1", "text": "Peptide growth factors, as well as the immediate early gene products c-Jun, v-Fos, and c-Myc, inhibit the activity of myogenin through a mechanism independent of its association with E2A products.", "text_with_entity_marker": "Peptide growth factors, as well as the immediate early gene products [E1]c-Jun[/E1], v-Fos, and [E2]c-Myc[/E2], inhibit the activity of myogenin through a mechanism independent of its association with E2A products.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Jun", "entity_1_idx": [[69, 74]], "entity_1_idx_in_text_with_entity_marker": [73, 78], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Myc", "entity_2_idx": [[87, 92]], "entity_2_idx_in_text_with_entity_marker": [100, 105], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d59.s524_AIMed.d59.s524.p2", "text": "Peptide growth factors, as well as the immediate early gene products c-Jun, v-Fos, and c-Myc, inhibit the activity of myogenin through a mechanism independent of its association with E2A products.", "text_with_entity_marker": "Peptide growth factors, as well as the immediate early gene products [E1]c-Jun[/E1], v-Fos, and c-Myc, inhibit the activity of myogenin through a mechanism independent of its association with [E2]E2A[/E2] products.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Jun", "entity_1_idx": [[69, 74]], "entity_1_idx_in_text_with_entity_marker": [73, 78], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2A", "entity_2_idx": [[183, 186]], "entity_2_idx_in_text_with_entity_marker": [196, 199], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d59.s524_AIMed.d59.s524.p3", "text": "Peptide growth factors, as well as the immediate early gene products c-Jun, v-Fos, and c-Myc, inhibit the activity of myogenin through a mechanism independent of its association with E2A products.", "text_with_entity_marker": "Peptide growth factors, as well as the immediate early gene products c-Jun, [E1]v-Fos[/E1], and [E2]c-Myc[/E2], inhibit the activity of myogenin through a mechanism independent of its association with E2A products.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "v-Fos", "entity_1_idx": [[76, 81]], "entity_1_idx_in_text_with_entity_marker": [80, 85], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Myc", "entity_2_idx": [[87, 92]], "entity_2_idx_in_text_with_entity_marker": [100, 105], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d59.s524_AIMed.d59.s524.p4", "text": "Peptide growth factors, as well as the immediate early gene products c-Jun, v-Fos, and c-Myc, inhibit the activity of myogenin through a mechanism independent of its association with E2A products.", "text_with_entity_marker": "Peptide growth factors, as well as the immediate early gene products c-Jun, [E1]v-Fos[/E1], and c-Myc, inhibit the activity of myogenin through a mechanism independent of its association with [E2]E2A[/E2] products.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "v-Fos", "entity_1_idx": [[76, 81]], "entity_1_idx_in_text_with_entity_marker": [80, 85], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2A", "entity_2_idx": [[183, 186]], "entity_2_idx_in_text_with_entity_marker": [196, 199], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d59.s524_AIMed.d59.s524.p5", "text": "Peptide growth factors, as well as the immediate early gene products c-Jun, v-Fos, and c-Myc, inhibit the activity of myogenin through a mechanism independent of its association with E2A products.", "text_with_entity_marker": "Peptide growth factors, as well as the immediate early gene products c-Jun, v-Fos, and [E1]c-Myc[/E1], inhibit the activity of myogenin through a mechanism independent of its association with [E2]E2A[/E2] products.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Myc", "entity_1_idx": [[87, 92]], "entity_1_idx_in_text_with_entity_marker": [91, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2A", "entity_2_idx": [[183, 186]], "entity_2_idx_in_text_with_entity_marker": [196, 199], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d22.s181_AIMed.d22.s181.p0", "text": "Present data concerning the renin-angiotensin system of extrarenal origin.", "text_with_entity_marker": "Present data concerning the [E1]renin[/E1]-[E2]angiotensin[/E2] system of extrarenal origin.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "renin", "entity_1_idx": [[28, 33]], "entity_1_idx_in_text_with_entity_marker": [32, 37], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "angiotensin", "entity_2_idx": [[34, 45]], "entity_2_idx_in_text_with_entity_marker": [47, 58], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d22.s182_AIMed.d22.s182.p0", "text": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.", "text_with_entity_marker": "After a brief historical incursion regarding [E1]RAS[/E1] of renal origin, we present the main extrarenal [E2]angiotensin[/E2]-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAS", "entity_1_idx": [[45, 48]], "entity_1_idx_in_text_with_entity_marker": [49, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "angiotensin", "entity_2_idx": [[97, 108]], "entity_2_idx_in_text_with_entity_marker": [110, 121], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d22.s182_AIMed.d22.s182.p1", "text": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.", "text_with_entity_marker": "After a brief historical incursion regarding [E1]RAS[/E1] of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with [E2]isorenin[/E2], tonin, D and G cathepsin and ending with the conversion enzyme and chymase.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAS", "entity_1_idx": [[45, 48]], "entity_1_idx_in_text_with_entity_marker": [49, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "isorenin", "entity_2_idx": [[140, 148]], "entity_2_idx_in_text_with_entity_marker": [153, 161], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d22.s182_AIMed.d22.s182.p2", "text": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.", "text_with_entity_marker": "After a brief historical incursion regarding [E1]RAS[/E1] of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, [E2]tonin[/E2], D and G cathepsin and ending with the conversion enzyme and chymase.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAS", "entity_1_idx": [[45, 48]], "entity_1_idx_in_text_with_entity_marker": [49, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "tonin", "entity_2_idx": [[150, 155]], "entity_2_idx_in_text_with_entity_marker": [163, 168], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d22.s182_AIMed.d22.s182.p3", "text": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.", "text_with_entity_marker": "After a brief historical incursion regarding [E1]RAS[/E1] of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and [E2]G cathepsin[/E2] and ending with the conversion enzyme and chymase.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAS", "entity_1_idx": [[45, 48]], "entity_1_idx_in_text_with_entity_marker": [49, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "G cathepsin", "entity_2_idx": [[163, 174]], "entity_2_idx_in_text_with_entity_marker": [176, 187], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d22.s182_AIMed.d22.s182.p4", "text": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.", "text_with_entity_marker": "After a brief historical incursion regarding [E1]RAS[/E1] of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and [E2]chymase[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAS", "entity_1_idx": [[45, 48]], "entity_1_idx_in_text_with_entity_marker": [49, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "chymase", "entity_2_idx": [[217, 224]], "entity_2_idx_in_text_with_entity_marker": [230, 237], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d22.s182_AIMed.d22.s182.p5", "text": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.", "text_with_entity_marker": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal [E1]angiotensin[/E1]-forming enzymes, starting with [E2]isorenin[/E2], tonin, D and G cathepsin and ending with the conversion enzyme and chymase.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "angiotensin", "entity_1_idx": [[97, 108]], "entity_1_idx_in_text_with_entity_marker": [101, 112], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "isorenin", "entity_2_idx": [[140, 148]], "entity_2_idx_in_text_with_entity_marker": [153, 161], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d22.s182_AIMed.d22.s182.p6", "text": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.", "text_with_entity_marker": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal [E1]angiotensin[/E1]-forming enzymes, starting with isorenin, [E2]tonin[/E2], D and G cathepsin and ending with the conversion enzyme and chymase.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "angiotensin", "entity_1_idx": [[97, 108]], "entity_1_idx_in_text_with_entity_marker": [101, 112], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "tonin", "entity_2_idx": [[150, 155]], "entity_2_idx_in_text_with_entity_marker": [163, 168], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d22.s182_AIMed.d22.s182.p7", "text": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.", "text_with_entity_marker": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal [E1]angiotensin[/E1]-forming enzymes, starting with isorenin, tonin, D and [E2]G cathepsin[/E2] and ending with the conversion enzyme and chymase.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "angiotensin", "entity_1_idx": [[97, 108]], "entity_1_idx_in_text_with_entity_marker": [101, 112], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "G cathepsin", "entity_2_idx": [[163, 174]], "entity_2_idx_in_text_with_entity_marker": [176, 187], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d22.s182_AIMed.d22.s182.p8", "text": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.", "text_with_entity_marker": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal [E1]angiotensin[/E1]-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and [E2]chymase[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "angiotensin", "entity_1_idx": [[97, 108]], "entity_1_idx_in_text_with_entity_marker": [101, 112], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "chymase", "entity_2_idx": [[217, 224]], "entity_2_idx_in_text_with_entity_marker": [230, 237], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d22.s182_AIMed.d22.s182.p9", "text": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.", "text_with_entity_marker": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with [E1]isorenin[/E1], [E2]tonin[/E2], D and G cathepsin and ending with the conversion enzyme and chymase.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "isorenin", "entity_1_idx": [[140, 148]], "entity_1_idx_in_text_with_entity_marker": [144, 152], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "tonin", "entity_2_idx": [[150, 155]], "entity_2_idx_in_text_with_entity_marker": [163, 168], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d22.s182_AIMed.d22.s182.p10", "text": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.", "text_with_entity_marker": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with [E1]isorenin[/E1], tonin, D and [E2]G cathepsin[/E2] and ending with the conversion enzyme and chymase.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "isorenin", "entity_1_idx": [[140, 148]], "entity_1_idx_in_text_with_entity_marker": [144, 152], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "G cathepsin", "entity_2_idx": [[163, 174]], "entity_2_idx_in_text_with_entity_marker": [176, 187], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d22.s182_AIMed.d22.s182.p11", "text": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.", "text_with_entity_marker": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with [E1]isorenin[/E1], tonin, D and G cathepsin and ending with the conversion enzyme and [E2]chymase[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "isorenin", "entity_1_idx": [[140, 148]], "entity_1_idx_in_text_with_entity_marker": [144, 152], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "chymase", "entity_2_idx": [[217, 224]], "entity_2_idx_in_text_with_entity_marker": [230, 237], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d22.s182_AIMed.d22.s182.p12", "text": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.", "text_with_entity_marker": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, [E1]tonin[/E1], D and [E2]G cathepsin[/E2] and ending with the conversion enzyme and chymase.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "tonin", "entity_1_idx": [[150, 155]], "entity_1_idx_in_text_with_entity_marker": [154, 159], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "G cathepsin", "entity_2_idx": [[163, 174]], "entity_2_idx_in_text_with_entity_marker": [176, 187], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d22.s182_AIMed.d22.s182.p13", "text": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.", "text_with_entity_marker": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, [E1]tonin[/E1], D and G cathepsin and ending with the conversion enzyme and [E2]chymase[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "tonin", "entity_1_idx": [[150, 155]], "entity_1_idx_in_text_with_entity_marker": [154, 159], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "chymase", "entity_2_idx": [[217, 224]], "entity_2_idx_in_text_with_entity_marker": [230, 237], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d22.s182_AIMed.d22.s182.p14", "text": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.", "text_with_entity_marker": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and [E1]G cathepsin[/E1] and ending with the conversion enzyme and [E2]chymase[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "G cathepsin", "entity_1_idx": [[163, 174]], "entity_1_idx_in_text_with_entity_marker": [167, 178], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "chymase", "entity_2_idx": [[217, 224]], "entity_2_idx_in_text_with_entity_marker": [230, 237], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d22.s184_AIMed.d22.s184.p0", "text": "In the end we refer to the relations between circulating RAS of renal origin and the extrarenal RAS specific to tissue underlying the fact that the two RAS components cooperate and constitute a unitary hormonal system, regulating the major functions of the organism and maintaining the main homeostatic equilibria.", "text_with_entity_marker": "In the end we refer to the relations between circulating [E1]RAS[/E1] of renal origin and the extrarenal [E2]RAS[/E2] specific to tissue underlying the fact that the two RAS components cooperate and constitute a unitary hormonal system, regulating the major functions of the organism and maintaining the main homeostatic equilibria.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAS", "entity_1_idx": [[57, 60]], "entity_1_idx_in_text_with_entity_marker": [61, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAS", "entity_2_idx": [[96, 99]], "entity_2_idx_in_text_with_entity_marker": [109, 112], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d22.s184_AIMed.d22.s184.p1", "text": "In the end we refer to the relations between circulating RAS of renal origin and the extrarenal RAS specific to tissue underlying the fact that the two RAS components cooperate and constitute a unitary hormonal system, regulating the major functions of the organism and maintaining the main homeostatic equilibria.", "text_with_entity_marker": "In the end we refer to the relations between circulating [E1]RAS[/E1] of renal origin and the extrarenal RAS specific to tissue underlying the fact that the two [E2]RAS[/E2] components cooperate and constitute a unitary hormonal system, regulating the major functions of the organism and maintaining the main homeostatic equilibria.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAS", "entity_1_idx": [[57, 60]], "entity_1_idx_in_text_with_entity_marker": [61, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAS", "entity_2_idx": [[152, 155]], "entity_2_idx_in_text_with_entity_marker": [165, 168], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d22.s184_AIMed.d22.s184.p2", "text": "In the end we refer to the relations between circulating RAS of renal origin and the extrarenal RAS specific to tissue underlying the fact that the two RAS components cooperate and constitute a unitary hormonal system, regulating the major functions of the organism and maintaining the main homeostatic equilibria.", "text_with_entity_marker": "In the end we refer to the relations between circulating RAS of renal origin and the extrarenal [E1]RAS[/E1] specific to tissue underlying the fact that the two [E2]RAS[/E2] components cooperate and constitute a unitary hormonal system, regulating the major functions of the organism and maintaining the main homeostatic equilibria.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAS", "entity_1_idx": [[96, 99]], "entity_1_idx_in_text_with_entity_marker": [100, 103], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAS", "entity_2_idx": [[152, 155]], "entity_2_idx_in_text_with_entity_marker": [165, 168], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d22.s185_AIMed.d22.s185.p0", "text": "While the circulating RAS of renal origin is acutely activated to contribute to the accomplishment of short term homeostatic reactions, tissue RAS, in paracrine or autocrine ways, exerts local-regional adaptive actions of long duration.", "text_with_entity_marker": "While the circulating [E1]RAS[/E1] of renal origin is acutely activated to contribute to the accomplishment of short term homeostatic reactions, tissue [E2]RAS[/E2], in paracrine or autocrine ways, exerts local-regional adaptive actions of long duration.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAS", "entity_1_idx": [[22, 25]], "entity_1_idx_in_text_with_entity_marker": [26, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAS", "entity_2_idx": [[143, 146]], "entity_2_idx_in_text_with_entity_marker": [156, 159], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d157.s1328_AIMed.d157.s1328.p0", "text": "Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and phosphatase 2B [calcineurin (CaN)] are complexed by an A kinase anchoring protein, AKAP79.", "text_with_entity_marker": "Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase ([E1]PKA[/E1]) and [E2]phosphatase 2B[/E2] [calcineurin (CaN)] are complexed by an A kinase anchoring protein, AKAP79.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PKA", "entity_1_idx": [[97, 100]], "entity_1_idx_in_text_with_entity_marker": [101, 104], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "phosphatase 2B", "entity_2_idx": [[106, 120]], "entity_2_idx_in_text_with_entity_marker": [119, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d157.s1328_AIMed.d157.s1328.p1", "text": "Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and phosphatase 2B [calcineurin (CaN)] are complexed by an A kinase anchoring protein, AKAP79.", "text_with_entity_marker": "Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase ([E1]PKA[/E1]) and phosphatase 2B [[E2]calcineurin[/E2] (CaN)] are complexed by an A kinase anchoring protein, AKAP79.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PKA", "entity_1_idx": [[97, 100]], "entity_1_idx_in_text_with_entity_marker": [101, 104], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "calcineurin", "entity_2_idx": [[122, 133]], "entity_2_idx_in_text_with_entity_marker": [135, 146], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d157.s1328_AIMed.d157.s1328.p2", "text": "Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and phosphatase 2B [calcineurin (CaN)] are complexed by an A kinase anchoring protein, AKAP79.", "text_with_entity_marker": "Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase ([E1]PKA[/E1]) and phosphatase 2B [calcineurin ([E2]CaN[/E2])] are complexed by an A kinase anchoring protein, AKAP79.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PKA", "entity_1_idx": [[97, 100]], "entity_1_idx_in_text_with_entity_marker": [101, 104], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CaN", "entity_2_idx": [[135, 138]], "entity_2_idx_in_text_with_entity_marker": [148, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d157.s1328_AIMed.d157.s1328.p3", "text": "Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and phosphatase 2B [calcineurin (CaN)] are complexed by an A kinase anchoring protein, AKAP79.", "text_with_entity_marker": "Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase ([E1]PKA[/E1]) and phosphatase 2B [calcineurin (CaN)] are complexed by an [E2]A kinase anchoring protein[/E2], AKAP79.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PKA", "entity_1_idx": [[97, 100]], "entity_1_idx_in_text_with_entity_marker": [101, 104], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "A kinase anchoring protein", "entity_2_idx": [[161, 187]], "entity_2_idx_in_text_with_entity_marker": [174, 200], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d157.s1328_AIMed.d157.s1328.p4", "text": "Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and phosphatase 2B [calcineurin (CaN)] are complexed by an A kinase anchoring protein, AKAP79.", "text_with_entity_marker": "Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase ([E1]PKA[/E1]) and phosphatase 2B [calcineurin (CaN)] are complexed by an A kinase anchoring protein, [E2]AKAP79[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PKA", "entity_1_idx": [[97, 100]], "entity_1_idx_in_text_with_entity_marker": [101, 104], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "AKAP79", "entity_2_idx": [[189, 195]], "entity_2_idx_in_text_with_entity_marker": [202, 208], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d157.s1328_AIMed.d157.s1328.p5", "text": "Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and phosphatase 2B [calcineurin (CaN)] are complexed by an A kinase anchoring protein, AKAP79.", "text_with_entity_marker": "Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and [E1]phosphatase 2B[/E1] [[E2]calcineurin[/E2] (CaN)] are complexed by an A kinase anchoring protein, AKAP79.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "phosphatase 2B", "entity_1_idx": [[106, 120]], "entity_1_idx_in_text_with_entity_marker": [110, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "calcineurin", "entity_2_idx": [[122, 133]], "entity_2_idx_in_text_with_entity_marker": [135, 146], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d157.s1328_AIMed.d157.s1328.p6", "text": "Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and phosphatase 2B [calcineurin (CaN)] are complexed by an A kinase anchoring protein, AKAP79.", "text_with_entity_marker": "Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and [E1]phosphatase 2B[/E1] [calcineurin ([E2]CaN[/E2])] are complexed by an A kinase anchoring protein, AKAP79.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "phosphatase 2B", "entity_1_idx": [[106, 120]], "entity_1_idx_in_text_with_entity_marker": [110, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CaN", "entity_2_idx": [[135, 138]], "entity_2_idx_in_text_with_entity_marker": [148, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d157.s1328_AIMed.d157.s1328.p7", "text": "Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and phosphatase 2B [calcineurin (CaN)] are complexed by an A kinase anchoring protein, AKAP79.", "text_with_entity_marker": "Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and [E1]phosphatase 2B[/E1] [calcineurin (CaN)] are complexed by an [E2]A kinase anchoring protein[/E2], AKAP79.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "phosphatase 2B", "entity_1_idx": [[106, 120]], "entity_1_idx_in_text_with_entity_marker": [110, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "A kinase anchoring protein", "entity_2_idx": [[161, 187]], "entity_2_idx_in_text_with_entity_marker": [174, 200], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d157.s1328_AIMed.d157.s1328.p8", "text": "Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and phosphatase 2B [calcineurin (CaN)] are complexed by an A kinase anchoring protein, AKAP79.", "text_with_entity_marker": "Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and [E1]phosphatase 2B[/E1] [calcineurin (CaN)] are complexed by an A kinase anchoring protein, [E2]AKAP79[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "phosphatase 2B", "entity_1_idx": [[106, 120]], "entity_1_idx_in_text_with_entity_marker": [110, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "AKAP79", "entity_2_idx": [[189, 195]], "entity_2_idx_in_text_with_entity_marker": [202, 208], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d157.s1328_AIMed.d157.s1328.p9", "text": "Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and phosphatase 2B [calcineurin (CaN)] are complexed by an A kinase anchoring protein, AKAP79.", "text_with_entity_marker": "Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and phosphatase 2B [[E1]calcineurin[/E1] ([E2]CaN[/E2])] are complexed by an A kinase anchoring protein, AKAP79.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "calcineurin", "entity_1_idx": [[122, 133]], "entity_1_idx_in_text_with_entity_marker": [126, 137], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CaN", "entity_2_idx": [[135, 138]], "entity_2_idx_in_text_with_entity_marker": [148, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d157.s1328_AIMed.d157.s1328.p10", "text": "Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and phosphatase 2B [calcineurin (CaN)] are complexed by an A kinase anchoring protein, AKAP79.", "text_with_entity_marker": "Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and phosphatase 2B [[E1]calcineurin[/E1] (CaN)] are complexed by an [E2]A kinase anchoring protein[/E2], AKAP79.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "calcineurin", "entity_1_idx": [[122, 133]], "entity_1_idx_in_text_with_entity_marker": [126, 137], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "A kinase anchoring protein", "entity_2_idx": [[161, 187]], "entity_2_idx_in_text_with_entity_marker": [174, 200], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d157.s1328_AIMed.d157.s1328.p11", "text": "Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and phosphatase 2B [calcineurin (CaN)] are complexed by an A kinase anchoring protein, AKAP79.", "text_with_entity_marker": "Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and phosphatase 2B [[E1]calcineurin[/E1] (CaN)] are complexed by an A kinase anchoring protein, [E2]AKAP79[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "calcineurin", "entity_1_idx": [[122, 133]], "entity_1_idx_in_text_with_entity_marker": [126, 137], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "AKAP79", "entity_2_idx": [[189, 195]], "entity_2_idx_in_text_with_entity_marker": [202, 208], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d157.s1328_AIMed.d157.s1328.p12", "text": "Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and phosphatase 2B [calcineurin (CaN)] are complexed by an A kinase anchoring protein, AKAP79.", "text_with_entity_marker": "Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and phosphatase 2B [calcineurin ([E1]CaN[/E1])] are complexed by an [E2]A kinase anchoring protein[/E2], AKAP79.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CaN", "entity_1_idx": [[135, 138]], "entity_1_idx_in_text_with_entity_marker": [139, 142], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "A kinase anchoring protein", "entity_2_idx": [[161, 187]], "entity_2_idx_in_text_with_entity_marker": [174, 200], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d157.s1328_AIMed.d157.s1328.p13", "text": "Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and phosphatase 2B [calcineurin (CaN)] are complexed by an A kinase anchoring protein, AKAP79.", "text_with_entity_marker": "Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and phosphatase 2B [calcineurin ([E1]CaN[/E1])] are complexed by an A kinase anchoring protein, [E2]AKAP79[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CaN", "entity_1_idx": [[135, 138]], "entity_1_idx_in_text_with_entity_marker": [139, 142], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "AKAP79", "entity_2_idx": [[189, 195]], "entity_2_idx_in_text_with_entity_marker": [202, 208], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d157.s1328_AIMed.d157.s1328.p14", "text": "Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and phosphatase 2B [calcineurin (CaN)] are complexed by an A kinase anchoring protein, AKAP79.", "text_with_entity_marker": "Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and phosphatase 2B [calcineurin (CaN)] are complexed by an [E1]A kinase anchoring protein[/E1], [E2]AKAP79[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "A kinase anchoring protein", "entity_1_idx": [[161, 187]], "entity_1_idx_in_text_with_entity_marker": [165, 191], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "AKAP79", "entity_2_idx": [[189, 195]], "entity_2_idx_in_text_with_entity_marker": [202, 208], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d157.s1329_AIMed.d157.s1329.p0", "text": "Deletion analysis and binding studies demonstrate that a third enzyme, protein kinase C (PKC), binds AKAP79 at a site distinct from those bound by PKA or CaN.", "text_with_entity_marker": "Deletion analysis and binding studies demonstrate that a third enzyme, [E1]protein kinase C[/E1] ([E2]PKC[/E2]), binds AKAP79 at a site distinct from those bound by PKA or CaN.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "protein kinase C", "entity_1_idx": [[71, 87]], "entity_1_idx_in_text_with_entity_marker": [75, 91], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PKC", "entity_2_idx": [[89, 92]], "entity_2_idx_in_text_with_entity_marker": [102, 105], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d157.s1329_AIMed.d157.s1329.p1", "text": "Deletion analysis and binding studies demonstrate that a third enzyme, protein kinase C (PKC), binds AKAP79 at a site distinct from those bound by PKA or CaN.", "text_with_entity_marker": "Deletion analysis and binding studies demonstrate that a third enzyme, [E1]protein kinase C[/E1] (PKC), binds [E2]AKAP79[/E2] at a site distinct from those bound by PKA or CaN.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "protein kinase C", "entity_1_idx": [[71, 87]], "entity_1_idx_in_text_with_entity_marker": [75, 91], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "AKAP79", "entity_2_idx": [[101, 107]], "entity_2_idx_in_text_with_entity_marker": [114, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d157.s1329_AIMed.d157.s1329.p2", "text": "Deletion analysis and binding studies demonstrate that a third enzyme, protein kinase C (PKC), binds AKAP79 at a site distinct from those bound by PKA or CaN.", "text_with_entity_marker": "Deletion analysis and binding studies demonstrate that a third enzyme, [E1]protein kinase C[/E1] (PKC), binds AKAP79 at a site distinct from those bound by [E2]PKA[/E2] or CaN.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "protein kinase C", "entity_1_idx": [[71, 87]], "entity_1_idx_in_text_with_entity_marker": [75, 91], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PKA", "entity_2_idx": [[147, 150]], "entity_2_idx_in_text_with_entity_marker": [160, 163], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d157.s1329_AIMed.d157.s1329.p3", "text": "Deletion analysis and binding studies demonstrate that a third enzyme, protein kinase C (PKC), binds AKAP79 at a site distinct from those bound by PKA or CaN.", "text_with_entity_marker": "Deletion analysis and binding studies demonstrate that a third enzyme, [E1]protein kinase C[/E1] (PKC), binds AKAP79 at a site distinct from those bound by PKA or [E2]CaN[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "protein kinase C", "entity_1_idx": [[71, 87]], "entity_1_idx_in_text_with_entity_marker": [75, 91], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CaN", "entity_2_idx": [[154, 157]], "entity_2_idx_in_text_with_entity_marker": [167, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d157.s1329_AIMed.d157.s1329.p4", "text": "Deletion analysis and binding studies demonstrate that a third enzyme, protein kinase C (PKC), binds AKAP79 at a site distinct from those bound by PKA or CaN.", "text_with_entity_marker": "Deletion analysis and binding studies demonstrate that a third enzyme, protein kinase C ([E1]PKC[/E1]), binds [E2]AKAP79[/E2] at a site distinct from those bound by PKA or CaN.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PKC", "entity_1_idx": [[89, 92]], "entity_1_idx_in_text_with_entity_marker": [93, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "AKAP79", "entity_2_idx": [[101, 107]], "entity_2_idx_in_text_with_entity_marker": [114, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d157.s1329_AIMed.d157.s1329.p5", "text": "Deletion analysis and binding studies demonstrate that a third enzyme, protein kinase C (PKC), binds AKAP79 at a site distinct from those bound by PKA or CaN.", "text_with_entity_marker": "Deletion analysis and binding studies demonstrate that a third enzyme, protein kinase C ([E1]PKC[/E1]), binds AKAP79 at a site distinct from those bound by [E2]PKA[/E2] or CaN.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PKC", "entity_1_idx": [[89, 92]], "entity_1_idx_in_text_with_entity_marker": [93, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PKA", "entity_2_idx": [[147, 150]], "entity_2_idx_in_text_with_entity_marker": [160, 163], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d157.s1329_AIMed.d157.s1329.p6", "text": "Deletion analysis and binding studies demonstrate that a third enzyme, protein kinase C (PKC), binds AKAP79 at a site distinct from those bound by PKA or CaN.", "text_with_entity_marker": "Deletion analysis and binding studies demonstrate that a third enzyme, protein kinase C ([E1]PKC[/E1]), binds AKAP79 at a site distinct from those bound by PKA or [E2]CaN[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PKC", "entity_1_idx": [[89, 92]], "entity_1_idx_in_text_with_entity_marker": [93, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CaN", "entity_2_idx": [[154, 157]], "entity_2_idx_in_text_with_entity_marker": [167, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d157.s1329_AIMed.d157.s1329.p7", "text": "Deletion analysis and binding studies demonstrate that a third enzyme, protein kinase C (PKC), binds AKAP79 at a site distinct from those bound by PKA or CaN.", "text_with_entity_marker": "Deletion analysis and binding studies demonstrate that a third enzyme, protein kinase C (PKC), binds [E1]AKAP79[/E1] at a site distinct from those bound by [E2]PKA[/E2] or CaN.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "AKAP79", "entity_1_idx": [[101, 107]], "entity_1_idx_in_text_with_entity_marker": [105, 111], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PKA", "entity_2_idx": [[147, 150]], "entity_2_idx_in_text_with_entity_marker": [160, 163], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d157.s1329_AIMed.d157.s1329.p8", "text": "Deletion analysis and binding studies demonstrate that a third enzyme, protein kinase C (PKC), binds AKAP79 at a site distinct from those bound by PKA or CaN.", "text_with_entity_marker": "Deletion analysis and binding studies demonstrate that a third enzyme, protein kinase C (PKC), binds [E1]AKAP79[/E1] at a site distinct from those bound by PKA or [E2]CaN[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "AKAP79", "entity_1_idx": [[101, 107]], "entity_1_idx_in_text_with_entity_marker": [105, 111], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CaN", "entity_2_idx": [[154, 157]], "entity_2_idx_in_text_with_entity_marker": [167, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d157.s1329_AIMed.d157.s1329.p9", "text": "Deletion analysis and binding studies demonstrate that a third enzyme, protein kinase C (PKC), binds AKAP79 at a site distinct from those bound by PKA or CaN.", "text_with_entity_marker": "Deletion analysis and binding studies demonstrate that a third enzyme, protein kinase C (PKC), binds AKAP79 at a site distinct from those bound by [E1]PKA[/E1] or [E2]CaN[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PKA", "entity_1_idx": [[147, 150]], "entity_1_idx_in_text_with_entity_marker": [151, 154], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CaN", "entity_2_idx": [[154, 157]], "entity_2_idx_in_text_with_entity_marker": [167, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d157.s1330_AIMed.d157.s1330.p0", "text": "The subcellular distributions of PKC and AKAP79 were similar in neurons.", "text_with_entity_marker": "The subcellular distributions of [E1]PKC[/E1] and [E2]AKAP79[/E2] were similar in neurons.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PKC", "entity_1_idx": [[33, 36]], "entity_1_idx_in_text_with_entity_marker": [37, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "AKAP79", "entity_2_idx": [[41, 47]], "entity_2_idx_in_text_with_entity_marker": [54, 60], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d74.s627_AIMed.d74.s627.p0", "text": "Two cDNA clones encoding a receptor for human granulocyte-macrophage colony-stimulating factor (hGM-CSF-R) were isolated by expression screening of a library made from human placental mRNA.", "text_with_entity_marker": "Two cDNA clones encoding a receptor for human [E1]granulocyte-macrophage colony-stimulating factor[/E1] ([E2]hGM-CSF-R[/E2]) were isolated by expression screening of a library made from human placental mRNA.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "granulocyte-macrophage colony-stimulating factor", "entity_1_idx": [[46, 94]], "entity_1_idx_in_text_with_entity_marker": [50, 98], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hGM-CSF-R", "entity_2_idx": [[96, 105]], "entity_2_idx_in_text_with_entity_marker": [109, 118], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d74.s630_AIMed.d74.s630.p0", "text": "It does not contain a tyrosine kinase domain nor show homology with members of the immunoglobulin super gene family, but does show some significant sequence homologies with receptors for several other haemopoietic growth factors, including those for interleukin-6, erythropoietin and interleukin-2 (beta-chain) and also to the prolactin receptor.", "text_with_entity_marker": "It does not contain a tyrosine kinase domain nor show homology with members of the immunoglobulin super gene family, but does show some significant sequence homologies with receptors for several other haemopoietic growth factors, including those for [E1]interleukin-6[/E1], [E2]erythropoietin[/E2] and interleukin-2 (beta-chain) and also to the prolactin receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin-6", "entity_1_idx": [[250, 263]], "entity_1_idx_in_text_with_entity_marker": [254, 267], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "erythropoietin", "entity_2_idx": [[265, 279]], "entity_2_idx_in_text_with_entity_marker": [278, 292], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d74.s630_AIMed.d74.s630.p1", "text": "It does not contain a tyrosine kinase domain nor show homology with members of the immunoglobulin super gene family, but does show some significant sequence homologies with receptors for several other haemopoietic growth factors, including those for interleukin-6, erythropoietin and interleukin-2 (beta-chain) and also to the prolactin receptor.", "text_with_entity_marker": "It does not contain a tyrosine kinase domain nor show homology with members of the immunoglobulin super gene family, but does show some significant sequence homologies with receptors for several other haemopoietic growth factors, including those for [E1]interleukin-6[/E1], erythropoietin and [E2]interleukin-2[/E2] (beta-chain) and also to the prolactin receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin-6", "entity_1_idx": [[250, 263]], "entity_1_idx_in_text_with_entity_marker": [254, 267], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin-2", "entity_2_idx": [[284, 297]], "entity_2_idx_in_text_with_entity_marker": [297, 310], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d74.s630_AIMed.d74.s630.p2", "text": "It does not contain a tyrosine kinase domain nor show homology with members of the immunoglobulin super gene family, but does show some significant sequence homologies with receptors for several other haemopoietic growth factors, including those for interleukin-6, erythropoietin and interleukin-2 (beta-chain) and also to the prolactin receptor.", "text_with_entity_marker": "It does not contain a tyrosine kinase domain nor show homology with members of the immunoglobulin super gene family, but does show some significant sequence homologies with receptors for several other haemopoietic growth factors, including those for interleukin-6, [E1]erythropoietin[/E1] and [E2]interleukin-2[/E2] (beta-chain) and also to the prolactin receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "erythropoietin", "entity_1_idx": [[265, 279]], "entity_1_idx_in_text_with_entity_marker": [269, 283], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin-2", "entity_2_idx": [[284, 297]], "entity_2_idx_in_text_with_entity_marker": [297, 310], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d74.s631_AIMed.d74.s631.p0", "text": "When transfected into COS cells the cloned cDNA directed the expression of a GM-CSF-R showing a single class of affinity (KD = 2(-8) nM) and specificity for human GM-CSF but not interleukin-3.", "text_with_entity_marker": "When transfected into COS cells the cloned cDNA directed the expression of a [E1]GM-CSF-R[/E1] showing a single class of affinity (KD = 2(-8) nM) and specificity for human [E2]GM-CSF[/E2] but not interleukin-3.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GM-CSF-R", "entity_1_idx": [[77, 85]], "entity_1_idx_in_text_with_entity_marker": [81, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GM-CSF", "entity_2_idx": [[163, 169]], "entity_2_idx_in_text_with_entity_marker": [176, 182], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d74.s631_AIMed.d74.s631.p1", "text": "When transfected into COS cells the cloned cDNA directed the expression of a GM-CSF-R showing a single class of affinity (KD = 2(-8) nM) and specificity for human GM-CSF but not interleukin-3.", "text_with_entity_marker": "When transfected into COS cells the cloned cDNA directed the expression of a [E1]GM-CSF-R[/E1] showing a single class of affinity (KD = 2(-8) nM) and specificity for human GM-CSF but not [E2]interleukin-3[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GM-CSF-R", "entity_1_idx": [[77, 85]], "entity_1_idx_in_text_with_entity_marker": [81, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin-3", "entity_2_idx": [[178, 191]], "entity_2_idx_in_text_with_entity_marker": [191, 204], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d74.s631_AIMed.d74.s631.p2", "text": "When transfected into COS cells the cloned cDNA directed the expression of a GM-CSF-R showing a single class of affinity (KD = 2(-8) nM) and specificity for human GM-CSF but not interleukin-3.", "text_with_entity_marker": "When transfected into COS cells the cloned cDNA directed the expression of a GM-CSF-R showing a single class of affinity (KD = 2(-8) nM) and specificity for human [E1]GM-CSF[/E1] but not [E2]interleukin-3[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GM-CSF", "entity_1_idx": [[163, 169]], "entity_1_idx_in_text_with_entity_marker": [167, 173], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin-3", "entity_2_idx": [[178, 191]], "entity_2_idx_in_text_with_entity_marker": [191, 204], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d198.s1686_AIMed.d198.s1686.p0", "text": "Mutagenesis studies of the human erythropoietin receptor. Establishment of structure-function relationships.", "text_with_entity_marker": "Mutagenesis studies of the human [E1-E2]erythropoietin[/E1] receptor[/E2]. Establishment of structure-function relationships.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "erythropoietin", "entity_1_idx": [[33, 47]], "entity_1_idx_in_text_with_entity_marker": [40, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "erythropoietin[/E1] receptor", "entity_2_idx": [[33, 56]], "entity_2_idx_in_text_with_entity_marker": [40, 68], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d198.s1687_AIMed.d198.s1687.p0", "text": "Mutagenesis of the erythropoietin receptor (EPOR) permits analysis of the contribution that individual amino acid residues make to erythropoietin (EPO) binding.", "text_with_entity_marker": "Mutagenesis of the [E1-E2]erythropoietin[/E1] receptor[/E2] (EPOR) permits analysis of the contribution that individual amino acid residues make to erythropoietin (EPO) binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "erythropoietin", "entity_1_idx": [[19, 33]], "entity_1_idx_in_text_with_entity_marker": [26, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "erythropoietin[/E1] receptor", "entity_2_idx": [[19, 42]], "entity_2_idx_in_text_with_entity_marker": [26, 54], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d198.s1687_AIMed.d198.s1687.p1", "text": "Mutagenesis of the erythropoietin receptor (EPOR) permits analysis of the contribution that individual amino acid residues make to erythropoietin (EPO) binding.", "text_with_entity_marker": "Mutagenesis of the [E1]erythropoietin[/E1] receptor ([E2]EPOR[/E2]) permits analysis of the contribution that individual amino acid residues make to erythropoietin (EPO) binding.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "erythropoietin", "entity_1_idx": [[19, 33]], "entity_1_idx_in_text_with_entity_marker": [23, 37], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPOR", "entity_2_idx": [[44, 48]], "entity_2_idx_in_text_with_entity_marker": [57, 61], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d198.s1687_AIMed.d198.s1687.p2", "text": "Mutagenesis of the erythropoietin receptor (EPOR) permits analysis of the contribution that individual amino acid residues make to erythropoietin (EPO) binding.", "text_with_entity_marker": "Mutagenesis of the [E1]erythropoietin[/E1] receptor (EPOR) permits analysis of the contribution that individual amino acid residues make to [E2]erythropoietin[/E2] (EPO) binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "erythropoietin", "entity_1_idx": [[19, 33]], "entity_1_idx_in_text_with_entity_marker": [23, 37], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "erythropoietin", "entity_2_idx": [[131, 145]], "entity_2_idx_in_text_with_entity_marker": [144, 158], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d198.s1687_AIMed.d198.s1687.p3", "text": "Mutagenesis of the erythropoietin receptor (EPOR) permits analysis of the contribution that individual amino acid residues make to erythropoietin (EPO) binding.", "text_with_entity_marker": "Mutagenesis of the [E1]erythropoietin[/E1] receptor (EPOR) permits analysis of the contribution that individual amino acid residues make to erythropoietin ([E2]EPO[/E2]) binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "erythropoietin", "entity_1_idx": [[19, 33]], "entity_1_idx_in_text_with_entity_marker": [23, 37], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[147, 150]], "entity_2_idx_in_text_with_entity_marker": [160, 163], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d198.s1687_AIMed.d198.s1687.p4", "text": "Mutagenesis of the erythropoietin receptor (EPOR) permits analysis of the contribution that individual amino acid residues make to erythropoietin (EPO) binding.", "text_with_entity_marker": "Mutagenesis of the [E1]erythropoietin receptor[/E1] ([E2]EPOR[/E2]) permits analysis of the contribution that individual amino acid residues make to erythropoietin (EPO) binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "erythropoietin receptor", "entity_1_idx": [[19, 42]], "entity_1_idx_in_text_with_entity_marker": [23, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPOR", "entity_2_idx": [[44, 48]], "entity_2_idx_in_text_with_entity_marker": [57, 61], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d198.s1687_AIMed.d198.s1687.p5", "text": "Mutagenesis of the erythropoietin receptor (EPOR) permits analysis of the contribution that individual amino acid residues make to erythropoietin (EPO) binding.", "text_with_entity_marker": "Mutagenesis of the [E1]erythropoietin receptor[/E1] (EPOR) permits analysis of the contribution that individual amino acid residues make to [E2]erythropoietin[/E2] (EPO) binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "erythropoietin receptor", "entity_1_idx": [[19, 42]], "entity_1_idx_in_text_with_entity_marker": [23, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "erythropoietin", "entity_2_idx": [[131, 145]], "entity_2_idx_in_text_with_entity_marker": [144, 158], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d198.s1687_AIMed.d198.s1687.p6", "text": "Mutagenesis of the erythropoietin receptor (EPOR) permits analysis of the contribution that individual amino acid residues make to erythropoietin (EPO) binding.", "text_with_entity_marker": "Mutagenesis of the [E1]erythropoietin receptor[/E1] (EPOR) permits analysis of the contribution that individual amino acid residues make to erythropoietin ([E2]EPO[/E2]) binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "erythropoietin receptor", "entity_1_idx": [[19, 42]], "entity_1_idx_in_text_with_entity_marker": [23, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[147, 150]], "entity_2_idx_in_text_with_entity_marker": [160, 163], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d198.s1687_AIMed.d198.s1687.p7", "text": "Mutagenesis of the erythropoietin receptor (EPOR) permits analysis of the contribution that individual amino acid residues make to erythropoietin (EPO) binding.", "text_with_entity_marker": "Mutagenesis of the erythropoietin receptor ([E1]EPOR[/E1]) permits analysis of the contribution that individual amino acid residues make to [E2]erythropoietin[/E2] (EPO) binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPOR", "entity_1_idx": [[44, 48]], "entity_1_idx_in_text_with_entity_marker": [48, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "erythropoietin", "entity_2_idx": [[131, 145]], "entity_2_idx_in_text_with_entity_marker": [144, 158], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d198.s1687_AIMed.d198.s1687.p8", "text": "Mutagenesis of the erythropoietin receptor (EPOR) permits analysis of the contribution that individual amino acid residues make to erythropoietin (EPO) binding.", "text_with_entity_marker": "Mutagenesis of the erythropoietin receptor ([E1]EPOR[/E1]) permits analysis of the contribution that individual amino acid residues make to erythropoietin ([E2]EPO[/E2]) binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPOR", "entity_1_idx": [[44, 48]], "entity_1_idx_in_text_with_entity_marker": [48, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[147, 150]], "entity_2_idx_in_text_with_entity_marker": [160, 163], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d198.s1687_AIMed.d198.s1687.p9", "text": "Mutagenesis of the erythropoietin receptor (EPOR) permits analysis of the contribution that individual amino acid residues make to erythropoietin (EPO) binding.", "text_with_entity_marker": "Mutagenesis of the erythropoietin receptor (EPOR) permits analysis of the contribution that individual amino acid residues make to [E1]erythropoietin[/E1] ([E2]EPO[/E2]) binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "erythropoietin", "entity_1_idx": [[131, 145]], "entity_1_idx_in_text_with_entity_marker": [135, 149], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[147, 150]], "entity_2_idx_in_text_with_entity_marker": [160, 163], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d198.s1688_AIMed.d198.s1688.p0", "text": "We employed both random and site-specific mutagenesis to determine the function of amino acid residues in the extracellular domain (referred to as EPO binding protein, EBP) of the EPOR.", "text_with_entity_marker": "We employed both random and site-specific mutagenesis to determine the function of amino acid residues in the extracellular domain (referred to as [E1-E2]EPO[/E1] binding protein[/E2], EBP) of the EPOR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPO", "entity_1_idx": [[147, 150]], "entity_1_idx_in_text_with_entity_marker": [154, 157], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO[/E1] binding protein", "entity_2_idx": [[147, 166]], "entity_2_idx_in_text_with_entity_marker": [154, 178], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d198.s1688_AIMed.d198.s1688.p1", "text": "We employed both random and site-specific mutagenesis to determine the function of amino acid residues in the extracellular domain (referred to as EPO binding protein, EBP) of the EPOR.", "text_with_entity_marker": "We employed both random and site-specific mutagenesis to determine the function of amino acid residues in the extracellular domain (referred to as [E1]EPO[/E1] binding protein, [E2]EBP[/E2]) of the EPOR.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "EPO", "entity_1_idx": [[147, 150]], "entity_1_idx_in_text_with_entity_marker": [151, 154], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EBP", "entity_2_idx": [[168, 171]], "entity_2_idx_in_text_with_entity_marker": [181, 184], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d198.s1688_AIMed.d198.s1688.p2", "text": "We employed both random and site-specific mutagenesis to determine the function of amino acid residues in the extracellular domain (referred to as EPO binding protein, EBP) of the EPOR.", "text_with_entity_marker": "We employed both random and site-specific mutagenesis to determine the function of amino acid residues in the extracellular domain (referred to as [E1]EPO[/E1] binding protein, EBP) of the [E2]EPOR[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPO", "entity_1_idx": [[147, 150]], "entity_1_idx_in_text_with_entity_marker": [151, 154], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPOR", "entity_2_idx": [[180, 184]], "entity_2_idx_in_text_with_entity_marker": [193, 197], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d198.s1688_AIMed.d198.s1688.p3", "text": "We employed both random and site-specific mutagenesis to determine the function of amino acid residues in the extracellular domain (referred to as EPO binding protein, EBP) of the EPOR.", "text_with_entity_marker": "We employed both random and site-specific mutagenesis to determine the function of amino acid residues in the extracellular domain (referred to as [E1]EPO binding protein[/E1], [E2]EBP[/E2]) of the EPOR.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPO binding protein", "entity_1_idx": [[147, 166]], "entity_1_idx_in_text_with_entity_marker": [151, 170], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EBP", "entity_2_idx": [[168, 171]], "entity_2_idx_in_text_with_entity_marker": [181, 184], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d198.s1688_AIMed.d198.s1688.p4", "text": "We employed both random and site-specific mutagenesis to determine the function of amino acid residues in the extracellular domain (referred to as EPO binding protein, EBP) of the EPOR.", "text_with_entity_marker": "We employed both random and site-specific mutagenesis to determine the function of amino acid residues in the extracellular domain (referred to as [E1]EPO binding protein[/E1], EBP) of the [E2]EPOR[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPO binding protein", "entity_1_idx": [[147, 166]], "entity_1_idx_in_text_with_entity_marker": [151, 170], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPOR", "entity_2_idx": [[180, 184]], "entity_2_idx_in_text_with_entity_marker": [193, 197], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d198.s1688_AIMed.d198.s1688.p5", "text": "We employed both random and site-specific mutagenesis to determine the function of amino acid residues in the extracellular domain (referred to as EPO binding protein, EBP) of the EPOR.", "text_with_entity_marker": "We employed both random and site-specific mutagenesis to determine the function of amino acid residues in the extracellular domain (referred to as EPO binding protein, [E1]EBP[/E1]) of the [E2]EPOR[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EBP", "entity_1_idx": [[168, 171]], "entity_1_idx_in_text_with_entity_marker": [172, 175], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPOR", "entity_2_idx": [[180, 184]], "entity_2_idx_in_text_with_entity_marker": [193, 197], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d198.s1690_AIMed.d198.s1690.p0", "text": "Site-specific mutants were expressed in Escherichia coli as soluble EBP and analyzed for EPO binding in several different assay formats.", "text_with_entity_marker": "Site-specific mutants were expressed in Escherichia coli as soluble [E1]EBP[/E1] and analyzed for [E2]EPO[/E2] binding in several different assay formats.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EBP", "entity_1_idx": [[68, 71]], "entity_1_idx_in_text_with_entity_marker": [72, 75], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[89, 92]], "entity_2_idx_in_text_with_entity_marker": [102, 105], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d198.s1691_AIMed.d198.s1691.p0", "text": "In addition, selected mutant proteins were expressed as full-length EPOR on the surface of COS cells and analyzed for 125I-EPO binding in receptor binding assays.", "text_with_entity_marker": "In addition, selected mutant proteins were expressed as full-length [E1]EPOR[/E1] on the surface of COS cells and analyzed for 125I-[E2]EPO[/E2] binding in receptor binding assays.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPOR", "entity_1_idx": [[68, 72]], "entity_1_idx_in_text_with_entity_marker": [72, 76], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[123, 126]], "entity_2_idx_in_text_with_entity_marker": [136, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d198.s1692_AIMed.d198.s1692.p0", "text": "Using these methods, we have identified residues that appear to be involved in EPO binding as well as other residues, most of which are conserved in receptors of the cytokine receptor family, that appear to be necessary for the proper folding and/or stability of the EPOR.", "text_with_entity_marker": "Using these methods, we have identified residues that appear to be involved in [E1]EPO[/E1] binding as well as other residues, most of which are conserved in receptors of the cytokine receptor family, that appear to be necessary for the proper folding and/or stability of the [E2]EPOR[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPO", "entity_1_idx": [[79, 82]], "entity_1_idx_in_text_with_entity_marker": [83, 86], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPOR", "entity_2_idx": [[267, 271]], "entity_2_idx_in_text_with_entity_marker": [280, 284], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d14.s117_AIMed.d14.s117.p0", "text": "Concentrations of glial fibrillary acidic protein (GFAp) and light subunit neurofilament protein (NFL) in cerebrospinal fluid (CSF) were measured in patients with second-stage Trypanosoma brucei gambiense sleeping sickness.", "text_with_entity_marker": "Concentrations of [E1]glial fibrillary acidic protein[/E1] ([E2]GFAp[/E2]) and light subunit neurofilament protein (NFL) in cerebrospinal fluid (CSF) were measured in patients with second-stage Trypanosoma brucei gambiense sleeping sickness.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "glial fibrillary acidic protein", "entity_1_idx": [[18, 49]], "entity_1_idx_in_text_with_entity_marker": [22, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GFAp", "entity_2_idx": [[51, 55]], "entity_2_idx_in_text_with_entity_marker": [64, 68], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d14.s117_AIMed.d14.s117.p1", "text": "Concentrations of glial fibrillary acidic protein (GFAp) and light subunit neurofilament protein (NFL) in cerebrospinal fluid (CSF) were measured in patients with second-stage Trypanosoma brucei gambiense sleeping sickness.", "text_with_entity_marker": "Concentrations of [E1]glial fibrillary acidic protein[/E1] (GFAp) and [E2]light subunit neurofilament protein[/E2] (NFL) in cerebrospinal fluid (CSF) were measured in patients with second-stage Trypanosoma brucei gambiense sleeping sickness.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "glial fibrillary acidic protein", "entity_1_idx": [[18, 49]], "entity_1_idx_in_text_with_entity_marker": [22, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "light subunit neurofilament protein", "entity_2_idx": [[61, 96]], "entity_2_idx_in_text_with_entity_marker": [74, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d14.s117_AIMed.d14.s117.p2", "text": "Concentrations of glial fibrillary acidic protein (GFAp) and light subunit neurofilament protein (NFL) in cerebrospinal fluid (CSF) were measured in patients with second-stage Trypanosoma brucei gambiense sleeping sickness.", "text_with_entity_marker": "Concentrations of [E1]glial fibrillary acidic protein[/E1] (GFAp) and light subunit neurofilament protein ([E2]NFL[/E2]) in cerebrospinal fluid (CSF) were measured in patients with second-stage Trypanosoma brucei gambiense sleeping sickness.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "glial fibrillary acidic protein", "entity_1_idx": [[18, 49]], "entity_1_idx_in_text_with_entity_marker": [22, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NFL", "entity_2_idx": [[98, 101]], "entity_2_idx_in_text_with_entity_marker": [111, 114], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d14.s117_AIMed.d14.s117.p3", "text": "Concentrations of glial fibrillary acidic protein (GFAp) and light subunit neurofilament protein (NFL) in cerebrospinal fluid (CSF) were measured in patients with second-stage Trypanosoma brucei gambiense sleeping sickness.", "text_with_entity_marker": "Concentrations of glial fibrillary acidic protein ([E1]GFAp[/E1]) and [E2]light subunit neurofilament protein[/E2] (NFL) in cerebrospinal fluid (CSF) were measured in patients with second-stage Trypanosoma brucei gambiense sleeping sickness.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GFAp", "entity_1_idx": [[51, 55]], "entity_1_idx_in_text_with_entity_marker": [55, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "light subunit neurofilament protein", "entity_2_idx": [[61, 96]], "entity_2_idx_in_text_with_entity_marker": [74, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d14.s117_AIMed.d14.s117.p4", "text": "Concentrations of glial fibrillary acidic protein (GFAp) and light subunit neurofilament protein (NFL) in cerebrospinal fluid (CSF) were measured in patients with second-stage Trypanosoma brucei gambiense sleeping sickness.", "text_with_entity_marker": "Concentrations of glial fibrillary acidic protein ([E1]GFAp[/E1]) and light subunit neurofilament protein ([E2]NFL[/E2]) in cerebrospinal fluid (CSF) were measured in patients with second-stage Trypanosoma brucei gambiense sleeping sickness.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GFAp", "entity_1_idx": [[51, 55]], "entity_1_idx_in_text_with_entity_marker": [55, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NFL", "entity_2_idx": [[98, 101]], "entity_2_idx_in_text_with_entity_marker": [111, 114], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d14.s117_AIMed.d14.s117.p5", "text": "Concentrations of glial fibrillary acidic protein (GFAp) and light subunit neurofilament protein (NFL) in cerebrospinal fluid (CSF) were measured in patients with second-stage Trypanosoma brucei gambiense sleeping sickness.", "text_with_entity_marker": "Concentrations of glial fibrillary acidic protein (GFAp) and [E1]light subunit neurofilament protein[/E1] ([E2]NFL[/E2]) in cerebrospinal fluid (CSF) were measured in patients with second-stage Trypanosoma brucei gambiense sleeping sickness.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "light subunit neurofilament protein", "entity_1_idx": [[61, 96]], "entity_1_idx_in_text_with_entity_marker": [65, 100], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NFL", "entity_2_idx": [[98, 101]], "entity_2_idx_in_text_with_entity_marker": [111, 114], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d14.s118_AIMed.d14.s118.p0", "text": "Correlations between GFAp and NFL in CSF as markers for astrogliosis and neurodegeneration, and clinical and biological data were investigated.", "text_with_entity_marker": "Correlations between [E1]GFAp[/E1] and [E2]NFL[/E2] in CSF as markers for astrogliosis and neurodegeneration, and clinical and biological data were investigated.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GFAp", "entity_1_idx": [[21, 25]], "entity_1_idx_in_text_with_entity_marker": [25, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NFL", "entity_2_idx": [[30, 33]], "entity_2_idx_in_text_with_entity_marker": [43, 46], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d14.s119_AIMed.d14.s119.p0", "text": "Abnormal levels of GFAp and NFL were significantly associated with increasing CSF cell number and protein concentration, and with the absence of lymph nodes or the absence of trypanosomes in lymph node aspirate.", "text_with_entity_marker": "Abnormal levels of [E1]GFAp[/E1] and [E2]NFL[/E2] were significantly associated with increasing CSF cell number and protein concentration, and with the absence of lymph nodes or the absence of trypanosomes in lymph node aspirate.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GFAp", "entity_1_idx": [[19, 23]], "entity_1_idx_in_text_with_entity_marker": [23, 27], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NFL", "entity_2_idx": [[28, 31]], "entity_2_idx_in_text_with_entity_marker": [41, 44], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d114.s961_AIMed.d114.s961.p0", "text": "Syntrophin binds to an alternatively spliced exon of dystrophin.", "text_with_entity_marker": "[E1]Syntrophin[/E1] binds to an alternatively spliced exon of [E2]dystrophin[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Syntrophin", "entity_1_idx": [[0, 10]], "entity_1_idx_in_text_with_entity_marker": [4, 14], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "dystrophin", "entity_2_idx": [[53, 63]], "entity_2_idx_in_text_with_entity_marker": [66, 76], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d114.s964_AIMed.d114.s964.p0", "text": "We expressed the cDNA of human beta 1-syntrophin and the COOH terminus of human dystrophin in reticulocyte lysates using an in vitro transcription/translation system.", "text_with_entity_marker": "We expressed the cDNA of human [E1]beta 1-syntrophin[/E1] and the COOH terminus of human [E2]dystrophin[/E2] in reticulocyte lysates using an in vitro transcription/translation system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "beta 1-syntrophin", "entity_1_idx": [[31, 48]], "entity_1_idx_in_text_with_entity_marker": [35, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "dystrophin", "entity_2_idx": [[80, 90]], "entity_2_idx_in_text_with_entity_marker": [93, 103], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d114.s966_AIMed.d114.s966.p0", "text": "We demonstrate that the 53 amino acids encoded on exon 74 of dystrophin, an alternatively spliced exon, are necessary and sufficient for interaction with translated beta 1-syntrophin in our assay.", "text_with_entity_marker": "We demonstrate that the 53 amino acids encoded on exon 74 of [E1]dystrophin[/E1], an alternatively spliced exon, are necessary and sufficient for interaction with translated [E2]beta 1-syntrophin[/E2] in our assay.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "dystrophin", "entity_1_idx": [[61, 71]], "entity_1_idx_in_text_with_entity_marker": [65, 75], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "beta 1-syntrophin", "entity_2_idx": [[165, 182]], "entity_2_idx_in_text_with_entity_marker": [178, 195], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d114.s968_AIMed.d114.s968.p0", "text": "In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "text_with_entity_marker": "In this recombinant expression system, the [E1]dystrophin[/E1] relatives, human [E2]dystrophin[/E2] related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "dystrophin", "entity_1_idx": [[43, 53]], "entity_1_idx_in_text_with_entity_marker": [47, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "dystrophin", "entity_2_idx": [[71, 81]], "entity_2_idx_in_text_with_entity_marker": [84, 94], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d114.s968_AIMed.d114.s968.p1", "text": "In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "text_with_entity_marker": "In this recombinant expression system, the [E1]dystrophin[/E1] relatives, human [E2]dystrophin related protein[/E2] (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "dystrophin", "entity_1_idx": [[43, 53]], "entity_1_idx_in_text_with_entity_marker": [47, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "dystrophin related protein", "entity_2_idx": [[71, 97]], "entity_2_idx_in_text_with_entity_marker": [84, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d114.s968_AIMed.d114.s968.p2", "text": "In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "text_with_entity_marker": "In this recombinant expression system, the [E1]dystrophin[/E1] relatives, human dystrophin related protein ([E2]DRP[/E2] or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "dystrophin", "entity_1_idx": [[43, 53]], "entity_1_idx_in_text_with_entity_marker": [47, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "DRP", "entity_2_idx": [[99, 102]], "entity_2_idx_in_text_with_entity_marker": [112, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d114.s968_AIMed.d114.s968.p3", "text": "In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "text_with_entity_marker": "In this recombinant expression system, the [E1]dystrophin[/E1] relatives, human dystrophin related protein (DRP or [E2]utrophin[/E2]) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "dystrophin", "entity_1_idx": [[43, 53]], "entity_1_idx_in_text_with_entity_marker": [47, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "utrophin", "entity_2_idx": [[106, 114]], "entity_2_idx_in_text_with_entity_marker": [119, 127], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d114.s968_AIMed.d114.s968.p4", "text": "In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "text_with_entity_marker": "In this recombinant expression system, the [E1]dystrophin[/E1] relatives, human dystrophin related protein (DRP or utrophin) and the [E2]87K postsynaptic protein[/E2] from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "dystrophin", "entity_1_idx": [[43, 53]], "entity_1_idx_in_text_with_entity_marker": [47, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "87K postsynaptic protein", "entity_2_idx": [[124, 148]], "entity_2_idx_in_text_with_entity_marker": [137, 161], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d114.s968_AIMed.d114.s968.p5", "text": "In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "text_with_entity_marker": "In this recombinant expression system, the [E1]dystrophin[/E1] relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated [E2]beta 1-syntrophin[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "dystrophin", "entity_1_idx": [[43, 53]], "entity_1_idx_in_text_with_entity_marker": [47, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "beta 1-syntrophin", "entity_2_idx": [[202, 219]], "entity_2_idx_in_text_with_entity_marker": [215, 232], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d114.s968_AIMed.d114.s968.p6", "text": "In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "text_with_entity_marker": "In this recombinant expression system, the dystrophin relatives, human [E1-E2]dystrophin[/E1] related protein[/E2] (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "dystrophin", "entity_1_idx": [[71, 81]], "entity_1_idx_in_text_with_entity_marker": [78, 88], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "dystrophin[/E1] related protein", "entity_2_idx": [[71, 97]], "entity_2_idx_in_text_with_entity_marker": [78, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d114.s968_AIMed.d114.s968.p7", "text": "In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "text_with_entity_marker": "In this recombinant expression system, the dystrophin relatives, human [E1]dystrophin[/E1] related protein ([E2]DRP[/E2] or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "dystrophin", "entity_1_idx": [[71, 81]], "entity_1_idx_in_text_with_entity_marker": [75, 85], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "DRP", "entity_2_idx": [[99, 102]], "entity_2_idx_in_text_with_entity_marker": [112, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d114.s968_AIMed.d114.s968.p8", "text": "In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "text_with_entity_marker": "In this recombinant expression system, the dystrophin relatives, human [E1]dystrophin[/E1] related protein (DRP or [E2]utrophin[/E2]) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "dystrophin", "entity_1_idx": [[71, 81]], "entity_1_idx_in_text_with_entity_marker": [75, 85], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "utrophin", "entity_2_idx": [[106, 114]], "entity_2_idx_in_text_with_entity_marker": [119, 127], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d114.s968_AIMed.d114.s968.p9", "text": "In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "text_with_entity_marker": "In this recombinant expression system, the dystrophin relatives, human [E1]dystrophin[/E1] related protein (DRP or utrophin) and the [E2]87K postsynaptic protein[/E2] from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "dystrophin", "entity_1_idx": [[71, 81]], "entity_1_idx_in_text_with_entity_marker": [75, 85], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "87K postsynaptic protein", "entity_2_idx": [[124, 148]], "entity_2_idx_in_text_with_entity_marker": [137, 161], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d114.s968_AIMed.d114.s968.p10", "text": "In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "text_with_entity_marker": "In this recombinant expression system, the dystrophin relatives, human [E1]dystrophin[/E1] related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated [E2]beta 1-syntrophin[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "dystrophin", "entity_1_idx": [[71, 81]], "entity_1_idx_in_text_with_entity_marker": [75, 85], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "beta 1-syntrophin", "entity_2_idx": [[202, 219]], "entity_2_idx_in_text_with_entity_marker": [215, 232], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d114.s968_AIMed.d114.s968.p11", "text": "In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "text_with_entity_marker": "In this recombinant expression system, the dystrophin relatives, human [E1]dystrophin related protein[/E1] ([E2]DRP[/E2] or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "dystrophin related protein", "entity_1_idx": [[71, 97]], "entity_1_idx_in_text_with_entity_marker": [75, 101], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "DRP", "entity_2_idx": [[99, 102]], "entity_2_idx_in_text_with_entity_marker": [112, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d114.s968_AIMed.d114.s968.p12", "text": "In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "text_with_entity_marker": "In this recombinant expression system, the dystrophin relatives, human [E1]dystrophin related protein[/E1] (DRP or [E2]utrophin[/E2]) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "dystrophin related protein", "entity_1_idx": [[71, 97]], "entity_1_idx_in_text_with_entity_marker": [75, 101], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "utrophin", "entity_2_idx": [[106, 114]], "entity_2_idx_in_text_with_entity_marker": [119, 127], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d114.s968_AIMed.d114.s968.p13", "text": "In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "text_with_entity_marker": "In this recombinant expression system, the dystrophin relatives, human [E1]dystrophin related protein[/E1] (DRP or utrophin) and the [E2]87K postsynaptic protein[/E2] from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "dystrophin related protein", "entity_1_idx": [[71, 97]], "entity_1_idx_in_text_with_entity_marker": [75, 101], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "87K postsynaptic protein", "entity_2_idx": [[124, 148]], "entity_2_idx_in_text_with_entity_marker": [137, 161], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d114.s968_AIMed.d114.s968.p14", "text": "In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "text_with_entity_marker": "In this recombinant expression system, the dystrophin relatives, human [E1]dystrophin related protein[/E1] (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated [E2]beta 1-syntrophin[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "dystrophin related protein", "entity_1_idx": [[71, 97]], "entity_1_idx_in_text_with_entity_marker": [75, 101], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "beta 1-syntrophin", "entity_2_idx": [[202, 219]], "entity_2_idx_in_text_with_entity_marker": [215, 232], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d114.s968_AIMed.d114.s968.p15", "text": "In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "text_with_entity_marker": "In this recombinant expression system, the dystrophin relatives, human dystrophin related protein ([E1]DRP[/E1] or [E2]utrophin[/E2]) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "DRP", "entity_1_idx": [[99, 102]], "entity_1_idx_in_text_with_entity_marker": [103, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "utrophin", "entity_2_idx": [[106, 114]], "entity_2_idx_in_text_with_entity_marker": [119, 127], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d114.s968_AIMed.d114.s968.p16", "text": "In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "text_with_entity_marker": "In this recombinant expression system, the dystrophin relatives, human dystrophin related protein ([E1]DRP[/E1] or utrophin) and the [E2]87K postsynaptic protein[/E2] from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "DRP", "entity_1_idx": [[99, 102]], "entity_1_idx_in_text_with_entity_marker": [103, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "87K postsynaptic protein", "entity_2_idx": [[124, 148]], "entity_2_idx_in_text_with_entity_marker": [137, 161], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d114.s968_AIMed.d114.s968.p17", "text": "In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "text_with_entity_marker": "In this recombinant expression system, the dystrophin relatives, human dystrophin related protein ([E1]DRP[/E1] or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated [E2]beta 1-syntrophin[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "DRP", "entity_1_idx": [[99, 102]], "entity_1_idx_in_text_with_entity_marker": [103, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "beta 1-syntrophin", "entity_2_idx": [[202, 219]], "entity_2_idx_in_text_with_entity_marker": [215, 232], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d114.s968_AIMed.d114.s968.p18", "text": "In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "text_with_entity_marker": "In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or [E1]utrophin[/E1]) and the [E2]87K postsynaptic protein[/E2] from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "utrophin", "entity_1_idx": [[106, 114]], "entity_1_idx_in_text_with_entity_marker": [110, 118], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "87K postsynaptic protein", "entity_2_idx": [[124, 148]], "entity_2_idx_in_text_with_entity_marker": [137, 161], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d114.s968_AIMed.d114.s968.p19", "text": "In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "text_with_entity_marker": "In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or [E1]utrophin[/E1]) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated [E2]beta 1-syntrophin[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "utrophin", "entity_1_idx": [[106, 114]], "entity_1_idx_in_text_with_entity_marker": [110, 118], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "beta 1-syntrophin", "entity_2_idx": [[202, 219]], "entity_2_idx_in_text_with_entity_marker": [215, 232], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d114.s968_AIMed.d114.s968.p20", "text": "In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "text_with_entity_marker": "In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the [E1]87K postsynaptic protein[/E1] from Torpedo electric organ, also bind to translated [E2]beta 1-syntrophin[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "87K postsynaptic protein", "entity_1_idx": [[124, 148]], "entity_1_idx_in_text_with_entity_marker": [128, 152], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "beta 1-syntrophin", "entity_2_idx": [[202, 219]], "entity_2_idx_in_text_with_entity_marker": [215, 232], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d114.s969_AIMed.d114.s969.p0", "text": "We have found a COOH-terminal 37-kD fragment of beta 1-syntrophin sufficient to interact with translated dystrophin and its homologues, suggesting that the dystrophin binding site on beta 1-syntrophin occurs on a region that is conserved among the three syntrophin homologues.", "text_with_entity_marker": "We have found a COOH-terminal 37-kD fragment of [E1]beta 1-syntrophin[/E1] sufficient to interact with translated [E2]dystrophin[/E2] and its homologues, suggesting that the dystrophin binding site on beta 1-syntrophin occurs on a region that is conserved among the three syntrophin homologues.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "beta 1-syntrophin", "entity_1_idx": [[48, 65]], "entity_1_idx_in_text_with_entity_marker": [52, 69], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "dystrophin", "entity_2_idx": [[105, 115]], "entity_2_idx_in_text_with_entity_marker": [118, 128], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d114.s969_AIMed.d114.s969.p1", "text": "We have found a COOH-terminal 37-kD fragment of beta 1-syntrophin sufficient to interact with translated dystrophin and its homologues, suggesting that the dystrophin binding site on beta 1-syntrophin occurs on a region that is conserved among the three syntrophin homologues.", "text_with_entity_marker": "We have found a COOH-terminal 37-kD fragment of [E1]beta 1-syntrophin[/E1] sufficient to interact with translated dystrophin and its homologues, suggesting that the [E2]dystrophin[/E2] binding site on beta 1-syntrophin occurs on a region that is conserved among the three syntrophin homologues.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "beta 1-syntrophin", "entity_1_idx": [[48, 65]], "entity_1_idx_in_text_with_entity_marker": [52, 69], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "dystrophin", "entity_2_idx": [[156, 166]], "entity_2_idx_in_text_with_entity_marker": [169, 179], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d114.s969_AIMed.d114.s969.p2", "text": "We have found a COOH-terminal 37-kD fragment of beta 1-syntrophin sufficient to interact with translated dystrophin and its homologues, suggesting that the dystrophin binding site on beta 1-syntrophin occurs on a region that is conserved among the three syntrophin homologues.", "text_with_entity_marker": "We have found a COOH-terminal 37-kD fragment of [E1]beta 1-syntrophin[/E1] sufficient to interact with translated dystrophin and its homologues, suggesting that the dystrophin binding site on [E2]beta 1-syntrophin[/E2] occurs on a region that is conserved among the three syntrophin homologues.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "beta 1-syntrophin", "entity_1_idx": [[48, 65]], "entity_1_idx_in_text_with_entity_marker": [52, 69], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "beta 1-syntrophin", "entity_2_idx": [[183, 200]], "entity_2_idx_in_text_with_entity_marker": [196, 213], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d114.s969_AIMed.d114.s969.p3", "text": "We have found a COOH-terminal 37-kD fragment of beta 1-syntrophin sufficient to interact with translated dystrophin and its homologues, suggesting that the dystrophin binding site on beta 1-syntrophin occurs on a region that is conserved among the three syntrophin homologues.", "text_with_entity_marker": "We have found a COOH-terminal 37-kD fragment of beta 1-syntrophin sufficient to interact with translated [E1]dystrophin[/E1] and its homologues, suggesting that the [E2]dystrophin[/E2] binding site on beta 1-syntrophin occurs on a region that is conserved among the three syntrophin homologues.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "dystrophin", "entity_1_idx": [[105, 115]], "entity_1_idx_in_text_with_entity_marker": [109, 119], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "dystrophin", "entity_2_idx": [[156, 166]], "entity_2_idx_in_text_with_entity_marker": [169, 179], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d114.s969_AIMed.d114.s969.p4", "text": "We have found a COOH-terminal 37-kD fragment of beta 1-syntrophin sufficient to interact with translated dystrophin and its homologues, suggesting that the dystrophin binding site on beta 1-syntrophin occurs on a region that is conserved among the three syntrophin homologues.", "text_with_entity_marker": "We have found a COOH-terminal 37-kD fragment of beta 1-syntrophin sufficient to interact with translated [E1]dystrophin[/E1] and its homologues, suggesting that the dystrophin binding site on [E2]beta 1-syntrophin[/E2] occurs on a region that is conserved among the three syntrophin homologues.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "dystrophin", "entity_1_idx": [[105, 115]], "entity_1_idx_in_text_with_entity_marker": [109, 119], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "beta 1-syntrophin", "entity_2_idx": [[183, 200]], "entity_2_idx_in_text_with_entity_marker": [196, 213], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d114.s969_AIMed.d114.s969.p5", "text": "We have found a COOH-terminal 37-kD fragment of beta 1-syntrophin sufficient to interact with translated dystrophin and its homologues, suggesting that the dystrophin binding site on beta 1-syntrophin occurs on a region that is conserved among the three syntrophin homologues.", "text_with_entity_marker": "We have found a COOH-terminal 37-kD fragment of beta 1-syntrophin sufficient to interact with translated dystrophin and its homologues, suggesting that the [E1]dystrophin[/E1] binding site on [E2]beta 1-syntrophin[/E2] occurs on a region that is conserved among the three syntrophin homologues.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "dystrophin", "entity_1_idx": [[156, 166]], "entity_1_idx_in_text_with_entity_marker": [160, 170], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "beta 1-syntrophin", "entity_2_idx": [[183, 200]], "entity_2_idx_in_text_with_entity_marker": [196, 213], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d68.s578_AIMed.d68.s578.p0", "text": "Two previously unidentified human cdc25 genes have been isolated, cdc25A and cdc25B.", "text_with_entity_marker": "Two previously unidentified human [E1]cdc25[/E1] genes have been isolated, [E2]cdc25A[/E2] and cdc25B.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cdc25", "entity_1_idx": [[34, 39]], "entity_1_idx_in_text_with_entity_marker": [38, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cdc25A", "entity_2_idx": [[66, 72]], "entity_2_idx_in_text_with_entity_marker": [79, 85], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d68.s578_AIMed.d68.s578.p1", "text": "Two previously unidentified human cdc25 genes have been isolated, cdc25A and cdc25B.", "text_with_entity_marker": "Two previously unidentified human [E1]cdc25[/E1] genes have been isolated, cdc25A and [E2]cdc25B[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cdc25", "entity_1_idx": [[34, 39]], "entity_1_idx_in_text_with_entity_marker": [38, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cdc25B", "entity_2_idx": [[77, 83]], "entity_2_idx_in_text_with_entity_marker": [90, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d68.s578_AIMed.d68.s578.p2", "text": "Two previously unidentified human cdc25 genes have been isolated, cdc25A and cdc25B.", "text_with_entity_marker": "Two previously unidentified human cdc25 genes have been isolated, [E1]cdc25A[/E1] and [E2]cdc25B[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cdc25A", "entity_1_idx": [[66, 72]], "entity_1_idx_in_text_with_entity_marker": [70, 76], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cdc25B", "entity_2_idx": [[77, 83]], "entity_2_idx_in_text_with_entity_marker": [90, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d68.s580_AIMed.d68.s580.p0", "text": "Microinjection of anti-cdc25A antibodies into HeLa cells causes their arrest in mitosis. cdc25A and cdc25B display endogenous tyrosine phosphatase activity that is stimulated several-fold, in the absence of cdc2, by stoichiometric addition of either cyclin B1 or B2 but not A or D1.", "text_with_entity_marker": "Microinjection of anti-[E1]cdc25A[/E1] antibodies into HeLa cells causes their arrest in mitosis. [E2]cdc25A[/E2] and cdc25B display endogenous tyrosine phosphatase activity that is stimulated several-fold, in the absence of cdc2, by stoichiometric addition of either cyclin B1 or B2 but not A or D1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cdc25A", "entity_1_idx": [[23, 29]], "entity_1_idx_in_text_with_entity_marker": [27, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cdc25A", "entity_2_idx": [[89, 95]], "entity_2_idx_in_text_with_entity_marker": [102, 108], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d68.s580_AIMed.d68.s580.p1", "text": "Microinjection of anti-cdc25A antibodies into HeLa cells causes their arrest in mitosis. cdc25A and cdc25B display endogenous tyrosine phosphatase activity that is stimulated several-fold, in the absence of cdc2, by stoichiometric addition of either cyclin B1 or B2 but not A or D1.", "text_with_entity_marker": "Microinjection of anti-[E1]cdc25A[/E1] antibodies into HeLa cells causes their arrest in mitosis. cdc25A and [E2]cdc25B[/E2] display endogenous tyrosine phosphatase activity that is stimulated several-fold, in the absence of cdc2, by stoichiometric addition of either cyclin B1 or B2 but not A or D1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cdc25A", "entity_1_idx": [[23, 29]], "entity_1_idx_in_text_with_entity_marker": [27, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cdc25B", "entity_2_idx": [[100, 106]], "entity_2_idx_in_text_with_entity_marker": [113, 119], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d68.s580_AIMed.d68.s580.p2", "text": "Microinjection of anti-cdc25A antibodies into HeLa cells causes their arrest in mitosis. cdc25A and cdc25B display endogenous tyrosine phosphatase activity that is stimulated several-fold, in the absence of cdc2, by stoichiometric addition of either cyclin B1 or B2 but not A or D1.", "text_with_entity_marker": "Microinjection of anti-[E1]cdc25A[/E1] antibodies into HeLa cells causes their arrest in mitosis. cdc25A and cdc25B display endogenous tyrosine phosphatase activity that is stimulated several-fold, in the absence of cdc2, by stoichiometric addition of either [E2]cyclin B1[/E2] or B2 but not A or D1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cdc25A", "entity_1_idx": [[23, 29]], "entity_1_idx_in_text_with_entity_marker": [27, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin B1", "entity_2_idx": [[250, 259]], "entity_2_idx_in_text_with_entity_marker": [263, 272], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d68.s580_AIMed.d68.s580.p3", "text": "Microinjection of anti-cdc25A antibodies into HeLa cells causes their arrest in mitosis. cdc25A and cdc25B display endogenous tyrosine phosphatase activity that is stimulated several-fold, in the absence of cdc2, by stoichiometric addition of either cyclin B1 or B2 but not A or D1.", "text_with_entity_marker": "Microinjection of anti-cdc25A antibodies into HeLa cells causes their arrest in mitosis. [E1]cdc25A[/E1] and [E2]cdc25B[/E2] display endogenous tyrosine phosphatase activity that is stimulated several-fold, in the absence of cdc2, by stoichiometric addition of either cyclin B1 or B2 but not A or D1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cdc25A", "entity_1_idx": [[89, 95]], "entity_1_idx_in_text_with_entity_marker": [93, 99], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cdc25B", "entity_2_idx": [[100, 106]], "entity_2_idx_in_text_with_entity_marker": [113, 119], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d68.s580_AIMed.d68.s580.p4", "text": "Microinjection of anti-cdc25A antibodies into HeLa cells causes their arrest in mitosis. cdc25A and cdc25B display endogenous tyrosine phosphatase activity that is stimulated several-fold, in the absence of cdc2, by stoichiometric addition of either cyclin B1 or B2 but not A or D1.", "text_with_entity_marker": "Microinjection of anti-cdc25A antibodies into HeLa cells causes their arrest in mitosis. [E1]cdc25A[/E1] and cdc25B display endogenous tyrosine phosphatase activity that is stimulated several-fold, in the absence of cdc2, by stoichiometric addition of either [E2]cyclin B1[/E2] or B2 but not A or D1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cdc25A", "entity_1_idx": [[89, 95]], "entity_1_idx_in_text_with_entity_marker": [93, 99], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin B1", "entity_2_idx": [[250, 259]], "entity_2_idx_in_text_with_entity_marker": [263, 272], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d68.s580_AIMed.d68.s580.p5", "text": "Microinjection of anti-cdc25A antibodies into HeLa cells causes their arrest in mitosis. cdc25A and cdc25B display endogenous tyrosine phosphatase activity that is stimulated several-fold, in the absence of cdc2, by stoichiometric addition of either cyclin B1 or B2 but not A or D1.", "text_with_entity_marker": "Microinjection of anti-cdc25A antibodies into HeLa cells causes their arrest in mitosis. cdc25A and [E1]cdc25B[/E1] display endogenous tyrosine phosphatase activity that is stimulated several-fold, in the absence of cdc2, by stoichiometric addition of either [E2]cyclin B1[/E2] or B2 but not A or D1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cdc25B", "entity_1_idx": [[100, 106]], "entity_1_idx_in_text_with_entity_marker": [104, 110], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin B1", "entity_2_idx": [[250, 259]], "entity_2_idx_in_text_with_entity_marker": [263, 272], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d68.s581_AIMed.d68.s581.p0", "text": "Association between cdc25A and cyclin B1/cdc2 was detected in the HeLa cells.", "text_with_entity_marker": "Association between [E1]cdc25A[/E1] and [E2]cyclin B1[/E2]/cdc2 was detected in the HeLa cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "cdc25A", "entity_1_idx": [[20, 26]], "entity_1_idx_in_text_with_entity_marker": [24, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin B1", "entity_2_idx": [[31, 40]], "entity_2_idx_in_text_with_entity_marker": [44, 53], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d68.s581_AIMed.d68.s581.p1", "text": "Association between cdc25A and cyclin B1/cdc2 was detected in the HeLa cells.", "text_with_entity_marker": "Association between [E1]cdc25A[/E1] and cyclin B1/[E2]cdc2[/E2] was detected in the HeLa cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "cdc25A", "entity_1_idx": [[20, 26]], "entity_1_idx_in_text_with_entity_marker": [24, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cdc2", "entity_2_idx": [[41, 45]], "entity_2_idx_in_text_with_entity_marker": [54, 58], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d68.s581_AIMed.d68.s581.p2", "text": "Association between cdc25A and cyclin B1/cdc2 was detected in the HeLa cells.", "text_with_entity_marker": "Association between cdc25A and [E1]cyclin B1[/E1]/[E2]cdc2[/E2] was detected in the HeLa cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclin B1", "entity_1_idx": [[31, 40]], "entity_1_idx_in_text_with_entity_marker": [35, 44], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cdc2", "entity_2_idx": [[41, 45]], "entity_2_idx_in_text_with_entity_marker": [54, 58], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d68.s582_AIMed.d68.s582.p0", "text": "These findings indicate that B-type cyclins are multifunctional proteins that not only act as M phase regulatory subunits of the cdc2 protein kinase, but also activate the cdc25 tyrosine phosphatase, of which cdc2 is the physiological substrate.", "text_with_entity_marker": "These findings indicate that B-type cyclins are multifunctional proteins that not only act as M phase regulatory subunits of the [E1]cdc2[/E1] protein kinase, but also activate the [E2]cdc25[/E2] tyrosine phosphatase, of which cdc2 is the physiological substrate.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cdc2", "entity_1_idx": [[129, 133]], "entity_1_idx_in_text_with_entity_marker": [133, 137], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cdc25", "entity_2_idx": [[172, 177]], "entity_2_idx_in_text_with_entity_marker": [185, 190], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d68.s582_AIMed.d68.s582.p1", "text": "These findings indicate that B-type cyclins are multifunctional proteins that not only act as M phase regulatory subunits of the cdc2 protein kinase, but also activate the cdc25 tyrosine phosphatase, of which cdc2 is the physiological substrate.", "text_with_entity_marker": "These findings indicate that B-type cyclins are multifunctional proteins that not only act as M phase regulatory subunits of the [E1]cdc2[/E1] protein kinase, but also activate the cdc25 tyrosine phosphatase, of which [E2]cdc2[/E2] is the physiological substrate.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cdc2", "entity_1_idx": [[129, 133]], "entity_1_idx_in_text_with_entity_marker": [133, 137], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cdc2", "entity_2_idx": [[209, 213]], "entity_2_idx_in_text_with_entity_marker": [222, 226], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d68.s582_AIMed.d68.s582.p2", "text": "These findings indicate that B-type cyclins are multifunctional proteins that not only act as M phase regulatory subunits of the cdc2 protein kinase, but also activate the cdc25 tyrosine phosphatase, of which cdc2 is the physiological substrate.", "text_with_entity_marker": "These findings indicate that B-type cyclins are multifunctional proteins that not only act as M phase regulatory subunits of the cdc2 protein kinase, but also activate the [E1]cdc25[/E1] tyrosine phosphatase, of which [E2]cdc2[/E2] is the physiological substrate.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cdc25", "entity_1_idx": [[172, 177]], "entity_1_idx_in_text_with_entity_marker": [176, 181], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cdc2", "entity_2_idx": [[209, 213]], "entity_2_idx_in_text_with_entity_marker": [222, 226], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d68.s585_AIMed.d68.s585.p0", "text": "The motif may represent an activating domain that has to be provided to cdc25 by intermolecular interaction with cyclin B.", "text_with_entity_marker": "The motif may represent an activating domain that has to be provided to [E1]cdc25[/E1] by intermolecular interaction with [E2]cyclin B[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cdc25", "entity_1_idx": [[72, 77]], "entity_1_idx_in_text_with_entity_marker": [76, 81], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin B", "entity_2_idx": [[113, 121]], "entity_2_idx_in_text_with_entity_marker": [126, 134], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d85.s717_AIMed.d85.s717.p0", "text": "Wiskott-Aldrich syndrome protein physically associates with Nck through Src homology 3 domains.", "text_with_entity_marker": "[E1]Wiskott-Aldrich syndrome protein[/E1] physically associates with [E2]Nck[/E2] through Src homology 3 domains.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Wiskott-Aldrich syndrome protein", "entity_1_idx": [[0, 32]], "entity_1_idx_in_text_with_entity_marker": [4, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Nck", "entity_2_idx": [[60, 63]], "entity_2_idx_in_text_with_entity_marker": [73, 76], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d85.s718_AIMed.d85.s718.p0", "text": "In the second of a series of experiments designed to identify p47nck-Src homology 3 (SH3)-binding molecules, we report the cloning of SAKAP II (Src A box Nck-associated protein II) from an HL60 cDNA expression library.", "text_with_entity_marker": "In the second of a series of experiments designed to identify [E1]p47nck[/E1]-Src homology 3 (SH3)-binding molecules, we report the cloning of [E2]SAKAP II[/E2] (Src A box Nck-associated protein II) from an HL60 cDNA expression library.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p47nck", "entity_1_idx": [[62, 68]], "entity_1_idx_in_text_with_entity_marker": [66, 72], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SAKAP II", "entity_2_idx": [[134, 142]], "entity_2_idx_in_text_with_entity_marker": [147, 155], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d85.s718_AIMed.d85.s718.p1", "text": "In the second of a series of experiments designed to identify p47nck-Src homology 3 (SH3)-binding molecules, we report the cloning of SAKAP II (Src A box Nck-associated protein II) from an HL60 cDNA expression library.", "text_with_entity_marker": "In the second of a series of experiments designed to identify [E1]p47nck[/E1]-Src homology 3 (SH3)-binding molecules, we report the cloning of SAKAP II ([E2]Src A box Nck-associated protein II[/E2]) from an HL60 cDNA expression library.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p47nck", "entity_1_idx": [[62, 68]], "entity_1_idx_in_text_with_entity_marker": [66, 72], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Src A box Nck-associated protein II", "entity_2_idx": [[144, 179]], "entity_2_idx_in_text_with_entity_marker": [157, 192], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d85.s718_AIMed.d85.s718.p2", "text": "In the second of a series of experiments designed to identify p47nck-Src homology 3 (SH3)-binding molecules, we report the cloning of SAKAP II (Src A box Nck-associated protein II) from an HL60 cDNA expression library.", "text_with_entity_marker": "In the second of a series of experiments designed to identify p47nck-Src homology 3 (SH3)-binding molecules, we report the cloning of [E1]SAKAP II[/E1] ([E2]Src A box Nck-associated protein II[/E2]) from an HL60 cDNA expression library.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SAKAP II", "entity_1_idx": [[134, 142]], "entity_1_idx_in_text_with_entity_marker": [138, 146], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Src A box Nck-associated protein II", "entity_2_idx": [[144, 179]], "entity_2_idx_in_text_with_entity_marker": [157, 192], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d85.s720_AIMed.d85.s720.p0", "text": "Studies in vivo and in vitro demonstrated a highly specific interaction between the SH3 domains of p47nck and Wiskott-Aldrich syndrome protein.", "text_with_entity_marker": "Studies in vivo and in vitro demonstrated a highly specific interaction between the SH3 domains of [E1]p47nck[/E1] and [E2]Wiskott-Aldrich syndrome protein[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p47nck", "entity_1_idx": [[99, 105]], "entity_1_idx_in_text_with_entity_marker": [103, 109], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Wiskott-Aldrich syndrome protein", "entity_2_idx": [[110, 142]], "entity_2_idx_in_text_with_entity_marker": [123, 155], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d85.s722_AIMed.d85.s722.p0", "text": "In vitro translation studies identified the 66-kDa protein as the protein product of WASP, and subcellular fractionation experiments showed that p66WASP is mainly present in the cytosol fraction, although significant amounts are also present in membrane and nuclear fractions.", "text_with_entity_marker": "In vitro translation studies identified the 66-kDa protein as the protein product of [E1]WASP[/E1], and subcellular fractionation experiments showed that [E2]p66WASP[/E2] is mainly present in the cytosol fraction, although significant amounts are also present in membrane and nuclear fractions.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "WASP", "entity_1_idx": [[85, 89]], "entity_1_idx_in_text_with_entity_marker": [89, 93], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p66WASP", "entity_2_idx": [[145, 152]], "entity_2_idx_in_text_with_entity_marker": [158, 165], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d85.s723_AIMed.d85.s723.p0", "text": "The main p47nck region implicated in the association with p66WASP was found to be the carboxy-terminal SH3 domain.", "text_with_entity_marker": "The main [E1]p47nck[/E1] region implicated in the association with [E2]p66WASP[/E2] was found to be the carboxy-terminal SH3 domain.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p47nck", "entity_1_idx": [[9, 15]], "entity_1_idx_in_text_with_entity_marker": [13, 19], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p66WASP", "entity_2_idx": [[58, 65]], "entity_2_idx_in_text_with_entity_marker": [71, 78], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d206.s1779_AIMed.d206.s1779.p0", "text": "As CD9 forms complexes with beta 1 integrins and the integrins are known to regulate keratinocyte behaviour, we investigated CD9 expression and function in human epidermal keratinocytes.", "text_with_entity_marker": "As [E1]CD9[/E1] forms complexes with beta 1 integrins and the integrins are known to regulate keratinocyte behaviour, we investigated [E2]CD9[/E2] expression and function in human epidermal keratinocytes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD9", "entity_1_idx": [[3, 6]], "entity_1_idx_in_text_with_entity_marker": [7, 10], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD9", "entity_2_idx": [[125, 128]], "entity_2_idx_in_text_with_entity_marker": [138, 141], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d206.s1781_AIMed.d206.s1781.p0", "text": "There was extensive co-localisation of CD9 and beta 1 integrins on microvilli and at cell-cell borders of basal keratinocytes; however, in contrast to the integrins, CD9 was not found in focal adhesions.", "text_with_entity_marker": "There was extensive co-localisation of [E1]CD9[/E1] and beta 1 integrins on microvilli and at cell-cell borders of basal keratinocytes; however, in contrast to the integrins, [E2]CD9[/E2] was not found in focal adhesions.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD9", "entity_1_idx": [[39, 42]], "entity_1_idx_in_text_with_entity_marker": [43, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD9", "entity_2_idx": [[166, 169]], "entity_2_idx_in_text_with_entity_marker": [179, 182], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d206.s1782_AIMed.d206.s1782.p0", "text": "CD9 was detected in beta 1 integrin immunoprecipitates and also in immunoprecipitates of CD44 and syndecan, but not of cadherins.", "text_with_entity_marker": "[E1]CD9[/E1] was detected in beta 1 integrin immunoprecipitates and also in immunoprecipitates of [E2]CD44[/E2] and syndecan, but not of cadherins.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD9", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD44", "entity_2_idx": [[89, 93]], "entity_2_idx_in_text_with_entity_marker": [102, 106], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d206.s1782_AIMed.d206.s1782.p1", "text": "CD9 was detected in beta 1 integrin immunoprecipitates and also in immunoprecipitates of CD44 and syndecan, but not of cadherins.", "text_with_entity_marker": "[E1]CD9[/E1] was detected in beta 1 integrin immunoprecipitates and also in immunoprecipitates of CD44 and [E2]syndecan[/E2], but not of cadherins.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD9", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "syndecan", "entity_2_idx": [[98, 106]], "entity_2_idx_in_text_with_entity_marker": [111, 119], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d206.s1782_AIMed.d206.s1782.p2", "text": "CD9 was detected in beta 1 integrin immunoprecipitates and also in immunoprecipitates of CD44 and syndecan, but not of cadherins.", "text_with_entity_marker": "CD9 was detected in beta 1 integrin immunoprecipitates and also in immunoprecipitates of [E1]CD44[/E1] and [E2]syndecan[/E2], but not of cadherins.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD44", "entity_1_idx": [[89, 93]], "entity_1_idx_in_text_with_entity_marker": [93, 97], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "syndecan", "entity_2_idx": [[98, 106]], "entity_2_idx_in_text_with_entity_marker": [111, 119], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d206.s1783_AIMed.d206.s1783.p0", "text": "CD9 was associated with alpha 3 beta 1 but not alpha 5 beta 1; small amounts of CD9 also co-immunoprecipitated with antibodies to alpha 2 beta 1 and alpha 6 beta 4.", "text_with_entity_marker": "[E1]CD9[/E1] was associated with alpha 3 beta 1 but not alpha 5 beta 1; small amounts of [E2]CD9[/E2] also co-immunoprecipitated with antibodies to alpha 2 beta 1 and alpha 6 beta 4.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD9", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD9", "entity_2_idx": [[80, 83]], "entity_2_idx_in_text_with_entity_marker": [93, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d206.s1784_AIMed.d206.s1784.p0", "text": "Antibodies to CD9 did not affect the proportion of keratinocytes that adhered to laminin 1, type IV collagen and fibronectin, but did inhibit motility of keratinocytes on tissue culture plastic.", "text_with_entity_marker": "Antibodies to [E1]CD9[/E1] did not affect the proportion of keratinocytes that adhered to [E2]laminin 1[/E2], type IV collagen and fibronectin, but did inhibit motility of keratinocytes on tissue culture plastic.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD9", "entity_1_idx": [[14, 17]], "entity_1_idx_in_text_with_entity_marker": [18, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "laminin 1", "entity_2_idx": [[81, 90]], "entity_2_idx_in_text_with_entity_marker": [94, 103], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d206.s1784_AIMed.d206.s1784.p1", "text": "Antibodies to CD9 did not affect the proportion of keratinocytes that adhered to laminin 1, type IV collagen and fibronectin, but did inhibit motility of keratinocytes on tissue culture plastic.", "text_with_entity_marker": "Antibodies to [E1]CD9[/E1] did not affect the proportion of keratinocytes that adhered to laminin 1, [E2]type IV collagen[/E2] and fibronectin, but did inhibit motility of keratinocytes on tissue culture plastic.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD9", "entity_1_idx": [[14, 17]], "entity_1_idx_in_text_with_entity_marker": [18, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "type IV collagen", "entity_2_idx": [[92, 108]], "entity_2_idx_in_text_with_entity_marker": [105, 121], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d206.s1784_AIMed.d206.s1784.p2", "text": "Antibodies to CD9 did not affect the proportion of keratinocytes that adhered to laminin 1, type IV collagen and fibronectin, but did inhibit motility of keratinocytes on tissue culture plastic.", "text_with_entity_marker": "Antibodies to [E1]CD9[/E1] did not affect the proportion of keratinocytes that adhered to laminin 1, type IV collagen and [E2]fibronectin[/E2], but did inhibit motility of keratinocytes on tissue culture plastic.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD9", "entity_1_idx": [[14, 17]], "entity_1_idx_in_text_with_entity_marker": [18, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "fibronectin", "entity_2_idx": [[113, 124]], "entity_2_idx_in_text_with_entity_marker": [126, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d206.s1784_AIMed.d206.s1784.p3", "text": "Antibodies to CD9 did not affect the proportion of keratinocytes that adhered to laminin 1, type IV collagen and fibronectin, but did inhibit motility of keratinocytes on tissue culture plastic.", "text_with_entity_marker": "Antibodies to CD9 did not affect the proportion of keratinocytes that adhered to [E1]laminin 1[/E1], [E2]type IV collagen[/E2] and fibronectin, but did inhibit motility of keratinocytes on tissue culture plastic.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "laminin 1", "entity_1_idx": [[81, 90]], "entity_1_idx_in_text_with_entity_marker": [85, 94], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "type IV collagen", "entity_2_idx": [[92, 108]], "entity_2_idx_in_text_with_entity_marker": [105, 121], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d206.s1784_AIMed.d206.s1784.p4", "text": "Antibodies to CD9 did not affect the proportion of keratinocytes that adhered to laminin 1, type IV collagen and fibronectin, but did inhibit motility of keratinocytes on tissue culture plastic.", "text_with_entity_marker": "Antibodies to CD9 did not affect the proportion of keratinocytes that adhered to [E1]laminin 1[/E1], type IV collagen and [E2]fibronectin[/E2], but did inhibit motility of keratinocytes on tissue culture plastic.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "laminin 1", "entity_1_idx": [[81, 90]], "entity_1_idx_in_text_with_entity_marker": [85, 94], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "fibronectin", "entity_2_idx": [[113, 124]], "entity_2_idx_in_text_with_entity_marker": [126, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d206.s1784_AIMed.d206.s1784.p5", "text": "Antibodies to CD9 did not affect the proportion of keratinocytes that adhered to laminin 1, type IV collagen and fibronectin, but did inhibit motility of keratinocytes on tissue culture plastic.", "text_with_entity_marker": "Antibodies to CD9 did not affect the proportion of keratinocytes that adhered to laminin 1, [E1]type IV collagen[/E1] and [E2]fibronectin[/E2], but did inhibit motility of keratinocytes on tissue culture plastic.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "type IV collagen", "entity_1_idx": [[92, 108]], "entity_1_idx_in_text_with_entity_marker": [96, 112], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "fibronectin", "entity_2_idx": [[113, 124]], "entity_2_idx_in_text_with_entity_marker": [126, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d206.s1785_AIMed.d206.s1785.p0", "text": "Like antibodies to the beta 1 integrin subunit, anti-CD9 inhibited suspension-induced terminal differentiation.", "text_with_entity_marker": "Like antibodies to the [E1]beta 1 integrin[/E1] subunit, anti-[E2]CD9[/E2] inhibited suspension-induced terminal differentiation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "beta 1 integrin", "entity_1_idx": [[23, 38]], "entity_1_idx_in_text_with_entity_marker": [27, 42], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD9", "entity_2_idx": [[53, 56]], "entity_2_idx_in_text_with_entity_marker": [66, 69], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d182.s1545_AIMed.d182.s1545.p0", "text": "Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.", "text_with_entity_marker": "Structure of the [E1]MDM2[/E1] oncoprotein bound to the [E2]p53[/E2] tumor suppressor transactivation domain.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "MDM2", "entity_1_idx": [[17, 21]], "entity_1_idx_in_text_with_entity_marker": [21, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[47, 50]], "entity_2_idx_in_text_with_entity_marker": [60, 63], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d182.s1546_AIMed.d182.s1546.p0", "text": "The MDM2 oncoprotein is a cellular inhibitor of the p53 tumor suppressor in that it can bind the transactivation domain of p53 and downregulate its ability to activate transcription.", "text_with_entity_marker": "The [E1]MDM2[/E1] oncoprotein is a cellular inhibitor of the [E2]p53[/E2] tumor suppressor in that it can bind the transactivation domain of p53 and downregulate its ability to activate transcription.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "MDM2", "entity_1_idx": [[4, 8]], "entity_1_idx_in_text_with_entity_marker": [8, 12], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[52, 55]], "entity_2_idx_in_text_with_entity_marker": [65, 68], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d182.s1546_AIMed.d182.s1546.p1", "text": "The MDM2 oncoprotein is a cellular inhibitor of the p53 tumor suppressor in that it can bind the transactivation domain of p53 and downregulate its ability to activate transcription.", "text_with_entity_marker": "The [E1]MDM2[/E1] oncoprotein is a cellular inhibitor of the p53 tumor suppressor in that it can bind the transactivation domain of [E2]p53[/E2] and downregulate its ability to activate transcription.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "MDM2", "entity_1_idx": [[4, 8]], "entity_1_idx_in_text_with_entity_marker": [8, 12], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[123, 126]], "entity_2_idx_in_text_with_entity_marker": [136, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d182.s1546_AIMed.d182.s1546.p2", "text": "The MDM2 oncoprotein is a cellular inhibitor of the p53 tumor suppressor in that it can bind the transactivation domain of p53 and downregulate its ability to activate transcription.", "text_with_entity_marker": "The MDM2 oncoprotein is a cellular inhibitor of the [E1]p53[/E1] tumor suppressor in that it can bind the transactivation domain of [E2]p53[/E2] and downregulate its ability to activate transcription.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[52, 55]], "entity_1_idx_in_text_with_entity_marker": [56, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[123, 126]], "entity_2_idx_in_text_with_entity_marker": [136, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d182.s1547_AIMed.d182.s1547.p0", "text": "In certain cancers, MDM2 amplification is a common event and contributes to the inactivation of p53.", "text_with_entity_marker": "In certain cancers, [E1]MDM2[/E1] amplification is a common event and contributes to the inactivation of [E2]p53[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MDM2", "entity_1_idx": [[20, 24]], "entity_1_idx_in_text_with_entity_marker": [24, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[96, 99]], "entity_2_idx_in_text_with_entity_marker": [109, 112], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d182.s1548_AIMed.d182.s1548.p0", "text": "The crystal structure of the 109-residue amino-terminal domain of MDM2 bound to a 15-residue transactivation domain peptide of p53 revealed that MDM2 has a deep hydrophobic cleft on which the p53 peptide binds as an amphipathic alpha helix.", "text_with_entity_marker": "The crystal structure of the 109-residue amino-terminal domain of [E1]MDM2[/E1] bound to a 15-residue transactivation domain peptide of [E2]p53[/E2] revealed that MDM2 has a deep hydrophobic cleft on which the p53 peptide binds as an amphipathic alpha helix.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "MDM2", "entity_1_idx": [[66, 70]], "entity_1_idx_in_text_with_entity_marker": [70, 74], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[127, 130]], "entity_2_idx_in_text_with_entity_marker": [140, 143], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d182.s1548_AIMed.d182.s1548.p1", "text": "The crystal structure of the 109-residue amino-terminal domain of MDM2 bound to a 15-residue transactivation domain peptide of p53 revealed that MDM2 has a deep hydrophobic cleft on which the p53 peptide binds as an amphipathic alpha helix.", "text_with_entity_marker": "The crystal structure of the 109-residue amino-terminal domain of [E1]MDM2[/E1] bound to a 15-residue transactivation domain peptide of p53 revealed that [E2]MDM2[/E2] has a deep hydrophobic cleft on which the p53 peptide binds as an amphipathic alpha helix.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MDM2", "entity_1_idx": [[66, 70]], "entity_1_idx_in_text_with_entity_marker": [70, 74], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MDM2", "entity_2_idx": [[145, 149]], "entity_2_idx_in_text_with_entity_marker": [158, 162], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d182.s1548_AIMed.d182.s1548.p2", "text": "The crystal structure of the 109-residue amino-terminal domain of MDM2 bound to a 15-residue transactivation domain peptide of p53 revealed that MDM2 has a deep hydrophobic cleft on which the p53 peptide binds as an amphipathic alpha helix.", "text_with_entity_marker": "The crystal structure of the 109-residue amino-terminal domain of [E1]MDM2[/E1] bound to a 15-residue transactivation domain peptide of p53 revealed that MDM2 has a deep hydrophobic cleft on which the [E2]p53[/E2] peptide binds as an amphipathic alpha helix.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MDM2", "entity_1_idx": [[66, 70]], "entity_1_idx_in_text_with_entity_marker": [70, 74], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[192, 195]], "entity_2_idx_in_text_with_entity_marker": [205, 208], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d182.s1548_AIMed.d182.s1548.p3", "text": "The crystal structure of the 109-residue amino-terminal domain of MDM2 bound to a 15-residue transactivation domain peptide of p53 revealed that MDM2 has a deep hydrophobic cleft on which the p53 peptide binds as an amphipathic alpha helix.", "text_with_entity_marker": "The crystal structure of the 109-residue amino-terminal domain of MDM2 bound to a 15-residue transactivation domain peptide of [E1]p53[/E1] revealed that [E2]MDM2[/E2] has a deep hydrophobic cleft on which the p53 peptide binds as an amphipathic alpha helix.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[127, 130]], "entity_1_idx_in_text_with_entity_marker": [131, 134], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MDM2", "entity_2_idx": [[145, 149]], "entity_2_idx_in_text_with_entity_marker": [158, 162], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d182.s1548_AIMed.d182.s1548.p4", "text": "The crystal structure of the 109-residue amino-terminal domain of MDM2 bound to a 15-residue transactivation domain peptide of p53 revealed that MDM2 has a deep hydrophobic cleft on which the p53 peptide binds as an amphipathic alpha helix.", "text_with_entity_marker": "The crystal structure of the 109-residue amino-terminal domain of MDM2 bound to a 15-residue transactivation domain peptide of [E1]p53[/E1] revealed that MDM2 has a deep hydrophobic cleft on which the [E2]p53[/E2] peptide binds as an amphipathic alpha helix.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[127, 130]], "entity_1_idx_in_text_with_entity_marker": [131, 134], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[192, 195]], "entity_2_idx_in_text_with_entity_marker": [205, 208], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d182.s1548_AIMed.d182.s1548.p5", "text": "The crystal structure of the 109-residue amino-terminal domain of MDM2 bound to a 15-residue transactivation domain peptide of p53 revealed that MDM2 has a deep hydrophobic cleft on which the p53 peptide binds as an amphipathic alpha helix.", "text_with_entity_marker": "The crystal structure of the 109-residue amino-terminal domain of MDM2 bound to a 15-residue transactivation domain peptide of p53 revealed that [E1]MDM2[/E1] has a deep hydrophobic cleft on which the [E2]p53[/E2] peptide binds as an amphipathic alpha helix.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "MDM2", "entity_1_idx": [[145, 149]], "entity_1_idx_in_text_with_entity_marker": [149, 153], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[192, 195]], "entity_2_idx_in_text_with_entity_marker": [205, 208], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d182.s1549_AIMed.d182.s1549.p0", "text": "The interface relies on the steric complementarity between the MDM2 cleft and the hydrophobic face of the p53 alpha helix and, in particular, on a triad of p53 amino acids-Phe19, Trp23, and Leu26-which insert deep into the MDM2 cleft.", "text_with_entity_marker": "The interface relies on the steric complementarity between the [E1]MDM2[/E1] cleft and the hydrophobic face of the [E2]p53[/E2] alpha helix and, in particular, on a triad of p53 amino acids-Phe19, Trp23, and Leu26-which insert deep into the MDM2 cleft.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MDM2", "entity_1_idx": [[63, 67]], "entity_1_idx_in_text_with_entity_marker": [67, 71], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[106, 109]], "entity_2_idx_in_text_with_entity_marker": [119, 122], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d182.s1549_AIMed.d182.s1549.p1", "text": "The interface relies on the steric complementarity between the MDM2 cleft and the hydrophobic face of the p53 alpha helix and, in particular, on a triad of p53 amino acids-Phe19, Trp23, and Leu26-which insert deep into the MDM2 cleft.", "text_with_entity_marker": "The interface relies on the steric complementarity between the [E1]MDM2[/E1] cleft and the hydrophobic face of the p53 alpha helix and, in particular, on a triad of [E2]p53[/E2] amino acids-Phe19, Trp23, and Leu26-which insert deep into the MDM2 cleft.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MDM2", "entity_1_idx": [[63, 67]], "entity_1_idx_in_text_with_entity_marker": [67, 71], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[156, 159]], "entity_2_idx_in_text_with_entity_marker": [169, 172], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d182.s1549_AIMed.d182.s1549.p2", "text": "The interface relies on the steric complementarity between the MDM2 cleft and the hydrophobic face of the p53 alpha helix and, in particular, on a triad of p53 amino acids-Phe19, Trp23, and Leu26-which insert deep into the MDM2 cleft.", "text_with_entity_marker": "The interface relies on the steric complementarity between the [E1]MDM2[/E1] cleft and the hydrophobic face of the p53 alpha helix and, in particular, on a triad of p53 amino acids-Phe19, Trp23, and Leu26-which insert deep into the [E2]MDM2[/E2] cleft.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MDM2", "entity_1_idx": [[63, 67]], "entity_1_idx_in_text_with_entity_marker": [67, 71], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MDM2", "entity_2_idx": [[223, 227]], "entity_2_idx_in_text_with_entity_marker": [236, 240], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d182.s1549_AIMed.d182.s1549.p3", "text": "The interface relies on the steric complementarity between the MDM2 cleft and the hydrophobic face of the p53 alpha helix and, in particular, on a triad of p53 amino acids-Phe19, Trp23, and Leu26-which insert deep into the MDM2 cleft.", "text_with_entity_marker": "The interface relies on the steric complementarity between the MDM2 cleft and the hydrophobic face of the [E1]p53[/E1] alpha helix and, in particular, on a triad of [E2]p53[/E2] amino acids-Phe19, Trp23, and Leu26-which insert deep into the MDM2 cleft.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[106, 109]], "entity_1_idx_in_text_with_entity_marker": [110, 113], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[156, 159]], "entity_2_idx_in_text_with_entity_marker": [169, 172], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d182.s1549_AIMed.d182.s1549.p4", "text": "The interface relies on the steric complementarity between the MDM2 cleft and the hydrophobic face of the p53 alpha helix and, in particular, on a triad of p53 amino acids-Phe19, Trp23, and Leu26-which insert deep into the MDM2 cleft.", "text_with_entity_marker": "The interface relies on the steric complementarity between the MDM2 cleft and the hydrophobic face of the [E1]p53[/E1] alpha helix and, in particular, on a triad of p53 amino acids-Phe19, Trp23, and Leu26-which insert deep into the [E2]MDM2[/E2] cleft.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[106, 109]], "entity_1_idx_in_text_with_entity_marker": [110, 113], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MDM2", "entity_2_idx": [[223, 227]], "entity_2_idx_in_text_with_entity_marker": [236, 240], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d182.s1549_AIMed.d182.s1549.p5", "text": "The interface relies on the steric complementarity between the MDM2 cleft and the hydrophobic face of the p53 alpha helix and, in particular, on a triad of p53 amino acids-Phe19, Trp23, and Leu26-which insert deep into the MDM2 cleft.", "text_with_entity_marker": "The interface relies on the steric complementarity between the MDM2 cleft and the hydrophobic face of the p53 alpha helix and, in particular, on a triad of [E1]p53[/E1] amino acids-Phe19, Trp23, and Leu26-which insert deep into the [E2]MDM2[/E2] cleft.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p53", "entity_1_idx": [[156, 159]], "entity_1_idx_in_text_with_entity_marker": [160, 163], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MDM2", "entity_2_idx": [[223, 227]], "entity_2_idx_in_text_with_entity_marker": [236, 240], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d182.s1550_AIMed.d182.s1550.p0", "text": "These same p53 residues are also involved in transactivation, supporting the hypothesis that MDM2 inactivates p53 by concealing its transactivation domain.", "text_with_entity_marker": "These same [E1]p53[/E1] residues are also involved in transactivation, supporting the hypothesis that [E2]MDM2[/E2] inactivates p53 by concealing its transactivation domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[11, 14]], "entity_1_idx_in_text_with_entity_marker": [15, 18], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MDM2", "entity_2_idx": [[93, 97]], "entity_2_idx_in_text_with_entity_marker": [106, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d182.s1550_AIMed.d182.s1550.p1", "text": "These same p53 residues are also involved in transactivation, supporting the hypothesis that MDM2 inactivates p53 by concealing its transactivation domain.", "text_with_entity_marker": "These same [E1]p53[/E1] residues are also involved in transactivation, supporting the hypothesis that MDM2 inactivates [E2]p53[/E2] by concealing its transactivation domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[11, 14]], "entity_1_idx_in_text_with_entity_marker": [15, 18], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[110, 113]], "entity_2_idx_in_text_with_entity_marker": [123, 126], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d182.s1550_AIMed.d182.s1550.p2", "text": "These same p53 residues are also involved in transactivation, supporting the hypothesis that MDM2 inactivates p53 by concealing its transactivation domain.", "text_with_entity_marker": "These same p53 residues are also involved in transactivation, supporting the hypothesis that [E1]MDM2[/E1] inactivates [E2]p53[/E2] by concealing its transactivation domain.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "MDM2", "entity_1_idx": [[93, 97]], "entity_1_idx_in_text_with_entity_marker": [97, 101], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[110, 113]], "entity_2_idx_in_text_with_entity_marker": [123, 126], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d30.s250_AIMed.d30.s250.p0", "text": "Isolation of human delta-catenin and its binding specificity with presenilin 1.", "text_with_entity_marker": "Isolation of human [E1]delta-catenin[/E1] and its binding specificity with [E2]presenilin 1[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "delta-catenin", "entity_1_idx": [[19, 32]], "entity_1_idx_in_text_with_entity_marker": [23, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "presenilin 1", "entity_2_idx": [[66, 78]], "entity_2_idx_in_text_with_entity_marker": [79, 91], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d30.s251_AIMed.d30.s251.p0", "text": "We screened proteins for interaction with presenilin (PS) 1, and cloned the full-length cDNA of human delta-catenin, which encoded 1225 amino acids.", "text_with_entity_marker": "We screened proteins for interaction with [E1]presenilin (PS) 1[/E1], and cloned the full-length cDNA of human [E2]delta-catenin[/E2], which encoded 1225 amino acids.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "presenilin (PS) 1", "entity_1_idx": [[42, 59]], "entity_1_idx_in_text_with_entity_marker": [46, 63], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "delta-catenin", "entity_2_idx": [[102, 115]], "entity_2_idx_in_text_with_entity_marker": [115, 128], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d30.s252_AIMed.d30.s252.p0", "text": "Yeast two-hybrid assay, GST binding assay and immunoprecipitation demonstrated that delta-catenin interacted with a hydrophilic loop region in the endoproteolytic C-terminal fragment of PS1, but not with that of PS-2.", "text_with_entity_marker": "Yeast two-hybrid assay, GST binding assay and immunoprecipitation demonstrated that [E1]delta-catenin[/E1] interacted with a hydrophilic loop region in the endoproteolytic C-terminal fragment of [E2]PS1[/E2], but not with that of PS-2.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "delta-catenin", "entity_1_idx": [[84, 97]], "entity_1_idx_in_text_with_entity_marker": [88, 101], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PS1", "entity_2_idx": [[186, 189]], "entity_2_idx_in_text_with_entity_marker": [199, 202], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d30.s252_AIMed.d30.s252.p1", "text": "Yeast two-hybrid assay, GST binding assay and immunoprecipitation demonstrated that delta-catenin interacted with a hydrophilic loop region in the endoproteolytic C-terminal fragment of PS1, but not with that of PS-2.", "text_with_entity_marker": "Yeast two-hybrid assay, GST binding assay and immunoprecipitation demonstrated that [E1]delta-catenin[/E1] interacted with a hydrophilic loop region in the endoproteolytic C-terminal fragment of PS1, but not with that of [E2]PS-2[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "delta-catenin", "entity_1_idx": [[84, 97]], "entity_1_idx_in_text_with_entity_marker": [88, 101], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PS-2", "entity_2_idx": [[212, 216]], "entity_2_idx_in_text_with_entity_marker": [225, 229], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d30.s252_AIMed.d30.s252.p2", "text": "Yeast two-hybrid assay, GST binding assay and immunoprecipitation demonstrated that delta-catenin interacted with a hydrophilic loop region in the endoproteolytic C-terminal fragment of PS1, but not with that of PS-2.", "text_with_entity_marker": "Yeast two-hybrid assay, GST binding assay and immunoprecipitation demonstrated that delta-catenin interacted with a hydrophilic loop region in the endoproteolytic C-terminal fragment of [E1]PS1[/E1], but not with that of [E2]PS-2[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PS1", "entity_1_idx": [[186, 189]], "entity_1_idx_in_text_with_entity_marker": [190, 193], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PS-2", "entity_2_idx": [[212, 216]], "entity_2_idx_in_text_with_entity_marker": [225, 229], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d30.s253_AIMed.d30.s253.p0", "text": "These results suggest that PS1 and PS2 partly differ in function.", "text_with_entity_marker": "These results suggest that [E1]PS1[/E1] and [E2]PS2[/E2] partly differ in function.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PS1", "entity_1_idx": [[27, 30]], "entity_1_idx_in_text_with_entity_marker": [31, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PS2", "entity_2_idx": [[35, 38]], "entity_2_idx_in_text_with_entity_marker": [48, 51], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d30.s255_AIMed.d30.s255.p0", "text": "We also found another armadillo-protein, p0071, interacted with PS1.", "text_with_entity_marker": "We also found another [E1]armadillo-protein[/E1], [E2]p0071[/E2], interacted with PS1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "armadillo-protein", "entity_1_idx": [[22, 39]], "entity_1_idx_in_text_with_entity_marker": [26, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p0071", "entity_2_idx": [[41, 46]], "entity_2_idx_in_text_with_entity_marker": [54, 59], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d30.s255_AIMed.d30.s255.p1", "text": "We also found another armadillo-protein, p0071, interacted with PS1.", "text_with_entity_marker": "We also found another [E1]armadillo-protein[/E1], p0071, interacted with [E2]PS1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "armadillo-protein", "entity_1_idx": [[22, 39]], "entity_1_idx_in_text_with_entity_marker": [26, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PS1", "entity_2_idx": [[64, 67]], "entity_2_idx_in_text_with_entity_marker": [77, 80], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d30.s255_AIMed.d30.s255.p2", "text": "We also found another armadillo-protein, p0071, interacted with PS1.", "text_with_entity_marker": "We also found another armadillo-protein, [E1]p0071[/E1], interacted with [E2]PS1[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p0071", "entity_1_idx": [[41, 46]], "entity_1_idx_in_text_with_entity_marker": [45, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PS1", "entity_2_idx": [[64, 67]], "entity_2_idx_in_text_with_entity_marker": [77, 80], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d168.s1412_AIMed.d168.s1412.p0", "text": "Identification of a critical ligand binding determinant of the human erythropoietin receptor. Evidence for common ligand binding motifs in the cytokine receptor family.", "text_with_entity_marker": "Identification of a critical ligand binding determinant of the human [E1-E2]erythropoietin[/E1] receptor[/E2]. Evidence for common ligand binding motifs in the cytokine receptor family.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "erythropoietin", "entity_1_idx": [[69, 83]], "entity_1_idx_in_text_with_entity_marker": [76, 90], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "erythropoietin[/E1] receptor", "entity_2_idx": [[69, 92]], "entity_2_idx_in_text_with_entity_marker": [76, 104], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d168.s1413_AIMed.d168.s1413.p0", "text": "The erythropoietin receptor (EPOR) is a member of a family of cytokine and growth factor receptors that share conserved features in their extracellular and cytoplasmic domains.", "text_with_entity_marker": "The [E1-E2]erythropoietin[/E1] receptor[/E2] (EPOR) is a member of a family of cytokine and growth factor receptors that share conserved features in their extracellular and cytoplasmic domains.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "erythropoietin", "entity_1_idx": [[4, 18]], "entity_1_idx_in_text_with_entity_marker": [11, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "erythropoietin[/E1] receptor", "entity_2_idx": [[4, 27]], "entity_2_idx_in_text_with_entity_marker": [11, 39], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d168.s1413_AIMed.d168.s1413.p1", "text": "The erythropoietin receptor (EPOR) is a member of a family of cytokine and growth factor receptors that share conserved features in their extracellular and cytoplasmic domains.", "text_with_entity_marker": "The [E1]erythropoietin[/E1] receptor ([E2]EPOR[/E2]) is a member of a family of cytokine and growth factor receptors that share conserved features in their extracellular and cytoplasmic domains.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "erythropoietin", "entity_1_idx": [[4, 18]], "entity_1_idx_in_text_with_entity_marker": [8, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPOR", "entity_2_idx": [[29, 33]], "entity_2_idx_in_text_with_entity_marker": [42, 46], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d168.s1413_AIMed.d168.s1413.p2", "text": "The erythropoietin receptor (EPOR) is a member of a family of cytokine and growth factor receptors that share conserved features in their extracellular and cytoplasmic domains.", "text_with_entity_marker": "The [E1]erythropoietin receptor[/E1] ([E2]EPOR[/E2]) is a member of a family of cytokine and growth factor receptors that share conserved features in their extracellular and cytoplasmic domains.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "erythropoietin receptor", "entity_1_idx": [[4, 27]], "entity_1_idx_in_text_with_entity_marker": [8, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPOR", "entity_2_idx": [[29, 33]], "entity_2_idx_in_text_with_entity_marker": [42, 46], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d168.s1414_AIMed.d168.s1414.p0", "text": "We have used site-specific mutagenesis within the extracellular domain of the EPOR to search for amino acid residues involved in erythropoietin (EPO) binding.", "text_with_entity_marker": "We have used site-specific mutagenesis within the extracellular domain of the [E1]EPOR[/E1] to search for amino acid residues involved in [E2]erythropoietin[/E2] (EPO) binding.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "EPOR", "entity_1_idx": [[78, 82]], "entity_1_idx_in_text_with_entity_marker": [82, 86], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "erythropoietin", "entity_2_idx": [[129, 143]], "entity_2_idx_in_text_with_entity_marker": [142, 156], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d168.s1414_AIMed.d168.s1414.p1", "text": "We have used site-specific mutagenesis within the extracellular domain of the EPOR to search for amino acid residues involved in erythropoietin (EPO) binding.", "text_with_entity_marker": "We have used site-specific mutagenesis within the extracellular domain of the [E1]EPOR[/E1] to search for amino acid residues involved in erythropoietin ([E2]EPO[/E2]) binding.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "EPOR", "entity_1_idx": [[78, 82]], "entity_1_idx_in_text_with_entity_marker": [82, 86], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[145, 148]], "entity_2_idx_in_text_with_entity_marker": [158, 161], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d168.s1414_AIMed.d168.s1414.p2", "text": "We have used site-specific mutagenesis within the extracellular domain of the EPOR to search for amino acid residues involved in erythropoietin (EPO) binding.", "text_with_entity_marker": "We have used site-specific mutagenesis within the extracellular domain of the EPOR to search for amino acid residues involved in [E1]erythropoietin[/E1] ([E2]EPO[/E2]) binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "erythropoietin", "entity_1_idx": [[129, 143]], "entity_1_idx_in_text_with_entity_marker": [133, 147], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[145, 148]], "entity_2_idx_in_text_with_entity_marker": [158, 161], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d168.s1415_AIMed.d168.s1415.p0", "text": "Mutant proteins were expressed in bacteria as soluble EPO binding proteins (EBP) and characterized for EPO binding activity in a number of different assays.", "text_with_entity_marker": "Mutant proteins were expressed in bacteria as soluble [E1]EPO[/E1] binding proteins ([E2]EBP[/E2]) and characterized for EPO binding activity in a number of different assays.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "EPO", "entity_1_idx": [[54, 57]], "entity_1_idx_in_text_with_entity_marker": [58, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EBP", "entity_2_idx": [[76, 79]], "entity_2_idx_in_text_with_entity_marker": [89, 92], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d168.s1415_AIMed.d168.s1415.p1", "text": "Mutant proteins were expressed in bacteria as soluble EPO binding proteins (EBP) and characterized for EPO binding activity in a number of different assays.", "text_with_entity_marker": "Mutant proteins were expressed in bacteria as soluble [E1]EPO[/E1] binding proteins (EBP) and characterized for [E2]EPO[/E2] binding activity in a number of different assays.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EPO", "entity_1_idx": [[54, 57]], "entity_1_idx_in_text_with_entity_marker": [58, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[103, 106]], "entity_2_idx_in_text_with_entity_marker": [116, 119], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d168.s1415_AIMed.d168.s1415.p2", "text": "Mutant proteins were expressed in bacteria as soluble EPO binding proteins (EBP) and characterized for EPO binding activity in a number of different assays.", "text_with_entity_marker": "Mutant proteins were expressed in bacteria as soluble EPO binding proteins ([E1]EBP[/E1]) and characterized for [E2]EPO[/E2] binding activity in a number of different assays.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EBP", "entity_1_idx": [[76, 79]], "entity_1_idx_in_text_with_entity_marker": [80, 83], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[103, 106]], "entity_2_idx_in_text_with_entity_marker": [116, 119], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d168.s1416_AIMed.d168.s1416.p0", "text": "Substitution of phenylalanine at position 93 (Phe93) with alanine (F93A mutation) resulted in a drastic reduction in EPO binding in the EBP.", "text_with_entity_marker": "Substitution of phenylalanine at position 93 (Phe93) with alanine (F93A mutation) resulted in a drastic reduction in [E1]EPO[/E1] binding in the [E2]EBP[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "EPO", "entity_1_idx": [[117, 120]], "entity_1_idx_in_text_with_entity_marker": [121, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EBP", "entity_2_idx": [[136, 139]], "entity_2_idx_in_text_with_entity_marker": [149, 152], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d168.s1419_AIMed.d168.s1419.p0", "text": "Furthermore, the F93A mutation in full-length EPOR expressed in COS cells abolished detectable EPO binding.", "text_with_entity_marker": "Furthermore, the F93A mutation in full-length [E1]EPOR[/E1] expressed in COS cells abolished detectable [E2]EPO[/E2] binding.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "EPOR", "entity_1_idx": [[46, 50]], "entity_1_idx_in_text_with_entity_marker": [50, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPO", "entity_2_idx": [[95, 98]], "entity_2_idx_in_text_with_entity_marker": [108, 111], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d168.s1422_AIMed.d168.s1422.p0", "text": "These data indicate that Phe93 is a critical EPO binding determinant of the EPOR.", "text_with_entity_marker": "These data indicate that Phe93 is a critical [E1]EPO[/E1] binding determinant of the [E2]EPOR[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "EPO", "entity_1_idx": [[45, 48]], "entity_1_idx_in_text_with_entity_marker": [49, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EPOR", "entity_2_idx": [[76, 80]], "entity_2_idx_in_text_with_entity_marker": [89, 93], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d212.s1835_AIMed.d212.s1835.p0", "text": "Interaction between ATM protein and c-Abl in response to DNA damage.", "text_with_entity_marker": "Interaction between [E1]ATM[/E1] protein and [E2]c-Abl[/E2] in response to DNA damage.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "ATM", "entity_1_idx": [[20, 23]], "entity_1_idx_in_text_with_entity_marker": [24, 27], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Abl", "entity_2_idx": [[36, 41]], "entity_2_idx_in_text_with_entity_marker": [49, 54], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d212.s1836_AIMed.d212.s1836.p0", "text": "The gene mutated in the autosomal recessive disorder ataxia telangiectasia (AT), designated ATM (for 'AT mutated'), is a member of a family of phosphatidylinositol-3-kinase-like enzymes that are involved in cell-cycle control, meiotic recombination, telomere length monitoring and DNA-damage response.", "text_with_entity_marker": "The gene mutated in the autosomal recessive disorder ataxia telangiectasia (AT), designated [E1]ATM[/E1] (for '[E2]AT mutated[/E2]'), is a member of a family of phosphatidylinositol-3-kinase-like enzymes that are involved in cell-cycle control, meiotic recombination, telomere length monitoring and DNA-damage response.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ATM", "entity_1_idx": [[92, 95]], "entity_1_idx_in_text_with_entity_marker": [96, 99], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "AT mutated", "entity_2_idx": [[102, 112]], "entity_2_idx_in_text_with_entity_marker": [115, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d212.s1838_AIMed.d212.s1838.p0", "text": "Because cells lacking the protein tyrosine kinase c-Abl are also defective in radiation-induced G1 arrest, we investigated the possibility that ATM might interact with c-Abl in response to radiation damage.", "text_with_entity_marker": "Because cells lacking the protein tyrosine kinase [E1]c-Abl[/E1] are also defective in radiation-induced G1 arrest, we investigated the possibility that [E2]ATM[/E2] might interact with c-Abl in response to radiation damage.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Abl", "entity_1_idx": [[50, 55]], "entity_1_idx_in_text_with_entity_marker": [54, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ATM", "entity_2_idx": [[144, 147]], "entity_2_idx_in_text_with_entity_marker": [157, 160], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d212.s1838_AIMed.d212.s1838.p1", "text": "Because cells lacking the protein tyrosine kinase c-Abl are also defective in radiation-induced G1 arrest, we investigated the possibility that ATM might interact with c-Abl in response to radiation damage.", "text_with_entity_marker": "Because cells lacking the protein tyrosine kinase [E1]c-Abl[/E1] are also defective in radiation-induced G1 arrest, we investigated the possibility that ATM might interact with [E2]c-Abl[/E2] in response to radiation damage.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Abl", "entity_1_idx": [[50, 55]], "entity_1_idx_in_text_with_entity_marker": [54, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Abl", "entity_2_idx": [[168, 173]], "entity_2_idx_in_text_with_entity_marker": [181, 186], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d212.s1838_AIMed.d212.s1838.p2", "text": "Because cells lacking the protein tyrosine kinase c-Abl are also defective in radiation-induced G1 arrest, we investigated the possibility that ATM might interact with c-Abl in response to radiation damage.", "text_with_entity_marker": "Because cells lacking the protein tyrosine kinase c-Abl are also defective in radiation-induced G1 arrest, we investigated the possibility that [E1]ATM[/E1] might interact with [E2]c-Abl[/E2] in response to radiation damage.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "ATM", "entity_1_idx": [[144, 147]], "entity_1_idx_in_text_with_entity_marker": [148, 151], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Abl", "entity_2_idx": [[168, 173]], "entity_2_idx_in_text_with_entity_marker": [181, 186], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d212.s1839_AIMed.d212.s1839.p0", "text": "Here we show that ATM binds c-Abl constitutively in control cells but not in AT cells.", "text_with_entity_marker": "Here we show that [E1]ATM[/E1] binds [E2]c-Abl[/E2] constitutively in control cells but not in AT cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "ATM", "entity_1_idx": [[18, 21]], "entity_1_idx_in_text_with_entity_marker": [22, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Abl", "entity_2_idx": [[28, 33]], "entity_2_idx_in_text_with_entity_marker": [41, 46], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d212.s1840_AIMed.d212.s1840.p0", "text": "Our results demonstrate that the SH3 domain of c-Abl interacts with a DPAPNPPHFP motif (residues 1,373-1,382) of ATM.", "text_with_entity_marker": "Our results demonstrate that the SH3 domain of [E1]c-Abl[/E1] interacts with a DPAPNPPHFP motif (residues 1,373-1,382) of [E2]ATM[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "c-Abl", "entity_1_idx": [[47, 52]], "entity_1_idx_in_text_with_entity_marker": [51, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ATM", "entity_2_idx": [[113, 116]], "entity_2_idx_in_text_with_entity_marker": [126, 129], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d212.s1842_AIMed.d212.s1842.p0", "text": "These findings indicate that ATM is involved in the activation of c-Abl by DNA damage and this interaction may in part mediate radiation-induced G1 arrest.", "text_with_entity_marker": "These findings indicate that [E1]ATM[/E1] is involved in the activation of [E2]c-Abl[/E2] by DNA damage and this interaction may in part mediate radiation-induced G1 arrest.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "ATM", "entity_1_idx": [[29, 32]], "entity_1_idx_in_text_with_entity_marker": [33, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Abl", "entity_2_idx": [[66, 71]], "entity_2_idx_in_text_with_entity_marker": [79, 84], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d123.s1043_AIMed.d123.s1043.p0", "text": "Characterization of an interaction between insulin receptor substrate 1 and the insulin receptor by using the two-hybrid system.", "text_with_entity_marker": "Characterization of an interaction between [E1]insulin receptor substrate 1[/E1] and the [E2]insulin receptor[/E2] by using the two-hybrid system.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "insulin receptor substrate 1", "entity_1_idx": [[43, 71]], "entity_1_idx_in_text_with_entity_marker": [47, 75], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin receptor", "entity_2_idx": [[80, 96]], "entity_2_idx_in_text_with_entity_marker": [93, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d123.s1044_AIMed.d123.s1044.p0", "text": "Insulin receptor substrate 1 (IRS-1) is a major substrate of the insulin receptor and has been implicated in insulin signaling.", "text_with_entity_marker": "[E1]Insulin receptor substrate 1[/E1] ([E2]IRS-1[/E2]) is a major substrate of the insulin receptor and has been implicated in insulin signaling.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Insulin receptor substrate 1", "entity_1_idx": [[0, 28]], "entity_1_idx_in_text_with_entity_marker": [4, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[30, 35]], "entity_2_idx_in_text_with_entity_marker": [43, 48], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d123.s1044_AIMed.d123.s1044.p1", "text": "Insulin receptor substrate 1 (IRS-1) is a major substrate of the insulin receptor and has been implicated in insulin signaling.", "text_with_entity_marker": "[E1]Insulin receptor substrate 1[/E1] (IRS-1) is a major substrate of the [E2]insulin receptor[/E2] and has been implicated in insulin signaling.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Insulin receptor substrate 1", "entity_1_idx": [[0, 28]], "entity_1_idx_in_text_with_entity_marker": [4, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin receptor", "entity_2_idx": [[65, 81]], "entity_2_idx_in_text_with_entity_marker": [78, 94], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d123.s1044_AIMed.d123.s1044.p2", "text": "Insulin receptor substrate 1 (IRS-1) is a major substrate of the insulin receptor and has been implicated in insulin signaling.", "text_with_entity_marker": "[E1]Insulin receptor substrate 1[/E1] (IRS-1) is a major substrate of the insulin receptor and has been implicated in [E2]insulin[/E2] signaling.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Insulin receptor substrate 1", "entity_1_idx": [[0, 28]], "entity_1_idx_in_text_with_entity_marker": [4, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin", "entity_2_idx": [[109, 116]], "entity_2_idx_in_text_with_entity_marker": [122, 129], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d123.s1044_AIMed.d123.s1044.p3", "text": "Insulin receptor substrate 1 (IRS-1) is a major substrate of the insulin receptor and has been implicated in insulin signaling.", "text_with_entity_marker": "Insulin receptor substrate 1 ([E1]IRS-1[/E1]) is a major substrate of the [E2]insulin receptor[/E2] and has been implicated in insulin signaling.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IRS-1", "entity_1_idx": [[30, 35]], "entity_1_idx_in_text_with_entity_marker": [34, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin receptor", "entity_2_idx": [[65, 81]], "entity_2_idx_in_text_with_entity_marker": [78, 94], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d123.s1044_AIMed.d123.s1044.p4", "text": "Insulin receptor substrate 1 (IRS-1) is a major substrate of the insulin receptor and has been implicated in insulin signaling.", "text_with_entity_marker": "Insulin receptor substrate 1 ([E1]IRS-1[/E1]) is a major substrate of the insulin receptor and has been implicated in [E2]insulin[/E2] signaling.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRS-1", "entity_1_idx": [[30, 35]], "entity_1_idx_in_text_with_entity_marker": [34, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin", "entity_2_idx": [[109, 116]], "entity_2_idx_in_text_with_entity_marker": [122, 129], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d123.s1044_AIMed.d123.s1044.p5", "text": "Insulin receptor substrate 1 (IRS-1) is a major substrate of the insulin receptor and has been implicated in insulin signaling.", "text_with_entity_marker": "Insulin receptor substrate 1 (IRS-1) is a major substrate of the [E1]insulin receptor[/E1] and has been implicated in [E2]insulin[/E2] signaling.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin receptor", "entity_1_idx": [[65, 81]], "entity_1_idx_in_text_with_entity_marker": [69, 85], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin", "entity_2_idx": [[109, 116]], "entity_2_idx_in_text_with_entity_marker": [122, 129], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d123.s1045_AIMed.d123.s1045.p0", "text": "Although IRS-1 is thought to interact with the insulin receptor, the nature of the interaction has not been defined.", "text_with_entity_marker": "Although [E1]IRS-1[/E1] is thought to interact with the [E2]insulin[/E2] receptor, the nature of the interaction has not been defined.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRS-1", "entity_1_idx": [[9, 14]], "entity_1_idx_in_text_with_entity_marker": [13, 18], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin", "entity_2_idx": [[47, 54]], "entity_2_idx_in_text_with_entity_marker": [60, 67], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d123.s1045_AIMed.d123.s1045.p1", "text": "Although IRS-1 is thought to interact with the insulin receptor, the nature of the interaction has not been defined.", "text_with_entity_marker": "Although [E1]IRS-1[/E1] is thought to interact with the [E2]insulin receptor[/E2], the nature of the interaction has not been defined.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IRS-1", "entity_1_idx": [[9, 14]], "entity_1_idx_in_text_with_entity_marker": [13, 18], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin receptor", "entity_2_idx": [[47, 63]], "entity_2_idx_in_text_with_entity_marker": [60, 76], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d123.s1045_AIMed.d123.s1045.p2", "text": "Although IRS-1 is thought to interact with the insulin receptor, the nature of the interaction has not been defined.", "text_with_entity_marker": "Although IRS-1 is thought to interact with the [E1-E2]insulin[/E1] receptor[/E2], the nature of the interaction has not been defined.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin", "entity_1_idx": [[47, 54]], "entity_1_idx_in_text_with_entity_marker": [54, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin[/E1] receptor", "entity_2_idx": [[47, 63]], "entity_2_idx_in_text_with_entity_marker": [54, 75], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d123.s1046_AIMed.d123.s1046.p0", "text": "In this study, we used the two-hybrid assay of protein-protein interaction in the yeast Saccharomyces cerevisiae to study the interaction between human IRS-1 and the insulin receptor.", "text_with_entity_marker": "In this study, we used the two-hybrid assay of protein-protein interaction in the yeast Saccharomyces cerevisiae to study the interaction between human [E1]IRS-1[/E1] and the [E2]insulin[/E2] receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRS-1", "entity_1_idx": [[152, 157]], "entity_1_idx_in_text_with_entity_marker": [156, 161], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin", "entity_2_idx": [[166, 173]], "entity_2_idx_in_text_with_entity_marker": [179, 186], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d123.s1046_AIMed.d123.s1046.p1", "text": "In this study, we used the two-hybrid assay of protein-protein interaction in the yeast Saccharomyces cerevisiae to study the interaction between human IRS-1 and the insulin receptor.", "text_with_entity_marker": "In this study, we used the two-hybrid assay of protein-protein interaction in the yeast Saccharomyces cerevisiae to study the interaction between human [E1]IRS-1[/E1] and the [E2]insulin receptor[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IRS-1", "entity_1_idx": [[152, 157]], "entity_1_idx_in_text_with_entity_marker": [156, 161], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin receptor", "entity_2_idx": [[166, 182]], "entity_2_idx_in_text_with_entity_marker": [179, 195], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d123.s1046_AIMed.d123.s1046.p2", "text": "In this study, we used the two-hybrid assay of protein-protein interaction in the yeast Saccharomyces cerevisiae to study the interaction between human IRS-1 and the insulin receptor.", "text_with_entity_marker": "In this study, we used the two-hybrid assay of protein-protein interaction in the yeast Saccharomyces cerevisiae to study the interaction between human IRS-1 and the [E1-E2]insulin[/E1] receptor[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin", "entity_1_idx": [[166, 173]], "entity_1_idx_in_text_with_entity_marker": [173, 180], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin[/E1] receptor", "entity_2_idx": [[166, 182]], "entity_2_idx_in_text_with_entity_marker": [173, 194], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d123.s1047_AIMed.d123.s1047.p0", "text": "We demonstrate that IRS-1 forms a specific complex with the cytoplasmic domain of the insulin receptor when both are expressed as hybrid proteins in yeast cells.", "text_with_entity_marker": "We demonstrate that [E1]IRS-1[/E1] forms a specific complex with the cytoplasmic domain of the [E2]insulin receptor[/E2] when both are expressed as hybrid proteins in yeast cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IRS-1", "entity_1_idx": [[20, 25]], "entity_1_idx_in_text_with_entity_marker": [24, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin receptor", "entity_2_idx": [[86, 102]], "entity_2_idx_in_text_with_entity_marker": [99, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d123.s1052_AIMed.d123.s1052.p0", "text": "Lastly, in agreement with our findings for yeast cells, we show that the insulin receptor is unable to phosphorylate an IRS-1 protein containing a deletion of amino acids 45 to 516 when expressed in COS cells.", "text_with_entity_marker": "Lastly, in agreement with our findings for yeast cells, we show that the [E1]insulin receptor[/E1] is unable to phosphorylate an [E2]IRS-1[/E2] protein containing a deletion of amino acids 45 to 516 when expressed in COS cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin receptor", "entity_1_idx": [[73, 89]], "entity_1_idx_in_text_with_entity_marker": [77, 93], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[120, 125]], "entity_2_idx_in_text_with_entity_marker": [133, 138], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1284_AIMed.d151.s1284.p0", "text": "The proximal sequence element (PSE)-binding transcription factor (PTF) specifically recognizes the PSEs of both RNA polymerase II- and RNA polymerase III-transcribed small nuclear RNA (snRNA) genes.", "text_with_entity_marker": "The [E1]proximal sequence element (PSE)-binding transcription factor[/E1] ([E2]PTF[/E2]) specifically recognizes the PSEs of both RNA polymerase II- and RNA polymerase III-transcribed small nuclear RNA (snRNA) genes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "proximal sequence element (PSE)-binding transcription factor", "entity_1_idx": [[4, 64]], "entity_1_idx_in_text_with_entity_marker": [8, 68], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PTF", "entity_2_idx": [[66, 69]], "entity_2_idx_in_text_with_entity_marker": [79, 82], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1285_AIMed.d151.s1285.p0", "text": "We previously have shown that PTF purified from human HeLa cells is a multisubunit complex of four polypeptides designated PTF alpha, -beta, -gamma, and -delta.", "text_with_entity_marker": "We previously have shown that [E1]PTF[/E1] purified from human HeLa cells is a multisubunit complex of four polypeptides designated [E2]PTF[/E2] alpha, -beta, -gamma, and -delta.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTF", "entity_1_idx": [[30, 33]], "entity_1_idx_in_text_with_entity_marker": [34, 37], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PTF", "entity_2_idx": [[123, 126]], "entity_2_idx_in_text_with_entity_marker": [136, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1285_AIMed.d151.s1285.p1", "text": "We previously have shown that PTF purified from human HeLa cells is a multisubunit complex of four polypeptides designated PTF alpha, -beta, -gamma, and -delta.", "text_with_entity_marker": "We previously have shown that [E1]PTF[/E1] purified from human HeLa cells is a multisubunit complex of four polypeptides designated [E2]PTF alpha[/E2], -beta, -gamma, and -delta.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTF", "entity_1_idx": [[30, 33]], "entity_1_idx_in_text_with_entity_marker": [34, 37], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PTF alpha", "entity_2_idx": [[123, 132]], "entity_2_idx_in_text_with_entity_marker": [136, 145], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1285_AIMed.d151.s1285.p2", "text": "We previously have shown that PTF purified from human HeLa cells is a multisubunit complex of four polypeptides designated PTF alpha, -beta, -gamma, and -delta.", "text_with_entity_marker": "We previously have shown that PTF purified from human HeLa cells is a multisubunit complex of four polypeptides designated [E1-E2]PTF[/E1] alpha[/E2], -beta, -gamma, and -delta.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTF", "entity_1_idx": [[123, 126]], "entity_1_idx_in_text_with_entity_marker": [130, 133], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PTF[/E1] alpha", "entity_2_idx": [[123, 132]], "entity_2_idx_in_text_with_entity_marker": [130, 144], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1286_AIMed.d151.s1286.p0", "text": "We now report the isolation and expression of cDNAs encoding PTF gamma and PTF delta, as well as functional studies with cognate antibodies that recognize the native PTF complex in HeLa extracts.", "text_with_entity_marker": "We now report the isolation and expression of cDNAs encoding [E1]PTF[/E1] gamma and [E2]PTF[/E2] delta, as well as functional studies with cognate antibodies that recognize the native PTF complex in HeLa extracts.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTF", "entity_1_idx": [[61, 64]], "entity_1_idx_in_text_with_entity_marker": [65, 68], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PTF", "entity_2_idx": [[75, 78]], "entity_2_idx_in_text_with_entity_marker": [88, 91], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1286_AIMed.d151.s1286.p1", "text": "We now report the isolation and expression of cDNAs encoding PTF gamma and PTF delta, as well as functional studies with cognate antibodies that recognize the native PTF complex in HeLa extracts.", "text_with_entity_marker": "We now report the isolation and expression of cDNAs encoding [E1]PTF[/E1] gamma and PTF delta, as well as functional studies with cognate antibodies that recognize the native [E2]PTF[/E2] complex in HeLa extracts.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTF", "entity_1_idx": [[61, 64]], "entity_1_idx_in_text_with_entity_marker": [65, 68], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PTF", "entity_2_idx": [[166, 169]], "entity_2_idx_in_text_with_entity_marker": [179, 182], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1286_AIMed.d151.s1286.p2", "text": "We now report the isolation and expression of cDNAs encoding PTF gamma and PTF delta, as well as functional studies with cognate antibodies that recognize the native PTF complex in HeLa extracts.", "text_with_entity_marker": "We now report the isolation and expression of cDNAs encoding PTF gamma and [E1]PTF[/E1] delta, as well as functional studies with cognate antibodies that recognize the native [E2]PTF[/E2] complex in HeLa extracts.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTF", "entity_1_idx": [[75, 78]], "entity_1_idx_in_text_with_entity_marker": [79, 82], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PTF", "entity_2_idx": [[166, 169]], "entity_2_idx_in_text_with_entity_marker": [179, 182], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1287_AIMed.d151.s1287.p0", "text": "Immunoprecipitation studies confirm that the four PTF subunits originally found to copurify during conventional chromatography indeed form a tightly associated complex; they further show that the PTF so defined, including the gamma and delta subunits specifically, is essential for transcription of both class II and class III snRNA genes.", "text_with_entity_marker": "Immunoprecipitation studies confirm that the four [E1]PTF[/E1] subunits originally found to copurify during conventional chromatography indeed form a tightly associated complex; they further show that the [E2]PTF[/E2] so defined, including the gamma and delta subunits specifically, is essential for transcription of both class II and class III snRNA genes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTF", "entity_1_idx": [[50, 53]], "entity_1_idx_in_text_with_entity_marker": [54, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PTF", "entity_2_idx": [[196, 199]], "entity_2_idx_in_text_with_entity_marker": [209, 212], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1288_AIMed.d151.s1288.p0", "text": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "text_with_entity_marker": "Immunoprecipitation assays also show a weak substoichiometric association of the [E1]TATA-binding protein[/E1] ([E2]TBP[/E2]) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TATA-binding protein", "entity_1_idx": [[81, 101]], "entity_1_idx_in_text_with_entity_marker": [85, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[103, 106]], "entity_2_idx_in_text_with_entity_marker": [116, 119], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1288_AIMed.d151.s1288.p1", "text": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "text_with_entity_marker": "Immunoprecipitation assays also show a weak substoichiometric association of the [E1]TATA-binding protein[/E1] (TBP) with [E2]PTF[/E2], consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TATA-binding protein", "entity_1_idx": [[81, 101]], "entity_1_idx_in_text_with_entity_marker": [85, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PTF", "entity_2_idx": [[113, 116]], "entity_2_idx_in_text_with_entity_marker": [126, 129], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1288_AIMed.d151.s1288.p2", "text": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "text_with_entity_marker": "Immunoprecipitation assays also show a weak substoichiometric association of the [E1]TATA-binding protein[/E1] (TBP) with PTF, consistent with the previous report of a [E2]PTF[/E2]-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TATA-binding protein", "entity_1_idx": [[81, 101]], "entity_1_idx_in_text_with_entity_marker": [85, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PTF", "entity_2_idx": [[159, 162]], "entity_2_idx_in_text_with_entity_marker": [172, 175], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1288_AIMed.d151.s1288.p3", "text": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "text_with_entity_marker": "Immunoprecipitation assays also show a weak substoichiometric association of the [E1]TATA-binding protein[/E1] (TBP) with PTF, consistent with the previous report of a PTF-related complex ([E2]SNAPc[/E2]) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TATA-binding protein", "entity_1_idx": [[81, 101]], "entity_1_idx_in_text_with_entity_marker": [85, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SNAPc", "entity_2_idx": [[180, 185]], "entity_2_idx_in_text_with_entity_marker": [193, 198], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1288_AIMed.d151.s1288.p4", "text": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "text_with_entity_marker": "Immunoprecipitation assays also show a weak substoichiometric association of the [E1]TATA-binding protein[/E1] (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of [E2]TBP[/E2] and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TATA-binding protein", "entity_1_idx": [[81, 101]], "entity_1_idx_in_text_with_entity_marker": [85, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[226, 229]], "entity_2_idx_in_text_with_entity_marker": [239, 242], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1288_AIMed.d151.s1288.p5", "text": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "text_with_entity_marker": "Immunoprecipitation assays also show a weak substoichiometric association of the [E1]TATA-binding protein[/E1] (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component ([E2]SNAPc43[/E2]) identical in sequence to the PTF gamma reported here.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TATA-binding protein", "entity_1_idx": [[81, 101]], "entity_1_idx_in_text_with_entity_marker": [85, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SNAPc43", "entity_2_idx": [[247, 254]], "entity_2_idx_in_text_with_entity_marker": [260, 267], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1288_AIMed.d151.s1288.p6", "text": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "text_with_entity_marker": "Immunoprecipitation assays also show a weak substoichiometric association of the [E1]TATA-binding protein[/E1] (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the [E2]PTF[/E2] gamma reported here.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TATA-binding protein", "entity_1_idx": [[81, 101]], "entity_1_idx_in_text_with_entity_marker": [85, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PTF", "entity_2_idx": [[285, 288]], "entity_2_idx_in_text_with_entity_marker": [298, 301], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1288_AIMed.d151.s1288.p7", "text": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "text_with_entity_marker": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein ([E1]TBP[/E1]) with [E2]PTF[/E2], consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[103, 106]], "entity_1_idx_in_text_with_entity_marker": [107, 110], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PTF", "entity_2_idx": [[113, 116]], "entity_2_idx_in_text_with_entity_marker": [126, 129], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1288_AIMed.d151.s1288.p8", "text": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "text_with_entity_marker": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein ([E1]TBP[/E1]) with PTF, consistent with the previous report of a [E2]PTF[/E2]-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[103, 106]], "entity_1_idx_in_text_with_entity_marker": [107, 110], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PTF", "entity_2_idx": [[159, 162]], "entity_2_idx_in_text_with_entity_marker": [172, 175], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1288_AIMed.d151.s1288.p9", "text": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "text_with_entity_marker": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein ([E1]TBP[/E1]) with PTF, consistent with the previous report of a PTF-related complex ([E2]SNAPc[/E2]) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[103, 106]], "entity_1_idx_in_text_with_entity_marker": [107, 110], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SNAPc", "entity_2_idx": [[180, 185]], "entity_2_idx_in_text_with_entity_marker": [193, 198], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1288_AIMed.d151.s1288.p10", "text": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "text_with_entity_marker": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein ([E1]TBP[/E1]) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of [E2]TBP[/E2] and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[103, 106]], "entity_1_idx_in_text_with_entity_marker": [107, 110], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[226, 229]], "entity_2_idx_in_text_with_entity_marker": [239, 242], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1288_AIMed.d151.s1288.p11", "text": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "text_with_entity_marker": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein ([E1]TBP[/E1]) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component ([E2]SNAPc43[/E2]) identical in sequence to the PTF gamma reported here.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[103, 106]], "entity_1_idx_in_text_with_entity_marker": [107, 110], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SNAPc43", "entity_2_idx": [[247, 254]], "entity_2_idx_in_text_with_entity_marker": [260, 267], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1288_AIMed.d151.s1288.p12", "text": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "text_with_entity_marker": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein ([E1]TBP[/E1]) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the [E2]PTF[/E2] gamma reported here.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[103, 106]], "entity_1_idx_in_text_with_entity_marker": [107, 110], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PTF", "entity_2_idx": [[285, 288]], "entity_2_idx_in_text_with_entity_marker": [298, 301], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1288_AIMed.d151.s1288.p13", "text": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "text_with_entity_marker": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with [E1]PTF[/E1], consistent with the previous report of a [E2]PTF[/E2]-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTF", "entity_1_idx": [[113, 116]], "entity_1_idx_in_text_with_entity_marker": [117, 120], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PTF", "entity_2_idx": [[159, 162]], "entity_2_idx_in_text_with_entity_marker": [172, 175], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1288_AIMed.d151.s1288.p14", "text": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "text_with_entity_marker": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with [E1]PTF[/E1], consistent with the previous report of a PTF-related complex ([E2]SNAPc[/E2]) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTF", "entity_1_idx": [[113, 116]], "entity_1_idx_in_text_with_entity_marker": [117, 120], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SNAPc", "entity_2_idx": [[180, 185]], "entity_2_idx_in_text_with_entity_marker": [193, 198], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1288_AIMed.d151.s1288.p15", "text": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "text_with_entity_marker": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with [E1]PTF[/E1], consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of [E2]TBP[/E2] and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTF", "entity_1_idx": [[113, 116]], "entity_1_idx_in_text_with_entity_marker": [117, 120], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[226, 229]], "entity_2_idx_in_text_with_entity_marker": [239, 242], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1288_AIMed.d151.s1288.p16", "text": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "text_with_entity_marker": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with [E1]PTF[/E1], consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component ([E2]SNAPc43[/E2]) identical in sequence to the PTF gamma reported here.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTF", "entity_1_idx": [[113, 116]], "entity_1_idx_in_text_with_entity_marker": [117, 120], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SNAPc43", "entity_2_idx": [[247, 254]], "entity_2_idx_in_text_with_entity_marker": [260, 267], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1288_AIMed.d151.s1288.p17", "text": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "text_with_entity_marker": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with [E1]PTF[/E1], consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the [E2]PTF[/E2] gamma reported here.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTF", "entity_1_idx": [[113, 116]], "entity_1_idx_in_text_with_entity_marker": [117, 120], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PTF", "entity_2_idx": [[285, 288]], "entity_2_idx_in_text_with_entity_marker": [298, 301], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1288_AIMed.d151.s1288.p18", "text": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "text_with_entity_marker": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a [E1]PTF[/E1]-related complex ([E2]SNAPc[/E2]) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTF", "entity_1_idx": [[159, 162]], "entity_1_idx_in_text_with_entity_marker": [163, 166], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SNAPc", "entity_2_idx": [[180, 185]], "entity_2_idx_in_text_with_entity_marker": [193, 198], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1288_AIMed.d151.s1288.p19", "text": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "text_with_entity_marker": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a [E1]PTF[/E1]-related complex (SNAPc) containing substoichiometric levels of [E2]TBP[/E2] and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTF", "entity_1_idx": [[159, 162]], "entity_1_idx_in_text_with_entity_marker": [163, 166], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[226, 229]], "entity_2_idx_in_text_with_entity_marker": [239, 242], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1288_AIMed.d151.s1288.p20", "text": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "text_with_entity_marker": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a [E1]PTF[/E1]-related complex (SNAPc) containing substoichiometric levels of TBP and a component ([E2]SNAPc43[/E2]) identical in sequence to the PTF gamma reported here.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTF", "entity_1_idx": [[159, 162]], "entity_1_idx_in_text_with_entity_marker": [163, 166], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SNAPc43", "entity_2_idx": [[247, 254]], "entity_2_idx_in_text_with_entity_marker": [260, 267], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1288_AIMed.d151.s1288.p21", "text": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "text_with_entity_marker": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a [E1]PTF[/E1]-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the [E2]PTF[/E2] gamma reported here.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTF", "entity_1_idx": [[159, 162]], "entity_1_idx_in_text_with_entity_marker": [163, 166], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PTF", "entity_2_idx": [[285, 288]], "entity_2_idx_in_text_with_entity_marker": [298, 301], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1288_AIMed.d151.s1288.p22", "text": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "text_with_entity_marker": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex ([E1]SNAPc[/E1]) containing substoichiometric levels of [E2]TBP[/E2] and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SNAPc", "entity_1_idx": [[180, 185]], "entity_1_idx_in_text_with_entity_marker": [184, 189], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[226, 229]], "entity_2_idx_in_text_with_entity_marker": [239, 242], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1288_AIMed.d151.s1288.p23", "text": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "text_with_entity_marker": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex ([E1]SNAPc[/E1]) containing substoichiometric levels of TBP and a component ([E2]SNAPc43[/E2]) identical in sequence to the PTF gamma reported here.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SNAPc", "entity_1_idx": [[180, 185]], "entity_1_idx_in_text_with_entity_marker": [184, 189], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SNAPc43", "entity_2_idx": [[247, 254]], "entity_2_idx_in_text_with_entity_marker": [260, 267], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1288_AIMed.d151.s1288.p24", "text": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "text_with_entity_marker": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex ([E1]SNAPc[/E1]) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the [E2]PTF[/E2] gamma reported here.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SNAPc", "entity_1_idx": [[180, 185]], "entity_1_idx_in_text_with_entity_marker": [184, 189], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PTF", "entity_2_idx": [[285, 288]], "entity_2_idx_in_text_with_entity_marker": [298, 301], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1288_AIMed.d151.s1288.p25", "text": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "text_with_entity_marker": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of [E1]TBP[/E1] and a component ([E2]SNAPc43[/E2]) identical in sequence to the PTF gamma reported here.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[226, 229]], "entity_1_idx_in_text_with_entity_marker": [230, 233], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SNAPc43", "entity_2_idx": [[247, 254]], "entity_2_idx_in_text_with_entity_marker": [260, 267], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1288_AIMed.d151.s1288.p26", "text": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "text_with_entity_marker": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of [E1]TBP[/E1] and a component (SNAPc43) identical in sequence to the [E2]PTF[/E2] gamma reported here.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[226, 229]], "entity_1_idx_in_text_with_entity_marker": [230, 233], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PTF", "entity_2_idx": [[285, 288]], "entity_2_idx_in_text_with_entity_marker": [298, 301], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1288_AIMed.d151.s1288.p27", "text": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.", "text_with_entity_marker": "Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component ([E1]SNAPc43[/E1]) identical in sequence to the [E2]PTF[/E2] gamma reported here.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SNAPc43", "entity_1_idx": [[247, 254]], "entity_1_idx_in_text_with_entity_marker": [251, 258], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PTF", "entity_2_idx": [[285, 288]], "entity_2_idx_in_text_with_entity_marker": [298, 301], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1289_AIMed.d151.s1289.p0", "text": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "text_with_entity_marker": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant [E1]PTF[/E1] gamma and [E2]PTF[/E2] delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTF", "entity_1_idx": [[117, 120]], "entity_1_idx_in_text_with_entity_marker": [121, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PTF", "entity_2_idx": [[131, 134]], "entity_2_idx_in_text_with_entity_marker": [144, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1289_AIMed.d151.s1289.p1", "text": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "text_with_entity_marker": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant [E1]PTF[/E1] gamma and PTF delta with [E2]TBP[/E2], consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTF", "entity_1_idx": [[117, 120]], "entity_1_idx_in_text_with_entity_marker": [121, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[146, 149]], "entity_2_idx_in_text_with_entity_marker": [159, 162], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1289_AIMed.d151.s1289.p2", "text": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "text_with_entity_marker": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant [E1]PTF[/E1] gamma and PTF delta with TBP, consistent either with the natural association of [E2]TBP[/E2] with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTF", "entity_1_idx": [[117, 120]], "entity_1_idx_in_text_with_entity_marker": [121, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[201, 204]], "entity_2_idx_in_text_with_entity_marker": [214, 217], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1289_AIMed.d151.s1289.p3", "text": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "text_with_entity_marker": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant [E1]PTF[/E1] gamma and PTF delta with TBP, consistent either with the natural association of TBP with [E2]PTF[/E2] in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTF", "entity_1_idx": [[117, 120]], "entity_1_idx_in_text_with_entity_marker": [121, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PTF", "entity_2_idx": [[210, 213]], "entity_2_idx_in_text_with_entity_marker": [223, 226], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1289_AIMed.d151.s1289.p4", "text": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "text_with_entity_marker": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant [E1]PTF[/E1] gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable [E2]TBP[/E2]-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTF", "entity_1_idx": [[117, 120]], "entity_1_idx_in_text_with_entity_marker": [121, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[230, 233]], "entity_2_idx_in_text_with_entity_marker": [243, 246], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1289_AIMed.d151.s1289.p5", "text": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "text_with_entity_marker": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant [E1]PTF[/E1] gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-[E2]TBP[/E2]-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTF", "entity_1_idx": [[117, 120]], "entity_1_idx_in_text_with_entity_marker": [121, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[234, 237]], "entity_2_idx_in_text_with_entity_marker": [247, 250], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1289_AIMed.d151.s1289.p6", "text": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "text_with_entity_marker": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant [E1]PTF[/E1] gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound [E2]PTF[/E2] and TATA-bound TBP during promoter activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTF", "entity_1_idx": [[117, 120]], "entity_1_idx_in_text_with_entity_marker": [121, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PTF", "entity_2_idx": [[323, 326]], "entity_2_idx_in_text_with_entity_marker": [336, 339], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1289_AIMed.d151.s1289.p7", "text": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "text_with_entity_marker": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant [E1]PTF[/E1] gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound [E2]TBP[/E2] during promoter activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTF", "entity_1_idx": [[117, 120]], "entity_1_idx_in_text_with_entity_marker": [121, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[342, 345]], "entity_2_idx_in_text_with_entity_marker": [355, 358], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1289_AIMed.d151.s1289.p8", "text": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "text_with_entity_marker": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and [E1]PTF[/E1] delta with [E2]TBP[/E2], consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTF", "entity_1_idx": [[131, 134]], "entity_1_idx_in_text_with_entity_marker": [135, 138], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[146, 149]], "entity_2_idx_in_text_with_entity_marker": [159, 162], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1289_AIMed.d151.s1289.p9", "text": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "text_with_entity_marker": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and [E1]PTF[/E1] delta with TBP, consistent either with the natural association of [E2]TBP[/E2] with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTF", "entity_1_idx": [[131, 134]], "entity_1_idx_in_text_with_entity_marker": [135, 138], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[201, 204]], "entity_2_idx_in_text_with_entity_marker": [214, 217], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1289_AIMed.d151.s1289.p10", "text": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "text_with_entity_marker": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and [E1]PTF[/E1] delta with TBP, consistent either with the natural association of TBP with [E2]PTF[/E2] in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTF", "entity_1_idx": [[131, 134]], "entity_1_idx_in_text_with_entity_marker": [135, 138], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PTF", "entity_2_idx": [[210, 213]], "entity_2_idx_in_text_with_entity_marker": [223, 226], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1289_AIMed.d151.s1289.p11", "text": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "text_with_entity_marker": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and [E1]PTF[/E1] delta with TBP, consistent either with the natural association of TBP with PTF in a semistable [E2]TBP[/E2]-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTF", "entity_1_idx": [[131, 134]], "entity_1_idx_in_text_with_entity_marker": [135, 138], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[230, 233]], "entity_2_idx_in_text_with_entity_marker": [243, 246], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1289_AIMed.d151.s1289.p12", "text": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "text_with_entity_marker": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and [E1]PTF[/E1] delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-[E2]TBP[/E2]-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTF", "entity_1_idx": [[131, 134]], "entity_1_idx_in_text_with_entity_marker": [135, 138], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[234, 237]], "entity_2_idx_in_text_with_entity_marker": [247, 250], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1289_AIMed.d151.s1289.p13", "text": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "text_with_entity_marker": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and [E1]PTF[/E1] delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound [E2]PTF[/E2] and TATA-bound TBP during promoter activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTF", "entity_1_idx": [[131, 134]], "entity_1_idx_in_text_with_entity_marker": [135, 138], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PTF", "entity_2_idx": [[323, 326]], "entity_2_idx_in_text_with_entity_marker": [336, 339], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1289_AIMed.d151.s1289.p14", "text": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "text_with_entity_marker": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and [E1]PTF[/E1] delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound [E2]TBP[/E2] during promoter activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTF", "entity_1_idx": [[131, 134]], "entity_1_idx_in_text_with_entity_marker": [135, 138], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[342, 345]], "entity_2_idx_in_text_with_entity_marker": [355, 358], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1289_AIMed.d151.s1289.p15", "text": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "text_with_entity_marker": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with [E1]TBP[/E1], consistent either with the natural association of [E2]TBP[/E2] with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[146, 149]], "entity_1_idx_in_text_with_entity_marker": [150, 153], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[201, 204]], "entity_2_idx_in_text_with_entity_marker": [214, 217], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1289_AIMed.d151.s1289.p16", "text": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "text_with_entity_marker": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with [E1]TBP[/E1], consistent either with the natural association of TBP with [E2]PTF[/E2] in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[146, 149]], "entity_1_idx_in_text_with_entity_marker": [150, 153], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PTF", "entity_2_idx": [[210, 213]], "entity_2_idx_in_text_with_entity_marker": [223, 226], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1289_AIMed.d151.s1289.p17", "text": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "text_with_entity_marker": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with [E1]TBP[/E1], consistent either with the natural association of TBP with PTF in a semistable [E2]TBP[/E2]-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[146, 149]], "entity_1_idx_in_text_with_entity_marker": [150, 153], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[230, 233]], "entity_2_idx_in_text_with_entity_marker": [243, 246], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1289_AIMed.d151.s1289.p18", "text": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "text_with_entity_marker": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with [E1]TBP[/E1], consistent either with the natural association of TBP with PTF in a semistable TBP-[E2]TBP[/E2]-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[146, 149]], "entity_1_idx_in_text_with_entity_marker": [150, 153], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[234, 237]], "entity_2_idx_in_text_with_entity_marker": [247, 250], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1289_AIMed.d151.s1289.p19", "text": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "text_with_entity_marker": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with [E1]TBP[/E1], consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound [E2]PTF[/E2] and TATA-bound TBP during promoter activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[146, 149]], "entity_1_idx_in_text_with_entity_marker": [150, 153], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PTF", "entity_2_idx": [[323, 326]], "entity_2_idx_in_text_with_entity_marker": [336, 339], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1289_AIMed.d151.s1289.p20", "text": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "text_with_entity_marker": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with [E1]TBP[/E1], consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound [E2]TBP[/E2] during promoter activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[146, 149]], "entity_1_idx_in_text_with_entity_marker": [150, 153], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[342, 345]], "entity_2_idx_in_text_with_entity_marker": [355, 358], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1289_AIMed.d151.s1289.p21", "text": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "text_with_entity_marker": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of [E1]TBP[/E1] with [E2]PTF[/E2] in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[201, 204]], "entity_1_idx_in_text_with_entity_marker": [205, 208], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PTF", "entity_2_idx": [[210, 213]], "entity_2_idx_in_text_with_entity_marker": [223, 226], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1289_AIMed.d151.s1289.p22", "text": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "text_with_entity_marker": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of [E1]TBP[/E1] with PTF in a semistable [E2]TBP[/E2]-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[201, 204]], "entity_1_idx_in_text_with_entity_marker": [205, 208], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[230, 233]], "entity_2_idx_in_text_with_entity_marker": [243, 246], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1289_AIMed.d151.s1289.p23", "text": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "text_with_entity_marker": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of [E1]TBP[/E1] with PTF in a semistable TBP-[E2]TBP[/E2]-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[201, 204]], "entity_1_idx_in_text_with_entity_marker": [205, 208], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[234, 237]], "entity_2_idx_in_text_with_entity_marker": [247, 250], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1289_AIMed.d151.s1289.p24", "text": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "text_with_entity_marker": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of [E1]TBP[/E1] with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound [E2]PTF[/E2] and TATA-bound TBP during promoter activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[201, 204]], "entity_1_idx_in_text_with_entity_marker": [205, 208], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PTF", "entity_2_idx": [[323, 326]], "entity_2_idx_in_text_with_entity_marker": [336, 339], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1289_AIMed.d151.s1289.p25", "text": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "text_with_entity_marker": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of [E1]TBP[/E1] with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound [E2]TBP[/E2] during promoter activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[201, 204]], "entity_1_idx_in_text_with_entity_marker": [205, 208], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[342, 345]], "entity_2_idx_in_text_with_entity_marker": [355, 358], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1289_AIMed.d151.s1289.p26", "text": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "text_with_entity_marker": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with [E1]PTF[/E1] in a semistable [E2]TBP[/E2]-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTF", "entity_1_idx": [[210, 213]], "entity_1_idx_in_text_with_entity_marker": [214, 217], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[230, 233]], "entity_2_idx_in_text_with_entity_marker": [243, 246], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1289_AIMed.d151.s1289.p27", "text": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "text_with_entity_marker": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with [E1]PTF[/E1] in a semistable TBP-[E2]TBP[/E2]-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTF", "entity_1_idx": [[210, 213]], "entity_1_idx_in_text_with_entity_marker": [214, 217], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[234, 237]], "entity_2_idx_in_text_with_entity_marker": [247, 250], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1289_AIMed.d151.s1289.p28", "text": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "text_with_entity_marker": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with [E1]PTF[/E1] in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound [E2]PTF[/E2] and TATA-bound TBP during promoter activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTF", "entity_1_idx": [[210, 213]], "entity_1_idx_in_text_with_entity_marker": [214, 217], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PTF", "entity_2_idx": [[323, 326]], "entity_2_idx_in_text_with_entity_marker": [336, 339], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1289_AIMed.d151.s1289.p29", "text": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "text_with_entity_marker": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with [E1]PTF[/E1] in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound [E2]TBP[/E2] during promoter activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTF", "entity_1_idx": [[210, 213]], "entity_1_idx_in_text_with_entity_marker": [214, 217], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[342, 345]], "entity_2_idx_in_text_with_entity_marker": [355, 358], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1289_AIMed.d151.s1289.p30", "text": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "text_with_entity_marker": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable [E1]TBP[/E1]-[E2]TBP[/E2]-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[230, 233]], "entity_1_idx_in_text_with_entity_marker": [234, 237], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[234, 237]], "entity_2_idx_in_text_with_entity_marker": [247, 250], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1289_AIMed.d151.s1289.p31", "text": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "text_with_entity_marker": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable [E1]TBP[/E1]-TBP-associated factor complex or with possible functional interactions between PSE-bound [E2]PTF[/E2] and TATA-bound TBP during promoter activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[230, 233]], "entity_1_idx_in_text_with_entity_marker": [234, 237], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PTF", "entity_2_idx": [[323, 326]], "entity_2_idx_in_text_with_entity_marker": [336, 339], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1289_AIMed.d151.s1289.p32", "text": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "text_with_entity_marker": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable [E1]TBP[/E1]-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound [E2]TBP[/E2] during promoter activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[230, 233]], "entity_1_idx_in_text_with_entity_marker": [234, 237], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[342, 345]], "entity_2_idx_in_text_with_entity_marker": [355, 358], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1289_AIMed.d151.s1289.p33", "text": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "text_with_entity_marker": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-[E1]TBP[/E1]-associated factor complex or with possible functional interactions between PSE-bound [E2]PTF[/E2] and TATA-bound TBP during promoter activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[234, 237]], "entity_1_idx_in_text_with_entity_marker": [238, 241], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PTF", "entity_2_idx": [[323, 326]], "entity_2_idx_in_text_with_entity_marker": [336, 339], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1289_AIMed.d151.s1289.p34", "text": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "text_with_entity_marker": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-[E1]TBP[/E1]-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound [E2]TBP[/E2] during promoter activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[234, 237]], "entity_1_idx_in_text_with_entity_marker": [238, 241], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[342, 345]], "entity_2_idx_in_text_with_entity_marker": [355, 358], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1289_AIMed.d151.s1289.p35", "text": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.", "text_with_entity_marker": "Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound [E1]PTF[/E1] and TATA-bound [E2]TBP[/E2] during promoter activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTF", "entity_1_idx": [[323, 326]], "entity_1_idx_in_text_with_entity_marker": [327, 330], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[342, 345]], "entity_2_idx_in_text_with_entity_marker": [355, 358], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1290_AIMed.d151.s1290.p0", "text": "In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.", "text_with_entity_marker": "In addition, we show that in extracts depleted of [E1]TBP[/E1] and [E2]TBP[/E2]-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[50, 53]], "entity_1_idx_in_text_with_entity_marker": [54, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[58, 61]], "entity_2_idx_in_text_with_entity_marker": [71, 74], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1290_AIMed.d151.s1290.p1", "text": "In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.", "text_with_entity_marker": "In addition, we show that in extracts depleted of [E1]TBP[/E1] and TBP-associated factors, transcription from the U1 promoter is restored by recombinant [E2]TBP[/E2] but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[50, 53]], "entity_1_idx_in_text_with_entity_marker": [54, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[144, 147]], "entity_2_idx_in_text_with_entity_marker": [157, 160], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1290_AIMed.d151.s1290.p2", "text": "In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.", "text_with_entity_marker": "In addition, we show that in extracts depleted of [E1]TBP[/E1] and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by [E2]TFIID[/E2] or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[50, 53]], "entity_1_idx_in_text_with_entity_marker": [54, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIID", "entity_2_idx": [[159, 164]], "entity_2_idx_in_text_with_entity_marker": [172, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1290_AIMed.d151.s1290.p3", "text": "In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.", "text_with_entity_marker": "In addition, we show that in extracts depleted of [E1]TBP[/E1] and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or [E2]TFIIIB[/E2], indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[50, 53]], "entity_1_idx_in_text_with_entity_marker": [54, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIIB", "entity_2_idx": [[168, 174]], "entity_2_idx_in_text_with_entity_marker": [181, 187], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1290_AIMed.d151.s1290.p4", "text": "In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.", "text_with_entity_marker": "In addition, we show that in extracts depleted of [E1]TBP[/E1] and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a [E2]TBP[/E2] complex different from the one used for mRNA-encoding genes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[50, 53]], "entity_1_idx_in_text_with_entity_marker": [54, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[241, 244]], "entity_2_idx_in_text_with_entity_marker": [254, 257], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1290_AIMed.d151.s1290.p5", "text": "In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.", "text_with_entity_marker": "In addition, we show that in extracts depleted of TBP and [E1]TBP[/E1]-associated factors, transcription from the U1 promoter is restored by recombinant [E2]TBP[/E2] but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[58, 61]], "entity_1_idx_in_text_with_entity_marker": [62, 65], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[144, 147]], "entity_2_idx_in_text_with_entity_marker": [157, 160], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1290_AIMed.d151.s1290.p6", "text": "In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.", "text_with_entity_marker": "In addition, we show that in extracts depleted of TBP and [E1]TBP[/E1]-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by [E2]TFIID[/E2] or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[58, 61]], "entity_1_idx_in_text_with_entity_marker": [62, 65], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIID", "entity_2_idx": [[159, 164]], "entity_2_idx_in_text_with_entity_marker": [172, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1290_AIMed.d151.s1290.p7", "text": "In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.", "text_with_entity_marker": "In addition, we show that in extracts depleted of TBP and [E1]TBP[/E1]-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or [E2]TFIIIB[/E2], indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[58, 61]], "entity_1_idx_in_text_with_entity_marker": [62, 65], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIIB", "entity_2_idx": [[168, 174]], "entity_2_idx_in_text_with_entity_marker": [181, 187], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1290_AIMed.d151.s1290.p8", "text": "In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.", "text_with_entity_marker": "In addition, we show that in extracts depleted of TBP and [E1]TBP[/E1]-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a [E2]TBP[/E2] complex different from the one used for mRNA-encoding genes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[58, 61]], "entity_1_idx_in_text_with_entity_marker": [62, 65], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[241, 244]], "entity_2_idx_in_text_with_entity_marker": [254, 257], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1290_AIMed.d151.s1290.p9", "text": "In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.", "text_with_entity_marker": "In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant [E1]TBP[/E1] but not by [E2]TFIID[/E2] or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[144, 147]], "entity_1_idx_in_text_with_entity_marker": [148, 151], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIID", "entity_2_idx": [[159, 164]], "entity_2_idx_in_text_with_entity_marker": [172, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1290_AIMed.d151.s1290.p10", "text": "In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.", "text_with_entity_marker": "In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant [E1]TBP[/E1] but not by TFIID or [E2]TFIIIB[/E2], indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[144, 147]], "entity_1_idx_in_text_with_entity_marker": [148, 151], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIIB", "entity_2_idx": [[168, 174]], "entity_2_idx_in_text_with_entity_marker": [181, 187], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1290_AIMed.d151.s1290.p11", "text": "In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.", "text_with_entity_marker": "In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant [E1]TBP[/E1] but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a [E2]TBP[/E2] complex different from the one used for mRNA-encoding genes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[144, 147]], "entity_1_idx_in_text_with_entity_marker": [148, 151], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[241, 244]], "entity_2_idx_in_text_with_entity_marker": [254, 257], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1290_AIMed.d151.s1290.p12", "text": "In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.", "text_with_entity_marker": "In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by [E1]TFIID[/E1] or [E2]TFIIIB[/E2], indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[159, 164]], "entity_1_idx_in_text_with_entity_marker": [163, 168], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIIB", "entity_2_idx": [[168, 174]], "entity_2_idx_in_text_with_entity_marker": [181, 187], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1290_AIMed.d151.s1290.p13", "text": "In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.", "text_with_entity_marker": "In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by [E1]TFIID[/E1] or TFIIIB, indicating that transcription of class II snRNA genes requires a [E2]TBP[/E2] complex different from the one used for mRNA-encoding genes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[159, 164]], "entity_1_idx_in_text_with_entity_marker": [163, 168], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[241, 244]], "entity_2_idx_in_text_with_entity_marker": [254, 257], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d151.s1290_AIMed.d151.s1290.p14", "text": "In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.", "text_with_entity_marker": "In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or [E1]TFIIIB[/E1], indicating that transcription of class II snRNA genes requires a [E2]TBP[/E2] complex different from the one used for mRNA-encoding genes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIIIB", "entity_1_idx": [[168, 174]], "entity_1_idx_in_text_with_entity_marker": [172, 178], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[241, 244]], "entity_2_idx_in_text_with_entity_marker": [254, 257], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d106.s893_AIMed.d106.s893.p0", "text": "Raf1 interaction with Cdc25 phosphatase ties mitogenic signal transduction to cell cycle activation.", "text_with_entity_marker": "[E1]Raf1[/E1] interaction with [E2]Cdc25 phosphatase[/E2] ties mitogenic signal transduction to cell cycle activation.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Raf1", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdc25 phosphatase", "entity_2_idx": [[22, 39]], "entity_2_idx_in_text_with_entity_marker": [35, 52], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d106.s894_AIMed.d106.s894.p0", "text": "The Ras and Raf1 proto-oncogenes transduce extracellular signals that promote cell growth.", "text_with_entity_marker": "The [E1]Ras[/E1] and [E2]Raf1[/E2] proto-oncogenes transduce extracellular signals that promote cell growth.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Ras", "entity_1_idx": [[4, 7]], "entity_1_idx_in_text_with_entity_marker": [8, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Raf1", "entity_2_idx": [[12, 16]], "entity_2_idx_in_text_with_entity_marker": [25, 29], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d106.s896_AIMed.d106.s896.p0", "text": "We show here that Cdc25 phosphatase associates with raf1 in somatic mammalian cells and in meiotic frog oocytes.", "text_with_entity_marker": "We show here that [E1]Cdc25 phosphatase[/E1] associates with [E2]raf1[/E2] in somatic mammalian cells and in meiotic frog oocytes.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Cdc25 phosphatase", "entity_1_idx": [[18, 35]], "entity_1_idx_in_text_with_entity_marker": [22, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "raf1", "entity_2_idx": [[52, 56]], "entity_2_idx_in_text_with_entity_marker": [65, 69], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d106.s897_AIMed.d106.s897.p0", "text": "Furthermore, Cdc25 phosphatase can be activated in vitro in a Raf1-dependent manner.", "text_with_entity_marker": "Furthermore, [E1]Cdc25 phosphatase[/E1] can be activated in vitro in a [E2]Raf1[/E2]-dependent manner.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Cdc25 phosphatase", "entity_1_idx": [[13, 30]], "entity_1_idx_in_text_with_entity_marker": [17, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Raf1", "entity_2_idx": [[62, 66]], "entity_2_idx_in_text_with_entity_marker": [75, 79], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d106.s898_AIMed.d106.s898.p0", "text": "We suggest that activation of the cell cycle by the Ras/Raf1 pathways might be mediated in part by Cdc25.", "text_with_entity_marker": "We suggest that activation of the cell cycle by the [E1]Ras[/E1]/[E2]Raf1[/E2] pathways might be mediated in part by Cdc25.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Ras", "entity_1_idx": [[52, 55]], "entity_1_idx_in_text_with_entity_marker": [56, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Raf1", "entity_2_idx": [[56, 60]], "entity_2_idx_in_text_with_entity_marker": [69, 73], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d106.s898_AIMed.d106.s898.p1", "text": "We suggest that activation of the cell cycle by the Ras/Raf1 pathways might be mediated in part by Cdc25.", "text_with_entity_marker": "We suggest that activation of the cell cycle by the [E1]Ras[/E1]/Raf1 pathways might be mediated in part by [E2]Cdc25[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Ras", "entity_1_idx": [[52, 55]], "entity_1_idx_in_text_with_entity_marker": [56, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdc25", "entity_2_idx": [[99, 104]], "entity_2_idx_in_text_with_entity_marker": [112, 117], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d106.s898_AIMed.d106.s898.p2", "text": "We suggest that activation of the cell cycle by the Ras/Raf1 pathways might be mediated in part by Cdc25.", "text_with_entity_marker": "We suggest that activation of the cell cycle by the Ras/[E1]Raf1[/E1] pathways might be mediated in part by [E2]Cdc25[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Raf1", "entity_1_idx": [[56, 60]], "entity_1_idx_in_text_with_entity_marker": [60, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdc25", "entity_2_idx": [[99, 104]], "entity_2_idx_in_text_with_entity_marker": [112, 117], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s30_AIMed.d3.s30.p0", "text": "Temporally following this growth arrest, the cells develop a senescence morphology and express senescence-associated beta-galactosidase (SA-beta-gal).", "text_with_entity_marker": "Temporally following this growth arrest, the cells develop a senescence morphology and express [E1]senescence-associated [E2]beta-galactosidase[/E1-E2] (SA-beta-gal).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "senescence-associated [E2]beta-galactosidase", "entity_1_idx": [[95, 135]], "entity_1_idx_in_text_with_entity_marker": [99, 143], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "beta-galactosidase", "entity_2_idx": [[117, 135]], "entity_2_idx_in_text_with_entity_marker": [125, 143], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s30_AIMed.d3.s30.p1", "text": "Temporally following this growth arrest, the cells develop a senescence morphology and express senescence-associated beta-galactosidase (SA-beta-gal).", "text_with_entity_marker": "Temporally following this growth arrest, the cells develop a senescence morphology and express senescence-associated [E1]beta-galactosidase[/E1] ([E2]SA-beta-gal[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "beta-galactosidase", "entity_1_idx": [[117, 135]], "entity_1_idx_in_text_with_entity_marker": [121, 139], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SA-beta-gal", "entity_2_idx": [[137, 148]], "entity_2_idx_in_text_with_entity_marker": [150, 161], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s30_AIMed.d3.s30.p2", "text": "Temporally following this growth arrest, the cells develop a senescence morphology and express senescence-associated beta-galactosidase (SA-beta-gal).", "text_with_entity_marker": "Temporally following this growth arrest, the cells develop a senescence morphology and express [E1]senescence-associated beta-galactosidase[/E1] ([E2]SA-beta-gal[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "senescence-associated beta-galactosidase", "entity_1_idx": [[95, 135]], "entity_1_idx_in_text_with_entity_marker": [99, 139], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SA-beta-gal", "entity_2_idx": [[137, 148]], "entity_2_idx_in_text_with_entity_marker": [150, 161], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s31_AIMed.d3.s31.p0", "text": "Levels of p16(INK4a) and p57(KIP2) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.", "text_with_entity_marker": "Levels of [E1]p16[/E1]([E2]INK4a[/E2]) and p57(KIP2) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p16", "entity_1_idx": [[10, 13]], "entity_1_idx_in_text_with_entity_marker": [14, 17], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "INK4a", "entity_2_idx": [[14, 19]], "entity_2_idx_in_text_with_entity_marker": [27, 32], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s31_AIMed.d3.s31.p1", "text": "Levels of p16(INK4a) and p57(KIP2) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.", "text_with_entity_marker": "Levels of [E1]p16[/E1](INK4a) and [E2]p57[/E2](KIP2) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p16", "entity_1_idx": [[10, 13]], "entity_1_idx_in_text_with_entity_marker": [14, 17], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p57", "entity_2_idx": [[25, 28]], "entity_2_idx_in_text_with_entity_marker": [38, 41], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s31_AIMed.d3.s31.p2", "text": "Levels of p16(INK4a) and p57(KIP2) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.", "text_with_entity_marker": "Levels of [E1]p16[/E1](INK4a) and p57([E2]KIP2[/E2]) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p16", "entity_1_idx": [[10, 13]], "entity_1_idx_in_text_with_entity_marker": [14, 17], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KIP2", "entity_2_idx": [[29, 33]], "entity_2_idx_in_text_with_entity_marker": [42, 46], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s31_AIMed.d3.s31.p3", "text": "Levels of p16(INK4a) and p57(KIP2) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.", "text_with_entity_marker": "Levels of [E1]p16[/E1](INK4a) and p57(KIP2) rise in HUCs during progressive passages, whereas only [E2]p16[/E2] increases in HPEC cultures.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p16", "entity_1_idx": [[10, 13]], "entity_1_idx_in_text_with_entity_marker": [14, 17], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p16", "entity_2_idx": [[90, 93]], "entity_2_idx_in_text_with_entity_marker": [103, 106], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s31_AIMed.d3.s31.p4", "text": "Levels of p16(INK4a) and p57(KIP2) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.", "text_with_entity_marker": "Levels of p16([E1]INK4a[/E1]) and [E2]p57[/E2](KIP2) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "INK4a", "entity_1_idx": [[14, 19]], "entity_1_idx_in_text_with_entity_marker": [18, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p57", "entity_2_idx": [[25, 28]], "entity_2_idx_in_text_with_entity_marker": [38, 41], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s31_AIMed.d3.s31.p5", "text": "Levels of p16(INK4a) and p57(KIP2) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.", "text_with_entity_marker": "Levels of p16([E1]INK4a[/E1]) and p57([E2]KIP2[/E2]) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "INK4a", "entity_1_idx": [[14, 19]], "entity_1_idx_in_text_with_entity_marker": [18, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KIP2", "entity_2_idx": [[29, 33]], "entity_2_idx_in_text_with_entity_marker": [42, 46], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s31_AIMed.d3.s31.p6", "text": "Levels of p16(INK4a) and p57(KIP2) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.", "text_with_entity_marker": "Levels of p16([E1]INK4a[/E1]) and p57(KIP2) rise in HUCs during progressive passages, whereas only [E2]p16[/E2] increases in HPEC cultures.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "INK4a", "entity_1_idx": [[14, 19]], "entity_1_idx_in_text_with_entity_marker": [18, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p16", "entity_2_idx": [[90, 93]], "entity_2_idx_in_text_with_entity_marker": [103, 106], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s31_AIMed.d3.s31.p7", "text": "Levels of p16(INK4a) and p57(KIP2) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.", "text_with_entity_marker": "Levels of p16(INK4a) and [E1]p57[/E1]([E2]KIP2[/E2]) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p57", "entity_1_idx": [[25, 28]], "entity_1_idx_in_text_with_entity_marker": [29, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KIP2", "entity_2_idx": [[29, 33]], "entity_2_idx_in_text_with_entity_marker": [42, 46], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s31_AIMed.d3.s31.p8", "text": "Levels of p16(INK4a) and p57(KIP2) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.", "text_with_entity_marker": "Levels of p16(INK4a) and [E1]p57[/E1](KIP2) rise in HUCs during progressive passages, whereas only [E2]p16[/E2] increases in HPEC cultures.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p57", "entity_1_idx": [[25, 28]], "entity_1_idx_in_text_with_entity_marker": [29, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p16", "entity_2_idx": [[90, 93]], "entity_2_idx_in_text_with_entity_marker": [103, 106], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s31_AIMed.d3.s31.p9", "text": "Levels of p16(INK4a) and p57(KIP2) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.", "text_with_entity_marker": "Levels of p16(INK4a) and p57([E1]KIP2[/E1]) rise in HUCs during progressive passages, whereas only [E2]p16[/E2] increases in HPEC cultures.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "KIP2", "entity_1_idx": [[29, 33]], "entity_1_idx_in_text_with_entity_marker": [33, 37], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p16", "entity_2_idx": [[90, 93]], "entity_2_idx_in_text_with_entity_marker": [103, 106], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s32_AIMed.d3.s32.p0", "text": "The induced expression of p57, similar to p16, produces a senescent-like phenotype.", "text_with_entity_marker": "The induced expression of [E1]p57[/E1], similar to [E2]p16[/E2], produces a senescent-like phenotype.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p57", "entity_1_idx": [[26, 29]], "entity_1_idx_in_text_with_entity_marker": [30, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p16", "entity_2_idx": [[42, 45]], "entity_2_idx_in_text_with_entity_marker": [55, 58], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s33_AIMed.d3.s33.p0", "text": "pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.", "text_with_entity_marker": "[E1]pRB[/E1], [E2]cyclin D[/E2], p19(INK4d) and p27(KIP1) decrease in both cell types.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pRB", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin D", "entity_2_idx": [[5, 13]], "entity_2_idx_in_text_with_entity_marker": [18, 26], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s33_AIMed.d3.s33.p1", "text": "pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.", "text_with_entity_marker": "[E1]pRB[/E1], cyclin D, [E2]p19[/E2](INK4d) and p27(KIP1) decrease in both cell types.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pRB", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p19", "entity_2_idx": [[15, 18]], "entity_2_idx_in_text_with_entity_marker": [28, 31], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s33_AIMed.d3.s33.p2", "text": "pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.", "text_with_entity_marker": "[E1]pRB[/E1], cyclin D, p19([E2]INK4d[/E2]) and p27(KIP1) decrease in both cell types.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pRB", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "INK4d", "entity_2_idx": [[19, 24]], "entity_2_idx_in_text_with_entity_marker": [32, 37], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s33_AIMed.d3.s33.p3", "text": "pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.", "text_with_entity_marker": "[E1]pRB[/E1], cyclin D, p19(INK4d) and [E2]p27[/E2](KIP1) decrease in both cell types.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pRB", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p27", "entity_2_idx": [[30, 33]], "entity_2_idx_in_text_with_entity_marker": [43, 46], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s33_AIMed.d3.s33.p4", "text": "pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.", "text_with_entity_marker": "[E1]pRB[/E1], cyclin D, p19(INK4d) and p27([E2]KIP1[/E2]) decrease in both cell types.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pRB", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KIP1", "entity_2_idx": [[34, 38]], "entity_2_idx_in_text_with_entity_marker": [47, 51], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s33_AIMed.d3.s33.p5", "text": "pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.", "text_with_entity_marker": "pRB, [E1]cyclin D[/E1], [E2]p19[/E2](INK4d) and p27(KIP1) decrease in both cell types.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclin D", "entity_1_idx": [[5, 13]], "entity_1_idx_in_text_with_entity_marker": [9, 17], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p19", "entity_2_idx": [[15, 18]], "entity_2_idx_in_text_with_entity_marker": [28, 31], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s33_AIMed.d3.s33.p6", "text": "pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.", "text_with_entity_marker": "pRB, [E1]cyclin D[/E1], p19([E2]INK4d[/E2]) and p27(KIP1) decrease in both cell types.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclin D", "entity_1_idx": [[5, 13]], "entity_1_idx_in_text_with_entity_marker": [9, 17], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "INK4d", "entity_2_idx": [[19, 24]], "entity_2_idx_in_text_with_entity_marker": [32, 37], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s33_AIMed.d3.s33.p7", "text": "pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.", "text_with_entity_marker": "pRB, [E1]cyclin D[/E1], p19(INK4d) and [E2]p27[/E2](KIP1) decrease in both cell types.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclin D", "entity_1_idx": [[5, 13]], "entity_1_idx_in_text_with_entity_marker": [9, 17], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p27", "entity_2_idx": [[30, 33]], "entity_2_idx_in_text_with_entity_marker": [43, 46], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s33_AIMed.d3.s33.p8", "text": "pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.", "text_with_entity_marker": "pRB, [E1]cyclin D[/E1], p19(INK4d) and p27([E2]KIP1[/E2]) decrease in both cell types.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cyclin D", "entity_1_idx": [[5, 13]], "entity_1_idx_in_text_with_entity_marker": [9, 17], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KIP1", "entity_2_idx": [[34, 38]], "entity_2_idx_in_text_with_entity_marker": [47, 51], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s33_AIMed.d3.s33.p9", "text": "pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.", "text_with_entity_marker": "pRB, cyclin D, [E1]p19[/E1]([E2]INK4d[/E2]) and p27(KIP1) decrease in both cell types.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p19", "entity_1_idx": [[15, 18]], "entity_1_idx_in_text_with_entity_marker": [19, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "INK4d", "entity_2_idx": [[19, 24]], "entity_2_idx_in_text_with_entity_marker": [32, 37], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s33_AIMed.d3.s33.p10", "text": "pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.", "text_with_entity_marker": "pRB, cyclin D, [E1]p19[/E1](INK4d) and [E2]p27[/E2](KIP1) decrease in both cell types.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p19", "entity_1_idx": [[15, 18]], "entity_1_idx_in_text_with_entity_marker": [19, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p27", "entity_2_idx": [[30, 33]], "entity_2_idx_in_text_with_entity_marker": [43, 46], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s33_AIMed.d3.s33.p11", "text": "pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.", "text_with_entity_marker": "pRB, cyclin D, [E1]p19[/E1](INK4d) and p27([E2]KIP1[/E2]) decrease in both cell types.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p19", "entity_1_idx": [[15, 18]], "entity_1_idx_in_text_with_entity_marker": [19, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KIP1", "entity_2_idx": [[34, 38]], "entity_2_idx_in_text_with_entity_marker": [47, 51], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s33_AIMed.d3.s33.p12", "text": "pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.", "text_with_entity_marker": "pRB, cyclin D, p19([E1]INK4d[/E1]) and [E2]p27[/E2](KIP1) decrease in both cell types.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "INK4d", "entity_1_idx": [[19, 24]], "entity_1_idx_in_text_with_entity_marker": [23, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p27", "entity_2_idx": [[30, 33]], "entity_2_idx_in_text_with_entity_marker": [43, 46], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s33_AIMed.d3.s33.p13", "text": "pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.", "text_with_entity_marker": "pRB, cyclin D, p19([E1]INK4d[/E1]) and p27([E2]KIP1[/E2]) decrease in both cell types.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "INK4d", "entity_1_idx": [[19, 24]], "entity_1_idx_in_text_with_entity_marker": [23, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KIP1", "entity_2_idx": [[34, 38]], "entity_2_idx_in_text_with_entity_marker": [47, 51], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s33_AIMed.d3.s33.p14", "text": "pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.", "text_with_entity_marker": "pRB, cyclin D, p19(INK4d) and [E1]p27[/E1]([E2]KIP1[/E2]) decrease in both cell types.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p27", "entity_1_idx": [[30, 33]], "entity_1_idx_in_text_with_entity_marker": [34, 37], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KIP1", "entity_2_idx": [[34, 38]], "entity_2_idx_in_text_with_entity_marker": [47, 51], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s34_AIMed.d3.s34.p0", "text": "We find that p53, p21(CIP1) and p15(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.", "text_with_entity_marker": "We find that [E1]p53[/E1], [E2]p21[/E2](CIP1) and p15(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[13, 16]], "entity_1_idx_in_text_with_entity_marker": [17, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p21", "entity_2_idx": [[18, 21]], "entity_2_idx_in_text_with_entity_marker": [31, 34], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s34_AIMed.d3.s34.p1", "text": "We find that p53, p21(CIP1) and p15(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.", "text_with_entity_marker": "We find that [E1]p53[/E1], p21([E2]CIP1[/E2]) and p15(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[13, 16]], "entity_1_idx_in_text_with_entity_marker": [17, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CIP1", "entity_2_idx": [[22, 26]], "entity_2_idx_in_text_with_entity_marker": [35, 39], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s34_AIMed.d3.s34.p2", "text": "We find that p53, p21(CIP1) and p15(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.", "text_with_entity_marker": "We find that [E1]p53[/E1], p21(CIP1) and [E2]p15[/E2](INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[13, 16]], "entity_1_idx_in_text_with_entity_marker": [17, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p15", "entity_2_idx": [[32, 35]], "entity_2_idx_in_text_with_entity_marker": [45, 48], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s34_AIMed.d3.s34.p3", "text": "We find that p53, p21(CIP1) and p15(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.", "text_with_entity_marker": "We find that [E1]p53[/E1], p21(CIP1) and p15([E2]INK4b[/E2]) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[13, 16]], "entity_1_idx_in_text_with_entity_marker": [17, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "INK4b", "entity_2_idx": [[36, 41]], "entity_2_idx_in_text_with_entity_marker": [49, 54], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s34_AIMed.d3.s34.p4", "text": "We find that p53, p21(CIP1) and p15(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.", "text_with_entity_marker": "We find that p53, [E1]p21[/E1]([E2]CIP1[/E2]) and p15(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p21", "entity_1_idx": [[18, 21]], "entity_1_idx_in_text_with_entity_marker": [22, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CIP1", "entity_2_idx": [[22, 26]], "entity_2_idx_in_text_with_entity_marker": [35, 39], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s34_AIMed.d3.s34.p5", "text": "We find that p53, p21(CIP1) and p15(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.", "text_with_entity_marker": "We find that p53, [E1]p21[/E1](CIP1) and [E2]p15[/E2](INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p21", "entity_1_idx": [[18, 21]], "entity_1_idx_in_text_with_entity_marker": [22, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p15", "entity_2_idx": [[32, 35]], "entity_2_idx_in_text_with_entity_marker": [45, 48], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s34_AIMed.d3.s34.p6", "text": "We find that p53, p21(CIP1) and p15(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.", "text_with_entity_marker": "We find that p53, [E1]p21[/E1](CIP1) and p15([E2]INK4b[/E2]) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p21", "entity_1_idx": [[18, 21]], "entity_1_idx_in_text_with_entity_marker": [22, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "INK4b", "entity_2_idx": [[36, 41]], "entity_2_idx_in_text_with_entity_marker": [49, 54], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s34_AIMed.d3.s34.p7", "text": "We find that p53, p21(CIP1) and p15(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.", "text_with_entity_marker": "We find that p53, p21([E1]CIP1[/E1]) and [E2]p15[/E2](INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CIP1", "entity_1_idx": [[22, 26]], "entity_1_idx_in_text_with_entity_marker": [26, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p15", "entity_2_idx": [[32, 35]], "entity_2_idx_in_text_with_entity_marker": [45, 48], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s34_AIMed.d3.s34.p8", "text": "We find that p53, p21(CIP1) and p15(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.", "text_with_entity_marker": "We find that p53, p21([E1]CIP1[/E1]) and p15([E2]INK4b[/E2]) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CIP1", "entity_1_idx": [[22, 26]], "entity_1_idx_in_text_with_entity_marker": [26, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "INK4b", "entity_2_idx": [[36, 41]], "entity_2_idx_in_text_with_entity_marker": [49, 54], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s34_AIMed.d3.s34.p9", "text": "We find that p53, p21(CIP1) and p15(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.", "text_with_entity_marker": "We find that p53, p21(CIP1) and [E1]p15[/E1]([E2]INK4b[/E2]) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p15", "entity_1_idx": [[32, 35]], "entity_1_idx_in_text_with_entity_marker": [36, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "INK4b", "entity_2_idx": [[36, 41]], "entity_2_idx_in_text_with_entity_marker": [49, 54], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s35_AIMed.d3.s35.p0", "text": "Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "text_with_entity_marker": "Analysis of [E1]p53[/E1], [E2]p21[/E2](CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[12, 15]], "entity_1_idx_in_text_with_entity_marker": [16, 19], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p21", "entity_2_idx": [[17, 20]], "entity_2_idx_in_text_with_entity_marker": [30, 33], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s35_AIMed.d3.s35.p1", "text": "Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "text_with_entity_marker": "Analysis of [E1]p53[/E1], p21([E2]CIP1[/E2]), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[12, 15]], "entity_1_idx_in_text_with_entity_marker": [16, 19], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CIP1", "entity_2_idx": [[21, 25]], "entity_2_idx_in_text_with_entity_marker": [34, 38], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s35_AIMed.d3.s35.p2", "text": "Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "text_with_entity_marker": "Analysis of [E1]p53[/E1], p21(CIP1), [E2]p15[/E2](INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[12, 15]], "entity_1_idx_in_text_with_entity_marker": [16, 19], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p15", "entity_2_idx": [[28, 31]], "entity_2_idx_in_text_with_entity_marker": [41, 44], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s35_AIMed.d3.s35.p3", "text": "Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "text_with_entity_marker": "Analysis of [E1]p53[/E1], p21(CIP1), p15([E2]INK4b[/E2]), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[12, 15]], "entity_1_idx_in_text_with_entity_marker": [16, 19], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "INK4b", "entity_2_idx": [[32, 37]], "entity_2_idx_in_text_with_entity_marker": [45, 50], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s35_AIMed.d3.s35.p4", "text": "Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "text_with_entity_marker": "Analysis of [E1]p53[/E1], p21(CIP1), p15(INK4b), [E2]p16[/E2](INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[12, 15]], "entity_1_idx_in_text_with_entity_marker": [16, 19], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p16", "entity_2_idx": [[40, 43]], "entity_2_idx_in_text_with_entity_marker": [53, 56], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s35_AIMed.d3.s35.p5", "text": "Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "text_with_entity_marker": "Analysis of [E1]p53[/E1], p21(CIP1), p15(INK4b), p16([E2]INK4a[/E2]), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[12, 15]], "entity_1_idx_in_text_with_entity_marker": [16, 19], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "INK4a", "entity_2_idx": [[44, 49]], "entity_2_idx_in_text_with_entity_marker": [57, 62], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s35_AIMed.d3.s35.p6", "text": "Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "text_with_entity_marker": "Analysis of [E1]p53[/E1], p21(CIP1), p15(INK4b), p16(INK4a), and [E2]p57[/E2](KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[12, 15]], "entity_1_idx_in_text_with_entity_marker": [16, 19], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p57", "entity_2_idx": [[56, 59]], "entity_2_idx_in_text_with_entity_marker": [69, 72], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s35_AIMed.d3.s35.p7", "text": "Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "text_with_entity_marker": "Analysis of [E1]p53[/E1], p21(CIP1), p15(INK4b), p16(INK4a), and p57([E2]KIP2[/E2]) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[12, 15]], "entity_1_idx_in_text_with_entity_marker": [16, 19], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KIP2", "entity_2_idx": [[60, 64]], "entity_2_idx_in_text_with_entity_marker": [73, 77], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s35_AIMed.d3.s35.p8", "text": "Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "text_with_entity_marker": "Analysis of p53, [E1]p21[/E1]([E2]CIP1[/E2]), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p21", "entity_1_idx": [[17, 20]], "entity_1_idx_in_text_with_entity_marker": [21, 24], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CIP1", "entity_2_idx": [[21, 25]], "entity_2_idx_in_text_with_entity_marker": [34, 38], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s35_AIMed.d3.s35.p9", "text": "Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "text_with_entity_marker": "Analysis of p53, [E1]p21[/E1](CIP1), [E2]p15[/E2](INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p21", "entity_1_idx": [[17, 20]], "entity_1_idx_in_text_with_entity_marker": [21, 24], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p15", "entity_2_idx": [[28, 31]], "entity_2_idx_in_text_with_entity_marker": [41, 44], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s35_AIMed.d3.s35.p10", "text": "Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "text_with_entity_marker": "Analysis of p53, [E1]p21[/E1](CIP1), p15([E2]INK4b[/E2]), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p21", "entity_1_idx": [[17, 20]], "entity_1_idx_in_text_with_entity_marker": [21, 24], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "INK4b", "entity_2_idx": [[32, 37]], "entity_2_idx_in_text_with_entity_marker": [45, 50], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s35_AIMed.d3.s35.p11", "text": "Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "text_with_entity_marker": "Analysis of p53, [E1]p21[/E1](CIP1), p15(INK4b), [E2]p16[/E2](INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p21", "entity_1_idx": [[17, 20]], "entity_1_idx_in_text_with_entity_marker": [21, 24], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p16", "entity_2_idx": [[40, 43]], "entity_2_idx_in_text_with_entity_marker": [53, 56], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s35_AIMed.d3.s35.p12", "text": "Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "text_with_entity_marker": "Analysis of p53, [E1]p21[/E1](CIP1), p15(INK4b), p16([E2]INK4a[/E2]), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p21", "entity_1_idx": [[17, 20]], "entity_1_idx_in_text_with_entity_marker": [21, 24], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "INK4a", "entity_2_idx": [[44, 49]], "entity_2_idx_in_text_with_entity_marker": [57, 62], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s35_AIMed.d3.s35.p13", "text": "Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "text_with_entity_marker": "Analysis of p53, [E1]p21[/E1](CIP1), p15(INK4b), p16(INK4a), and [E2]p57[/E2](KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p21", "entity_1_idx": [[17, 20]], "entity_1_idx_in_text_with_entity_marker": [21, 24], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p57", "entity_2_idx": [[56, 59]], "entity_2_idx_in_text_with_entity_marker": [69, 72], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s35_AIMed.d3.s35.p14", "text": "Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "text_with_entity_marker": "Analysis of p53, [E1]p21[/E1](CIP1), p15(INK4b), p16(INK4a), and p57([E2]KIP2[/E2]) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p21", "entity_1_idx": [[17, 20]], "entity_1_idx_in_text_with_entity_marker": [21, 24], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KIP2", "entity_2_idx": [[60, 64]], "entity_2_idx_in_text_with_entity_marker": [73, 77], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s35_AIMed.d3.s35.p15", "text": "Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "text_with_entity_marker": "Analysis of p53, p21([E1]CIP1[/E1]), [E2]p15[/E2](INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CIP1", "entity_1_idx": [[21, 25]], "entity_1_idx_in_text_with_entity_marker": [25, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p15", "entity_2_idx": [[28, 31]], "entity_2_idx_in_text_with_entity_marker": [41, 44], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s35_AIMed.d3.s35.p16", "text": "Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "text_with_entity_marker": "Analysis of p53, p21([E1]CIP1[/E1]), p15([E2]INK4b[/E2]), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CIP1", "entity_1_idx": [[21, 25]], "entity_1_idx_in_text_with_entity_marker": [25, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "INK4b", "entity_2_idx": [[32, 37]], "entity_2_idx_in_text_with_entity_marker": [45, 50], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s35_AIMed.d3.s35.p17", "text": "Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "text_with_entity_marker": "Analysis of p53, p21([E1]CIP1[/E1]), p15(INK4b), [E2]p16[/E2](INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CIP1", "entity_1_idx": [[21, 25]], "entity_1_idx_in_text_with_entity_marker": [25, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p16", "entity_2_idx": [[40, 43]], "entity_2_idx_in_text_with_entity_marker": [53, 56], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s35_AIMed.d3.s35.p18", "text": "Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "text_with_entity_marker": "Analysis of p53, p21([E1]CIP1[/E1]), p15(INK4b), p16([E2]INK4a[/E2]), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CIP1", "entity_1_idx": [[21, 25]], "entity_1_idx_in_text_with_entity_marker": [25, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "INK4a", "entity_2_idx": [[44, 49]], "entity_2_idx_in_text_with_entity_marker": [57, 62], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s35_AIMed.d3.s35.p19", "text": "Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "text_with_entity_marker": "Analysis of p53, p21([E1]CIP1[/E1]), p15(INK4b), p16(INK4a), and [E2]p57[/E2](KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CIP1", "entity_1_idx": [[21, 25]], "entity_1_idx_in_text_with_entity_marker": [25, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p57", "entity_2_idx": [[56, 59]], "entity_2_idx_in_text_with_entity_marker": [69, 72], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s35_AIMed.d3.s35.p20", "text": "Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "text_with_entity_marker": "Analysis of p53, p21([E1]CIP1[/E1]), p15(INK4b), p16(INK4a), and p57([E2]KIP2[/E2]) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CIP1", "entity_1_idx": [[21, 25]], "entity_1_idx_in_text_with_entity_marker": [25, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KIP2", "entity_2_idx": [[60, 64]], "entity_2_idx_in_text_with_entity_marker": [73, 77], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s35_AIMed.d3.s35.p21", "text": "Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "text_with_entity_marker": "Analysis of p53, p21(CIP1), [E1]p15[/E1]([E2]INK4b[/E2]), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p15", "entity_1_idx": [[28, 31]], "entity_1_idx_in_text_with_entity_marker": [32, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "INK4b", "entity_2_idx": [[32, 37]], "entity_2_idx_in_text_with_entity_marker": [45, 50], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s35_AIMed.d3.s35.p22", "text": "Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "text_with_entity_marker": "Analysis of p53, p21(CIP1), [E1]p15[/E1](INK4b), [E2]p16[/E2](INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p15", "entity_1_idx": [[28, 31]], "entity_1_idx_in_text_with_entity_marker": [32, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p16", "entity_2_idx": [[40, 43]], "entity_2_idx_in_text_with_entity_marker": [53, 56], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s35_AIMed.d3.s35.p23", "text": "Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "text_with_entity_marker": "Analysis of p53, p21(CIP1), [E1]p15[/E1](INK4b), p16([E2]INK4a[/E2]), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p15", "entity_1_idx": [[28, 31]], "entity_1_idx_in_text_with_entity_marker": [32, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "INK4a", "entity_2_idx": [[44, 49]], "entity_2_idx_in_text_with_entity_marker": [57, 62], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s35_AIMed.d3.s35.p24", "text": "Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "text_with_entity_marker": "Analysis of p53, p21(CIP1), [E1]p15[/E1](INK4b), p16(INK4a), and [E2]p57[/E2](KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p15", "entity_1_idx": [[28, 31]], "entity_1_idx_in_text_with_entity_marker": [32, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p57", "entity_2_idx": [[56, 59]], "entity_2_idx_in_text_with_entity_marker": [69, 72], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s35_AIMed.d3.s35.p25", "text": "Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "text_with_entity_marker": "Analysis of p53, p21(CIP1), [E1]p15[/E1](INK4b), p16(INK4a), and p57([E2]KIP2[/E2]) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p15", "entity_1_idx": [[28, 31]], "entity_1_idx_in_text_with_entity_marker": [32, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KIP2", "entity_2_idx": [[60, 64]], "entity_2_idx_in_text_with_entity_marker": [73, 77], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s35_AIMed.d3.s35.p26", "text": "Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "text_with_entity_marker": "Analysis of p53, p21(CIP1), p15([E1]INK4b[/E1]), [E2]p16[/E2](INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "INK4b", "entity_1_idx": [[32, 37]], "entity_1_idx_in_text_with_entity_marker": [36, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p16", "entity_2_idx": [[40, 43]], "entity_2_idx_in_text_with_entity_marker": [53, 56], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s35_AIMed.d3.s35.p27", "text": "Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "text_with_entity_marker": "Analysis of p53, p21(CIP1), p15([E1]INK4b[/E1]), p16([E2]INK4a[/E2]), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "INK4b", "entity_1_idx": [[32, 37]], "entity_1_idx_in_text_with_entity_marker": [36, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "INK4a", "entity_2_idx": [[44, 49]], "entity_2_idx_in_text_with_entity_marker": [57, 62], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s35_AIMed.d3.s35.p28", "text": "Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "text_with_entity_marker": "Analysis of p53, p21(CIP1), p15([E1]INK4b[/E1]), p16(INK4a), and [E2]p57[/E2](KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "INK4b", "entity_1_idx": [[32, 37]], "entity_1_idx_in_text_with_entity_marker": [36, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p57", "entity_2_idx": [[56, 59]], "entity_2_idx_in_text_with_entity_marker": [69, 72], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s35_AIMed.d3.s35.p29", "text": "Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "text_with_entity_marker": "Analysis of p53, p21(CIP1), p15([E1]INK4b[/E1]), p16(INK4a), and p57([E2]KIP2[/E2]) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "INK4b", "entity_1_idx": [[32, 37]], "entity_1_idx_in_text_with_entity_marker": [36, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KIP2", "entity_2_idx": [[60, 64]], "entity_2_idx_in_text_with_entity_marker": [73, 77], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s35_AIMed.d3.s35.p30", "text": "Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "text_with_entity_marker": "Analysis of p53, p21(CIP1), p15(INK4b), [E1]p16[/E1]([E2]INK4a[/E2]), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p16", "entity_1_idx": [[40, 43]], "entity_1_idx_in_text_with_entity_marker": [44, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "INK4a", "entity_2_idx": [[44, 49]], "entity_2_idx_in_text_with_entity_marker": [57, 62], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s35_AIMed.d3.s35.p31", "text": "Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "text_with_entity_marker": "Analysis of p53, p21(CIP1), p15(INK4b), [E1]p16[/E1](INK4a), and [E2]p57[/E2](KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p16", "entity_1_idx": [[40, 43]], "entity_1_idx_in_text_with_entity_marker": [44, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p57", "entity_2_idx": [[56, 59]], "entity_2_idx_in_text_with_entity_marker": [69, 72], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s35_AIMed.d3.s35.p32", "text": "Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "text_with_entity_marker": "Analysis of p53, p21(CIP1), p15(INK4b), [E1]p16[/E1](INK4a), and p57([E2]KIP2[/E2]) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p16", "entity_1_idx": [[40, 43]], "entity_1_idx_in_text_with_entity_marker": [44, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KIP2", "entity_2_idx": [[60, 64]], "entity_2_idx_in_text_with_entity_marker": [73, 77], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s35_AIMed.d3.s35.p33", "text": "Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "text_with_entity_marker": "Analysis of p53, p21(CIP1), p15(INK4b), p16([E1]INK4a[/E1]), and [E2]p57[/E2](KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "INK4a", "entity_1_idx": [[44, 49]], "entity_1_idx_in_text_with_entity_marker": [48, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p57", "entity_2_idx": [[56, 59]], "entity_2_idx_in_text_with_entity_marker": [69, 72], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s35_AIMed.d3.s35.p34", "text": "Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "text_with_entity_marker": "Analysis of p53, p21(CIP1), p15(INK4b), p16([E1]INK4a[/E1]), and p57([E2]KIP2[/E2]) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "INK4a", "entity_1_idx": [[44, 49]], "entity_1_idx_in_text_with_entity_marker": [48, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KIP2", "entity_2_idx": [[60, 64]], "entity_2_idx_in_text_with_entity_marker": [73, 77], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d3.s35_AIMed.d3.s35.p35", "text": "Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "text_with_entity_marker": "Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and [E1]p57[/E1]([E2]KIP2[/E2]) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p57", "entity_1_idx": [[56, 59]], "entity_1_idx_in_text_with_entity_marker": [60, 63], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KIP2", "entity_2_idx": [[60, 64]], "entity_2_idx_in_text_with_entity_marker": [73, 77], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d220.s1909_AIMed.d220.s1909.p0", "text": "Interactions between brain-derived neurotrophic factor and the TRKB receptor. Identification of two ligand binding domains in soluble TRKB by affinity separation and chemical cross-linking.", "text_with_entity_marker": "Interactions between [E1]brain-derived neurotrophic factor[/E1] and the [E2]TRKB[/E2] receptor. Identification of two ligand binding domains in soluble TRKB by affinity separation and chemical cross-linking.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "brain-derived neurotrophic factor", "entity_1_idx": [[21, 54]], "entity_1_idx_in_text_with_entity_marker": [25, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TRKB", "entity_2_idx": [[63, 67]], "entity_2_idx_in_text_with_entity_marker": [76, 80], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d220.s1909_AIMed.d220.s1909.p1", "text": "Interactions between brain-derived neurotrophic factor and the TRKB receptor. Identification of two ligand binding domains in soluble TRKB by affinity separation and chemical cross-linking.", "text_with_entity_marker": "Interactions between [E1]brain-derived neurotrophic factor[/E1] and the [E2]TRKB receptor[/E2]. Identification of two ligand binding domains in soluble TRKB by affinity separation and chemical cross-linking.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "brain-derived neurotrophic factor", "entity_1_idx": [[21, 54]], "entity_1_idx_in_text_with_entity_marker": [25, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TRKB receptor", "entity_2_idx": [[63, 76]], "entity_2_idx_in_text_with_entity_marker": [76, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d220.s1909_AIMed.d220.s1909.p2", "text": "Interactions between brain-derived neurotrophic factor and the TRKB receptor. Identification of two ligand binding domains in soluble TRKB by affinity separation and chemical cross-linking.", "text_with_entity_marker": "Interactions between [E1]brain-derived neurotrophic factor[/E1] and the TRKB receptor. Identification of two ligand binding domains in soluble [E2]TRKB[/E2] by affinity separation and chemical cross-linking.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "brain-derived neurotrophic factor", "entity_1_idx": [[21, 54]], "entity_1_idx_in_text_with_entity_marker": [25, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TRKB", "entity_2_idx": [[134, 138]], "entity_2_idx_in_text_with_entity_marker": [147, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d220.s1909_AIMed.d220.s1909.p3", "text": "Interactions between brain-derived neurotrophic factor and the TRKB receptor. Identification of two ligand binding domains in soluble TRKB by affinity separation and chemical cross-linking.", "text_with_entity_marker": "Interactions between brain-derived neurotrophic factor and the [E1-E2]TRKB[/E1] receptor[/E2]. Identification of two ligand binding domains in soluble TRKB by affinity separation and chemical cross-linking.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TRKB", "entity_1_idx": [[63, 67]], "entity_1_idx_in_text_with_entity_marker": [70, 74], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TRKB[/E1] receptor", "entity_2_idx": [[63, 76]], "entity_2_idx_in_text_with_entity_marker": [70, 88], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d220.s1909_AIMed.d220.s1909.p4", "text": "Interactions between brain-derived neurotrophic factor and the TRKB receptor. Identification of two ligand binding domains in soluble TRKB by affinity separation and chemical cross-linking.", "text_with_entity_marker": "Interactions between brain-derived neurotrophic factor and the [E1]TRKB[/E1] receptor. Identification of two ligand binding domains in soluble [E2]TRKB[/E2] by affinity separation and chemical cross-linking.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TRKB", "entity_1_idx": [[63, 67]], "entity_1_idx_in_text_with_entity_marker": [67, 71], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TRKB", "entity_2_idx": [[134, 138]], "entity_2_idx_in_text_with_entity_marker": [147, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d220.s1909_AIMed.d220.s1909.p5", "text": "Interactions between brain-derived neurotrophic factor and the TRKB receptor. Identification of two ligand binding domains in soluble TRKB by affinity separation and chemical cross-linking.", "text_with_entity_marker": "Interactions between brain-derived neurotrophic factor and the [E1]TRKB receptor[/E1]. Identification of two ligand binding domains in soluble [E2]TRKB[/E2] by affinity separation and chemical cross-linking.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TRKB receptor", "entity_1_idx": [[63, 76]], "entity_1_idx_in_text_with_entity_marker": [67, 80], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TRKB", "entity_2_idx": [[134, 138]], "entity_2_idx_in_text_with_entity_marker": [147, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d220.s1910_AIMed.d220.s1910.p0", "text": "The extracellular domain of the human neurotrophin TRKB receptor expressed in Chinese hamster ovary cells is a highly glycosylated protein, possessing binding ability for brain-derived neurotrophic factor (BDNF).", "text_with_entity_marker": "The extracellular domain of the human [E1]neurotrophin TRKB receptor[/E1][E2]TRKB[/E2] receptor expressed in Chinese hamster ovary cells is a highly glycosylated protein, possessing binding ability for brain-derived neurotrophic factor (BDNF).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "neurotrophin TRKB receptor", "entity_1_idx": [[38, 64]], "entity_1_idx_in_text_with_entity_marker": [42, 68], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TRKB", "entity_2_idx": [[51, 55]], "entity_2_idx_in_text_with_entity_marker": [77, 81], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d220.s1910_AIMed.d220.s1910.p1", "text": "The extracellular domain of the human neurotrophin TRKB receptor expressed in Chinese hamster ovary cells is a highly glycosylated protein, possessing binding ability for brain-derived neurotrophic factor (BDNF).", "text_with_entity_marker": "The extracellular domain of the human neurotrophin [E1]TRKB[/E1] receptor expressed in Chinese hamster ovary cells is a highly glycosylated protein, possessing binding ability for [E2]brain-derived neurotrophic factor[/E2] (BDNF).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TRKB", "entity_1_idx": [[51, 55]], "entity_1_idx_in_text_with_entity_marker": [55, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "brain-derived neurotrophic factor", "entity_2_idx": [[171, 204]], "entity_2_idx_in_text_with_entity_marker": [184, 217], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d220.s1910_AIMed.d220.s1910.p2", "text": "The extracellular domain of the human neurotrophin TRKB receptor expressed in Chinese hamster ovary cells is a highly glycosylated protein, possessing binding ability for brain-derived neurotrophic factor (BDNF).", "text_with_entity_marker": "The extracellular domain of the human neurotrophin [E1]TRKB[/E1] receptor expressed in Chinese hamster ovary cells is a highly glycosylated protein, possessing binding ability for brain-derived neurotrophic factor ([E2]BDNF[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TRKB", "entity_1_idx": [[51, 55]], "entity_1_idx_in_text_with_entity_marker": [55, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BDNF", "entity_2_idx": [[206, 210]], "entity_2_idx_in_text_with_entity_marker": [219, 223], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d220.s1910_AIMed.d220.s1910.p3", "text": "The extracellular domain of the human neurotrophin TRKB receptor expressed in Chinese hamster ovary cells is a highly glycosylated protein, possessing binding ability for brain-derived neurotrophic factor (BDNF).", "text_with_entity_marker": "The extracellular domain of the human [E1]neurotrophin TRKB receptor[/E1] expressed in Chinese hamster ovary cells is a highly glycosylated protein, possessing binding ability for [E2]brain-derived neurotrophic factor[/E2] (BDNF).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "neurotrophin TRKB receptor", "entity_1_idx": [[38, 64]], "entity_1_idx_in_text_with_entity_marker": [42, 68], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "brain-derived neurotrophic factor", "entity_2_idx": [[171, 204]], "entity_2_idx_in_text_with_entity_marker": [184, 217], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d220.s1910_AIMed.d220.s1910.p4", "text": "The extracellular domain of the human neurotrophin TRKB receptor expressed in Chinese hamster ovary cells is a highly glycosylated protein, possessing binding ability for brain-derived neurotrophic factor (BDNF).", "text_with_entity_marker": "The extracellular domain of the human [E1]neurotrophin TRKB receptor[/E1] expressed in Chinese hamster ovary cells is a highly glycosylated protein, possessing binding ability for brain-derived neurotrophic factor ([E2]BDNF[/E2]).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "neurotrophin TRKB receptor", "entity_1_idx": [[38, 64]], "entity_1_idx_in_text_with_entity_marker": [42, 68], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BDNF", "entity_2_idx": [[206, 210]], "entity_2_idx_in_text_with_entity_marker": [219, 223], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d220.s1910_AIMed.d220.s1910.p5", "text": "The extracellular domain of the human neurotrophin TRKB receptor expressed in Chinese hamster ovary cells is a highly glycosylated protein, possessing binding ability for brain-derived neurotrophic factor (BDNF).", "text_with_entity_marker": "The extracellular domain of the human neurotrophin TRKB receptor expressed in Chinese hamster ovary cells is a highly glycosylated protein, possessing binding ability for [E1]brain-derived neurotrophic factor[/E1] ([E2]BDNF[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "brain-derived neurotrophic factor", "entity_1_idx": [[171, 204]], "entity_1_idx_in_text_with_entity_marker": [175, 208], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BDNF", "entity_2_idx": [[206, 210]], "entity_2_idx_in_text_with_entity_marker": [219, 223], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d220.s1911_AIMed.d220.s1911.p0", "text": "Two distinct ligand binding domains of TRKB were isolated from proteolytic digests of the receptor by affinity separation on immobilized BDNF.", "text_with_entity_marker": "Two distinct ligand binding domains of [E1]TRKB[/E1] were isolated from proteolytic digests of the receptor by affinity separation on immobilized [E2]BDNF[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TRKB", "entity_1_idx": [[39, 43]], "entity_1_idx_in_text_with_entity_marker": [43, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BDNF", "entity_2_idx": [[137, 141]], "entity_2_idx_in_text_with_entity_marker": [150, 154], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d220.s1920_AIMed.d220.s1920.p0", "text": "These results, obtained from a variety of experimental techniques, highlight the importance of two distinct regions of the extracellular domain of the TRKB receptor in binding BDNF.", "text_with_entity_marker": "These results, obtained from a variety of experimental techniques, highlight the importance of two distinct regions of the extracellular domain of the [E1-E2]TRKB[/E1] receptor[/E2] in binding BDNF.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TRKB", "entity_1_idx": [[151, 155]], "entity_1_idx_in_text_with_entity_marker": [158, 162], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TRKB[/E1] receptor", "entity_2_idx": [[151, 164]], "entity_2_idx_in_text_with_entity_marker": [158, 176], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d220.s1920_AIMed.d220.s1920.p1", "text": "These results, obtained from a variety of experimental techniques, highlight the importance of two distinct regions of the extracellular domain of the TRKB receptor in binding BDNF.", "text_with_entity_marker": "These results, obtained from a variety of experimental techniques, highlight the importance of two distinct regions of the extracellular domain of the [E1]TRKB[/E1] receptor in binding [E2]BDNF[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TRKB", "entity_1_idx": [[151, 155]], "entity_1_idx_in_text_with_entity_marker": [155, 159], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BDNF", "entity_2_idx": [[176, 180]], "entity_2_idx_in_text_with_entity_marker": [189, 193], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d220.s1920_AIMed.d220.s1920.p2", "text": "These results, obtained from a variety of experimental techniques, highlight the importance of two distinct regions of the extracellular domain of the TRKB receptor in binding BDNF.", "text_with_entity_marker": "These results, obtained from a variety of experimental techniques, highlight the importance of two distinct regions of the extracellular domain of the [E1]TRKB receptor[/E1] in binding [E2]BDNF[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TRKB receptor", "entity_1_idx": [[151, 164]], "entity_1_idx_in_text_with_entity_marker": [155, 168], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BDNF", "entity_2_idx": [[176, 180]], "entity_2_idx_in_text_with_entity_marker": [189, 193], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
